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The United Kingdom Focal Point on Drugs
The United Kingdom (UK) Focal Point on Drugs is based at Public Health England (PHE). It is the 
national partner of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and 
provides comprehensive information to the centre on the drug situation in England, Scotland, 
Wales and Northern Ireland.
The Focal Point works closely with the Home Office, other government departments and the 
devolved administrations. In addition to this annual report, it collates an extensive range of data 
in the form of standard tables (STs) and responses to structured questionnaires, which are 
submitted regularly to the EMCDDA. It also contributes to other elements of the EMCDDA’s 
work such as the development and implementation of its five key epidemiological indicators, the 
Exchange on Drug Demand Reduction Action and the implementation of the Council Decision 
on New Psychoactive Substances (NPS).
Further information about the UK Focal Point, including previous annual reports can be found 
on the Focal Point website at http://www.nta.nhs.uk/focalpoint.aspx
The EMCDDA’s website is www.emcdda.europa.eu
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Technical Notes
Accompanying Tables
The accompanying tables referenced in the text are published alongside the report on the Focal 
Point webpage: http://www.nta.nhs.uk/focalpoint.aspx. A list of accompanying tables and their 
data sources is included in Part B of this document. 
Cut-off for updates
The 31st December 2016 was used as the cut-off date for developments or publications to be 
included in this report. Where the terms ‘latest’ or ‘most recent’ are used in relation to statistics, 
they should be interpreted as meaning the most recent data available as at the end of the 
calendar year. New statistics, reports, or other relevant developments between the end of the 
calendar year and the publication of the report have not been factored in.
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Executive summary
 • Overall drug prevalence in the general population is lower now than ten years ago, with 
cannabis being the main driver of that reduction. However, there has been little change 
in recent years. 
 • The order of drugs most commonly reported by respondents has not changed much 
over this time, with cannabis most prevalent (6.5%) followed by powder cocaine (2.2%) 
and ecstasy/MDMA (1.5%), according to the most recent Crime Survey for England and 
Wales.
 • Seizures data suggests that herbal cannabis has come to dominate the market. While 
resin was involved in around two-thirds of cannabis seizures in 2000, it was involved in 
only five per cent in 2015/16.
 • On 26 May 2016, the Psychoactive Substances Act 2016 came into force in the UK, 
prohibiting the production, supply, import/export and possession on prison grounds of 
psychoactive substances, other than those exempted by the legislation. This act was 
brought in to tackle the trade in new psychoactive substances (NPS) which has steadily 
grown in recent years. Over 350 premises in the UK trading in NPS have either closed or 
stopped selling substances covered by the legislation.
 • In addition, synthetic cannabinoid receptor agonists (SCRAs), a class of NPS whose 
use among the prison population and vulnerable people has caused concern, became 
controlled under the Misuse of Drugs Act 1971 as Class B substances in December 
2016. 
 • Temporary class drug orders on methylphenidate-related compounds (including 
ethylphenidate) and methiopropamine have been remade for another 12 months.
 • Using the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) definition, 
which refers to deaths caused directly by the consumption of at least one illicit drug, the 
total number of drug-related deaths (DRDs) in the UK during 2014 was 2,655; a five per 
cent increase from 2013 and the highest number reported to date. 
 • Due to substantial delays being typical between occurrence and registration of DRDs in 
England and Wales, UK-wide DRD figures are not yet available covering deaths occurring 
beyond 2014. However, published statistics for DRDs occurring in Scotland during 2015 
showed a 15% increase on 2014. 
 • Deaths registered in 2015 in England and Wales were notably higher than deaths 
registered in 2014. It is therefore likely that DRD figures for 2015 will set a new record.
 • Across the UK there were 2,304 deaths reported which featured an opioid (87% of 
UK cases). As in previous years, the substance with the largest number of associated 
deaths was heroin. In contrast to the UK as a whole, tramadol was the most commonly 
mentioned opioid drug in Northern Ireland. 
 • The proportion of deaths involving cocaine has risen; however, many of these deaths are 
believed to be heroin users who also use crack cocaine. 
 • The number of MDMA-associated deaths in England and Wales rose to 57 cases, 
returning to levels seen prior to the decrease in availability of MDMA in the late 2000s.
 • Over the last decade the average age of death has increased from 37.6 years in 2004 
to 41.6 in 2014, with males being younger than females (40.3 years and 44.6 years 
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respectively). The largest proportion of deaths in the UK in 2014 was in the 40–44 years 
age group. 
 • There were 124,234 treatment presentations in the UK in 2015. This total includes for the 
first time, data from individuals presenting to treatment services in prisons in England.
 • Fifty per cent of all treatment presentations in the UK were for primary opioid use, with 
26% of all service users presenting for treatment of cannabis use. However, among 
those who had never previously been in treatment, just under half (48%) of clients had 
a primary substance of cannabis, compared to 21% who presented for treatment of 
heroin. The proportions of users presenting for treatment of these substances appear to 
have stabilised over the past two years. 
 • The primary drugs cited by those presenting to specialist substance misuse treatment 
services varied notably between each of the four countries of the UK. While almost half 
of treatment entrants cited heroin in England, Scotland and Wales, less than 10% did in 
Northern Ireland. 
 • Benzodiazepines were cited as a primary problem substance in far greater proportion of 
cases in Scotland and Northern Ireland than in England or Wales, whereas Wales had a 
far higher proportion of clients citing amphetamines/methamphetamines than in any of 
the other countries. 
 • Treatment data from prisons showed that 27,836 individuals presented to treatment 
services in English prisons in 2015, with 564 presenting in prison in Northern Ireland; 
approximately one-quarter of the treatment clients from each country. Heroin was the 
most common primary substance among clients in England, whereas cannabis was the 
most common substance in Northern Ireland. 
 • The use of NPS, and SCRAs in particular, remains a growing concern in prisons in the 
UK. Surveys carried out in England, Wales and Scotland found that around 10% of 
prisoners reported use of SCRAs while in prison, behind cannabis with a prevalence at 
around 15%. 
 • The Prisons and Probation Ombudsman has found 64 deaths that occurred in prisons in 
England and Wales between June 2013 and April 2016 that were associated with NPS. 
NPS use has also been associated with self-harm incidents, intimidation and violence. 
 • National Take-Home Naloxone programmes continue to supply naloxone to those exiting 
prison in Scotland and Wales: there were 932 kits issued by NHS staff in prisons in 
Scotland, and 146 in Wales, in 2015/16.
 • Prevalence of HIV among people who inject drugs (PWID) participating in the Unlinked 
Anonymous Monitoring (UAM) survey in England, Wales and Northern Ireland in 2015 
was one per cent (a similar level to recent years). HIV prevalence among ‘recent initiates’ 
to injecting substantially increased in 2015 to 2.6%, the highest level seen in the last ten 
years. However, this likely represents an increase in prevalence among men who have 
sex with men rather than among the wider population who inject drugs.
 • There were 50 new diagnoses of HIV among PWID reported from Scotland, compared 
with 17 in 2014. This increase was due to an outbreak of HIV in PWID in Glasgow.
 • Around 90% of the hepatitis C infections diagnosed in the UK are acquired through 
injecting drug use. The prevalence of hepatitis C among PWID has remained fairly stable 
over the last ten years, and was 50% in the UAM survey of PWID in 2015. 
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 • Hepatitis B prevalence rates have also remained stable for 2015 at 13%. This is half the 
level seen ten years ago, with the decrease likely to be due to the increased uptake of the 
hepatitis B vaccination among the PWID population.
 • The level of direct sharing of needles and syringes reported by participants in the UAM 
Survey of PWID has declined over the last decade from 28% in 2005 to 16% in 2015. 
However, levels of concern have increased around the harms associated with people 
who inject NPS such as mephedrone. One-third of participants in the UAM survey of 
PWID who were currently injecting mephedrone reported they had shared needles or 
syringes previously used by someone else. 
 • An Independent review into the impact on employment outcomes of drug or alcohol 
addiction, and obesity was published in December 2016 and made a number of 
recommendations to promote employment of those with addictions, including that those 
making a claim should be required to attend a structured discussion with a healthcare 
professional on the impact of their health condition on their ability to work.
 • The Association for Young People’s Health, in conjunction with Public Health England, 
published A public health approach to promoting young people’s resilience, to aid policy 
makers and commissioners. Similarly, Mentor-ADEPIS published a briefing paper aimed 
at teachers and practitioners on how building resilience can prevent substance abuse.
 • The numbers of recorded incidents of possession and supply offences across the UK, 
and arrests for drug offences in England and Wales, have fallen in 2015/16, continuing 
the trends seen over the past five years. In 2015/16, 31,342 supply/trafficking offences 
and 157,271 possession offences were recorded in the UK. 
 • Heroin purity has continued to rise since the low level seen in the early 2010s, and in 
2015 was 44%, more than twice the purity seen in 2011 and 2012 when it reached its 
nadir. Similarly, cocaine purity, which was at its lowest in 2010, has risen since that time, 
and in 2015 was also 44%.
 • Street level price data from law enforcement agencies suggests that most recorded drug 
prices have remained stable in recent years.
 • The number of cannabis seizures in all forms in England and Wales in 2015/16 decreased, 
continuing the downwards trend seen in recent years. Cocaine, ecstasy and heroin 
seizure numbers all remained stable, while the number of crack seizures increased in 
2015/16.
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Overview of illicit drug use in the UK
1
1 Overview of illicit drug use in the UK
1.1 Introduction
The UK population was estimated to be 65.1 million according to the 2015 mid-year estimate 
(Office for National Statistics, 2016d). Eighty-four per cent (54.8 million) live in England, eight per 
cent (5.4 million) in Scotland, five per cent (3.1 million) in Wales and three per cent (1.9 million) 
in Northern Ireland. General population surveys (GPS) indicate that cannabis is the most 
commonly used illicit drug in the UK, and it has been in each year that relevant surveys have 
been conducted. Treatment demand for cannabis has risen for as far back as there is reliable 
data, despite prevalence having fallen. Cocaine (in powder form) is the next most commonly 
used drug, followed by ecstasy. 
Although its use in the general population is relatively uncommon (Home Office, 2016a), heroin 
is associated with causing substantial health and social harm to users as well as the most 
harm to society (for example in the form of drug-related crime). As such, heroin is of particular 
importance to policy makers in the UK. Around 80% of people in treatment for issues with drugs 
cite heroin as a problematic substance (see section 4.3.3). Crack cocaine is commonly cited as 
an adjunctive drug by heroin clients in treatment, but its use among the general population is 
rare in comparison to that of powder cocaine. Poly-use of benzodiazepines and heroin is also 
common in the UK, particularly in Scotland. 
Prevalence of new psychoactive substances (NPS) in GPS is low in comparison to the main 
traditional drugs (Home Office, 2016a). However, concerns have emerged in recent years 
regarding use of NPS among prisoners and problem drug users (see section 5.5.1).
Overall drug use in the UK is lower than it was 10 years ago, principally reflecting a decrease in 
cannabis use, which, due to its relatively high prevalence, is the main driver of the overall trend.
1.2 Cannabis 
1.2.1 Prevalence of cannabis
The most recent Crime Survey for England and Wales (CSEW) reported that the last year 
cannabis prevalence rate in 2015/16 was 6.5%, in comparison to 2.2% of respondents using 
cocaine, the second most commonly reported illicit drug (Home Office, 2016a). Use of cannabis 
in the general population had been on a long-term downward trend since 2003/04, but the 
trend since 2009/10 has been relatively flat (see Figure 1.1). Prior to this reduction in prevalence, 
last year cannabis use reported by the CSEW had been fairly high in comparison with that 
reported by other European countries; however, this is now at a level that is fairly typical to that 
seen elsewhere (European Monitoring Centre for Drugs and Drug Addiction, 2015). 
Use of cannabis is most common among younger respondents and the long-term downward 
trend is also more apparent among this group, with last year prevalence for 16–24 year-olds 
decreasing from a high of 28% in 1998 to 16% in 2015/16. However, this declining trend also 
appears to be levelling out (Home Office, 2016a). 
Similar proportions of last year cannabis use have also been reported in Scotland and Northern 
Ireland. The Scottish Crime and Justice Survey (SCJS) covering 2014/15 showed last year use 
as five per cent (Scottish Government, 2016c), and the most recent Drug use in Ireland and 
Northern Ireland – Drug Prevalence Survey covering 2014/15 reported last year use at 4.6% 
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(National Advisory Committee on Drugs and Alcohol (NACDA) & Department of Health Northern 
Ireland, 2016), although these surveys are not fully comparable. 
Figure 1.1: Percentage of adult respondents to prevalence surveys across the United Kingdom 
reporting last year use of cannabis, by country, 2006/07 to 2015/16
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Source: (Home Office, 2016a; National Advisory Committee on Drugs and Alcohol (NACDA) & Department of 
Health Northern Ireland, 2016; Scottish Government, 2016c)
Rates of use of cannabis in the last month are also fairly similar across the UK: 3.2% in England 
and Wales; 2.8% in Scotland; and 2.2% in Northern Ireland. The proportion of last year cannabis 
users in England and Wales that reported having done so more than once a month has fallen 
in recent years, from 52% in 2009/10 to 37% in the last CSEW (Home Office, 2016a). However, 
this remains a very high proportion of last year users compared to other drugs. 
GPS do not currently report on the use of herbal versus cannabis resin. The 2009/10 CSEW 
previously showed that 71% of last year cannabis users used herbal cannabis, with 38% using 
resin (Home Office, 2010a). Seizures data provides insight into the relative prevalence of these 
forms of cannabis over time. In 2000, over 60% of cannabis seizures made by police forces in 
England and Wales involved resin (Home Office, 2010b). The proportion of seizures involving 
herbal cannabis has since greatly increased and in 2015/16 accounted for 95% of cannabis 
seizures (excluding cannabis plant seizures (see Figure 1.2) (Home Office, 2016g).
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Figure 1.2: Percentage cannabis seizures made by police forces in England and Wales by type 
of cannabis (excluding plants), 2000 to 2015/16
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1.2.2 Commentary on cannabis trends
All GPS in the UK show a reduction in prevalence of cannabis use since around 2003/04; 
however, treatment presentations for cannabis (cited as the primary problematic substance) 
have risen in recent years (see section 4.4.4). There is no universally agreed explanation for 
the divergence of these trends, although one possibility is that while fewer people are using 
cannabis, those who are using it are experiencing greater harm and, as such, are more likely to 
seek treatment. 
Hospital inpatient discharges data produced for the UK Focal Point provides a further indication 
that the number of people experiencing harms associated with cannabis may be greater in recent 
years. Figure 1.3 shows data produced for the Focal Point on hospital inpatient discharges for 
mental and behavioural disorders where cannabinoids was given as one of the diagnoses. Due 
to the way that hospital data is recorded it is not possible to distinguish between cannabis and 
synthetic cannabinoid receptor agonists (SCRAs), so some of the rise during this period may be 
accounted for by NPS.
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Figure 1.3: Hospital inpatient discharges across the United Kingdom for mental and 
behavioural disorders with cannabinoids as one of the diagnoses, 2007/08 to 2013/14
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Source: Personal communication – Public Health England, NHS Wales Informatics Service, NHS National 
Services Scotland, Department of Health Northern Ireland
The increased dominance of high potency herbal cannabis within the UK market and/or the 
increasing strength and tetrahydrocannabinol to cannabidiol ratio of cannabis are reasons that 
increased harm from cannabis use might be expected. Freeman and Winstock, publishing 
on findings from the Global Drug Survey (GDS), found that high-potency skunk was far more 
commonly associated with negative effects such as memory loss and paranoia, despite being 
the most popular type of cannabis with respondents (Freeman & Winstock, 2015). Di Forti et al 
found far greater risk of first episode psychosis among those using skunk-like cannabis versus 
hash users (Di Forti et al., 2015). 
It should be noted that cannabis potency data is not reported for the UK; however, most cannabis 
consumed in the UK is imported via Europe (see section 9.2.2) where potency is reported to 
have risen (European Monitoring Centre for Drugs and Drug Addiction, 2016a). 
1.3 Stimulants
There has been a small, long-term downward trend in the overall use of any stimulant drug1 
among 16-59 year-olds reported in the CSEW since the beginning of the time series, from 4.4% 
in 1996 to around 3.5% in recent years. The dip to 3.0% reported in 2012/13 appears not to 
be reflective of the longer term trend (Home Office, 2016a). Last year prevalence of cocaine, 
amphetamine and ecstasy from both the CSEW and the SCJS are shown in Figure 1.4. Of the 
individual drugs included in the CSEW stimulant category, only amphetamine and amyl nitrite 
were statistically significantly reduced from 2005/06. 
1 ‘Any stimulant drug’ comprises powder cocaine, crack cocaine, ecstasy, amphetamines and amyl nitrite plus 
methamphetamine since 2008/09 and mephedrone since 2010/11
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Figure 1.4: Percentage of respondents to prevalence surveys in England & Wales and 
Scotland reporting last year use of selected drugs, 2006/07 to 2015/16
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Source: (Home Office, 2016a; Scottish Government, 2016c)
1.3.1 Cocaine
Powder cocaine is the most prevalent stimulant in the UK and the second most prevalent drug 
overall, with last year use reported at 2.2% in the latest CSEW (Home Office, 2016a). Although 
varying methodologies and sampling techniques place limitations on the comparability between 
surveys, this is high compared to prevalence reported for most other European countries 
(European Monitoring Centre for Drugs and Drug Addiction, 2016a). Analysis of wastewater in a 
selection of European cities suggests London consumes a relatively large amount of cocaine.2 
Last year use in both Scotland and Northern Ireland was 1.8% in the most recent surveys 
available (National Advisory Committee on Drugs and Alcohol (NACDA) & Department of Health 
Northern Ireland, 2016; Scottish Government, 2016c). 
Since 2008/09, an overall fall in the prevalence of cocaine use has been reported in the CSEW 
(Home Office, 2016a). This appears to have been driven by lower levels of use in younger 
age groups, suggesting there were fewer initiates among this generation; however, prevalence 
among those under 35 appear to have stabilised in the past two years. Use among the 35-44 
age group has increased over the past decade (see Figure 1.5). This may indicate that a greater 
proportion of people from this generation are continuing to use cocaine as they transition into 
middle age than was the case among those born a few years earlier.
2 See: http://www.emcdda.europa.eu/topics/pods/waste-water-analysis#panel2
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Figure 1.5: Prevalence of last year cocaine use among under 45s in England and Wales by 
age group, 2006/07 to 2015/16
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Source: Personal communication – Home Office
The proportion of powder cocaine users stating that they are frequent users of this drug (ie 
using powder cocaine more than once a month) dropped from 27% in 2008/09 to 13% in 
2009/10, and has remained at around this level since. Eleven per cent of cocaine users stated 
they were frequent users in 2015/16 (Home Office, 2016a).
Cocaine (powder) is also the most seized stimulant in the UK, both in terms of number and 
quantity of seizures (see section 9.5.1). Having been 51% in 2003, the purity of powder cocaine 
seized in small quantities (ie the category that includes seizures from users) fell to 20% in 2009. 
However, it has risen since then and was 44% in 2015 (see section 9.3.4). 
Use of crack cocaine is far less common among the general population than use of powder 
cocaine. Although crack cocaine use is relatively rare, it is associated with very problematic 
use and drug-related crime, predominantly among those also using opioids. Due to the often 
chaotic nature of users’ lives, it is likely that household surveys underestimate crack use. The 
last indirect point estimate of problematic crack use in England for 2011/12 put the rate at 
4.76 per 1,000 population aged 15-64 years (Hay, Rael dos Santos, & Worsley, 2014). 
Having dropped considerably from 2009 to 2011, drug-related deaths with cocaine mentioned 
on the death certificate (but not necessarily implicated) rose steeply year on year to a record 
high in 2015. However, this trend broadly reflects the trend in heroin-related deaths and may 
to an extent be an artefact of the high prevalence of crack cocaine among heroin users 
(see section 6.4.2). 
1.3.2 Ecstasy (MDMA)
Ecstasy (MDMA) is the second most commonly reported stimulant from UK household surveys: 
last year use was reported as 1.5% in the 2015/16 CSEW, 0.8% in 2014/15 in Northern Ireland 
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and 1.3% in the 2014/15 SCJS (Home Office, 2016a; National Advisory Committee on Drugs 
and Alcohol (NACDA) & Department of Health Northern Ireland, 2016; Scottish Government, 
2016c). Prevalence rates among survey respondents in England and Wales have remained 
generally stable over the past decade, with a small drop in usage seen in 2012/13.
Findings from the CSEW suggest a relatively small proportion of people who use ecstasy do so 
more than once a month (seven per cent compared with 11% of cocaine last year users) (Home 
Office, 2016a). As noted with cocaine, there was a large fall in the number of ecstasy users 
reporting frequent use between 2008/09 and 2009/10, from 14% to 5.5%, and this proportion 
has remained low since. The age profile for ecstasy is younger than cocaine and amphetamines. 
While the likelihood of having used any of the most common stimulants in the last year increases 
substantially with number of visits to nightclubs or to pubs/bars, this is particularly the case with 
ecstasy (Home Office, 2016a).
MDMA is sold in pill and powder/crystal form. Data for England and Wales shows there was a 
very sharp fall in the number of ecstasy pills seized from 2007/08 to 2008/09 and the level has 
not yet returned to that seen before the drop (see section 9.5.1). Data is not available on the 
quantity on MDMA seized in powder/crystal form.
Potency has risen in recent years with batches of super strength tablets causing some concern 
(European Monitoring Centre for Drugs and Drug Addiction, 2016b). After having dropped sharply 
to a low in 2009, deaths in England involving MDMA have risen in recent years to levels similar 
to those seen before the drop (Office for National Statistics, 2016c). However, aside from MDMA 
itself, there have been several deaths since 2011 resulting from overdoses of the far more toxic 
substances para-methoxyamphetamine (PMA) and para-methoxymethamphetamine (PMMA) 
which are likely to have been sold to users as ecstasy. 
1.3.3 Amphetamine
Last year prevalence of amphetamine use in England and Wales has more than halved since 
the 2005/06 CSEW. However, despite this long-term downward trend, amphetamine remains 
one of the most commonly reported stimulants in surveys (0.6% in the 2015/16 CSEW; 0.6% 
in the 2014/15 SCJS; and 0.5% in the 2014/15 Northern Irish prevalence survey) (Home Office, 
2016a; National Advisory Committee on Drugs and Alcohol (NACDA) & Department of Health 
Northern Ireland, 2016; Scottish Government, 2016c). Although amphetamine prevalence is 
lower than that of ecstasy, the overall number of amphetamine seizures in the UK is roughly 
twice that of ecstasy (see section 9.5.1). This may indicate that amphetamine users are more 
likely to come into contact with police, higher levels of consumption of amphetamine and/or that 
amphetamine users (like crack and heroin users) are less well represented in household surveys 
than users of other drugs.
1.3.4 Methamphetamine
Prevalence of methamphetamine use is low in the UK. Its use is mostly associated with men 
who have sex with men (MSM) involved in chemsex, and in these instances it is often used 
alongside mephedrone and GHB/GBL. Injecting and other risky behaviours are high among this 
group, making this an area for concern (see sections 7.3.1 and 7.6.3). Methamphetamine purity 
is high compared to that of the more commonly used stimulants (around 74% at street level 
compared with 44% for powder cocaine (personal communication – National Crime Agency)). 
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1.3.5 Mephedrone
Mephedrone is the only stimulant NPS to have become established alongside traditional 
substances among recreational drug users within the general population. However, prevalence 
has fallen since being controlled in 2010. Having been 1.3% (akin to ecstasy) in the 2010/11 
CSEW (the first year for which mephedrone prevalence was collected on the CSEW), last year 
use of mephedrone stood at 0.3% in England and Wales in 2015/16 (Home Office, 2016a). 
Last year prevalence of mephedrone in Scotland was reported at 0.3% in 2014/15 (Scottish 
Government, 2016c). Last year prevalence of mephedrone in Northern Ireland was double the 
level seen in the rest of the UK, at 0.6% in 2014/15 (National Advisory Committee on Drugs 
and Alcohol (NACDA) & Department of Health Northern Ireland, 2016). Like ecstasy, the age 
distribution of mephedrone users is younger than that of either cocaine or amphetamine. 
Use of mephedrone is of concern among specific groups such as injecting problematic drug 
users (particularly in Wales) and MSM due to its association with chemsex. 
Data from the European Drug Emergencies Network (Euro-DEN), set up to collect data on 
patients presenting to emergency departments (EDs) with toxicity caused by drugs of misuse, 
showed that between October 2013 and September 2014 mephedrone was involved in 
176 presentations to three EDs in the UK (two in London; one in York). This accounted for 11% 
of the total of 1,580 presentations to these centres (Dines et al., 2015). Of the 13 other EDs 
included in the study, only Dublin and Gdansk showed similarly high rates of presentations for 
mephedrone. 
1.4 Heroin/‘high risk drug use’ and other opioids
1.4.1 Heroin and ‘high risk drug users’
Heroin
Heroin is the most commonly used illicit opioid in the UK. While drugs such as cannabis, 
cocaine and ecstasy are used by a larger proportion of the population, heroin is associated 
with causing the most health and social harm to users as well as harms to society in the form of 
drug-related crime. As such, heroin is of key importance to policy-makers in the UK. 
Heroin users make up the majority of the population receiving structured drug treatment (see 
section 4.4.3). Of the 59,763 individuals presenting for treatment in 2015 citing an opioid as their 
primary problem substance, 85% cited heroin. Of the entire presenting population (n=124,234), 
heroin was cited as a secondary drug in just two per cent of cases, indicating that heroin is 
almost always seen as the most problematic substance for those who use it.
The number of people using heroin rose considerably during the 1980s and 1990s, and many 
of those still using the drug started using around this time with fewer starting since. As such, the 
cohort of heroin users is ageing. Since 2003/04 the percentage of primary heroin users entering 
treatment who were over the age of 40 years has more than trebled, increasing from 10% to 
35% in 2015 (see section 4.4.3).
Supply indicators suggest there was a lull in heroin availability from late 2010 through to 2012, 
with falls also seen in drug-related deaths and treatment presentations during this period. 
Heroin-related deaths have now surpassed levels seen before the heroin shortage and are at 
an all-time high (see section 6.4.1). The ageing cohort of heroin users is thought to be a factor 
behind the long-term upward trend in deaths. The median age of those dying from a drug-
related death has also risen. 
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High risk drug use estimates
Due to the association between illicit opioid use and both individual and societal harms, 
estimating the size of the problem opioid using population is a key element of the evidence 
base used to formulate policy and inform service provision. However, due to their often chaotic 
lives, problem opioid users are heavily underrepresented in household surveys (Home Office, 
2016a). As such, England, Scotland and Wales all commission regular indirect estimates of 
their problem drug using populations and they each include problem opioid users within their 
definitions. While none of the studies include estimates of the number of users of specific 
opioids, based on the methods used, the target populations are made up principally of current 
heroin users as well as former users who are successfully managing their problem through 
opioid substitution treatment (OST).
Estimates of problem drug use (PDU) in the UK are derived using two indirect measurement 
techniques: the capture-recapture method; and the multiple-indicator method. In England, 
estimates are produced for opioid and/or crack cocaine users (together and separately) and 
injecting among users of those drugs. In Scotland, PDU refers to the problematic use of opioids 
and/or the illicit use of benzodiazepines and drug injecting. Wales have commissioned a new 
suite of estimates over 11 years with an expanded scope; the last published estimates look at 
injecting drug use or long duration/regular use of opioids, cocaine and/or amphetamines. The 
last estimates in Northern Ireland covered 2004 and estimated high risk opioid and/or problem 
cocaine powder use.
In England, the latest estimates are for 2011/12 (Hay et al., 2014); in Scotland, 2012/13 (Information 
Services Division, 2014a); and in Wales, for 2014/15 (Public Health Wales, 2015). The estimates 
of the numbers of high risk drug users in each country are shown in Table 1.1.
Table 1.1: The estimated number of high risk drug users in Great Britain: number and rate per 
1,000 population aged 15 to 64, by country
Country Year Estimate 95% Confidence Interval Rate
95% Confidence 
Interval
England 2011/12 293,879 291,029 302,146 8.40 8.32 8.63
Scotland 2012/13 61,500 59,900 63,300 17.4 16.9 17.9
Wales 2014/15 58,186 53,104 63,507 – – –
Source: (Hay et al., 2014; Information Services Division, 2014a; Public Health Wales, 2015)
1.4.2 Diversion of opioid substitution treatment medications
Medications prescribed in OST are sometimes diverted from the treatment system and, as 
such, methadone and buprenorphine also form part of the range of drugs used illicitly by the 
problem opioid using population. Supervised consumption, the need for which is determined 
in accordance with clinical guidelines (Department of Health England and the devolved 
administrations, 2007), was introduced in the late 1990s and is an effective way of reducing 
diversion (Strang, 2010). Given both the source of supply and the population at risk of abusing 
them, diverted OST medications may be considered an adjunctive issue to the heroin problem.
Drug-related deaths figures from England, Scotland and Wales suggest there may have been 
an increase in use of diverted methadone during the ‘heroin drought’. This is in contrast to 
the drop in numbers accessing the treatment system over this period being prescribed this 
substance legitimately (Home Office, 2015a).
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1.4.3 Misuse of prescribed opioids
The misuse of opioids prescribed for pain–relief (for example tramadol and codeine) among the 
general population is a concern, particularly given the increasing practice of prescribing such 
medicines; however, the UK does not have a problem similar in scale to that of the USA.3 While 
7.4% of respondents to the CSEW in 2015/16 reported non-prescribed use of prescription only 
pain-killers, only 0.2% had done so for the feeling it gave (as opposed to having done so for 
medical reasons) (Home Office, 2016a). Although the number of tramadol-related deaths has 
risen substantially in recent years, the inclusion of such cases in official drug misuse death 
statistics is due to the definition used for these statistics which counts any death involving a 
substance controlled under the Misuse of Drugs Act 1971 (see section 6.4).
1.5 New psychoactive substances and other drugs
1.5.1 Prevalence of new psychoactive substances
Data from the 2015/16 CSEW shows that 2.7% of 16-59 year-olds in England and Wales reported 
ever taking an NPS, with 0.7% of 16-59 year-olds reporting having used an NPS in the past year 
(Home Office, 2016a). Those who reported use of an NPS in the last year had most commonly 
used a herbal smoking mixture (52%); one-fifth had used a powder, crystals or tablets (22%); 
three per cent had used a liquid; and 22% had used another type of substance. 
Prevalence of NPS use among the general population in Scotland and Northern Ireland is slightly 
lower than that seen in England and Wales. In 2014/15, 2.2% of adults aged 15-64 in Northern 
Ireland reported ever using an NPS (excluding mephedrone), and 0.3% reported last year use, 
compared to 2.8% and 0.8%, respectively, in England and Wales in the same year (Home 
Office, 2015a; National Advisory Committee on Drugs and Alcohol (NACDA) & Department of 
Health Northern Ireland, 2016). The SCJS in 2014/15 found that 1.6% of adults aged 16 and 
over had ever used an NPS or ‘legal high’, and 0.4% had used one of these substances in the 
last year (Scottish Government, 2016c). 
1.5.2 Synthetic cannabinoids
Prevalence of synthetic cannabinoids
When the CSEW asked about last year use of ‘Spice’ and other SCRAs in 2011/12, prevalence 
was low at 0.1% (Home Office, 2012). Although ‘Spice’ has been removed from the CSEW, 
respondents who report having used an NPS (0.7% of adults) are also asked what type of 
product they used on the last occasion. Over half (52%) of last year NPS users in 2015/16 
reported that the NPS they had last used was a herbal smoking mixture (Home Office, 2016a).
As with heroin use (see section 1.4.1), SCRA prevalence may be underestimated by household 
surveys such as the CSEW, as use of these substances is believed to be particularly high among 
homeless and vulnerable people, as well as those in prison (see section 5.4.2). In Scotland, a 
recent survey attempted to establish the level of use of NPS among a number of vulnerable 
or potentially at risk groups, including people who inject drugs, mental health service users, 
vulnerable young people, homeless people and MSM (Scottish Government, 2016e). SCRAs 
were the most commonly used type of NPS in the survey population alongside benzodiazepine-
type NPS (both used by 41% of users who had used NPS in the past six months). SCRA 
3 See: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/456464/ACMD_DISM_Interim_
Advice_-_Aug_15.pdf
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use was particularly high among those NPS users in contact with mental health services, and 
homeless people, vulnerable young people, and people who inject drugs.
SCRAs are rarely cited as problematic by those seeking help from specialist drug treatment 
services compared to traditional recreational drugs. Data from the English National Drug 
Treatment Monitoring System showed that 1,277 clients in treatment during 2015/16 cited either 
primary or adjunctive problematic use of SCRAs, whereas 59,918 cited cannabis (Public Health 
England, 2016a).
Problems associated with synthetic cannabinoids
Despite the apparent low prevalence of use and low treatment presentations, SCRAs have caused 
concern in the UK with regard to hospital presentations. The UK National Poisons Information 
Service (NPIS) provides advice to healthcare professionals on the clinical management of 
potentially poisoned patients via telephone enquiries from the healthcare workers, or via the 
online database TOXBASE. In 2014/15 SCRAs were the most enquired-about class of drugs 
of misuse to the NPIS, with 454 phone calls made to the service in this year, compared to the 
next most commonly enquired about substance, cocaine, with 164  calls (National Poisons 
Information Service, 2015). This represented a huge increase since 2011/12, when SCRAs were 
the 25th most common subject of telephone enquiries to the NPIS regarding drugs of misuse 
(National Poisons Information Service, 2012). 
The TOXBASE entry for SCRAs was the sixth most commonly accessed drug of misuse 
TOXBASE entry in 2015/16 with 4,770 accesses, an increase of 88% from 2,544 accesses 
in 2014/15 (National Poisons Information Service, 2016). This suggests that presentations to 
healthcare services by patients experiencing SCRA-induced toxicity are not uncommon. 
SCRAs have become an established drug within prisons in the UK. Recent reports have shown 
that 10% of prisoners surveyed in England and Wales, and nine per cent of prisoners in Scotland, 
had taken SCRAs while in prison (Her Majesty’s Inspectorate of Prisons, 2015; Scottish Prison 
Service, 2015a) (see section 5.4.2). There have been many reports of issues stemming from 
heavy use of SCRAs in prisons, including health effects, debt, violence, bullying, self-harm, 
suicide and death (see section 5.5.1). 
1.5.3 Synthetic cathinones
Mephedrone is the most established and prevalent synthetic cathinone in the UK, and is the 
only one specifically asked about on any of the GPS. Last year prevalence of mephedrone use 
in the latest CSEW (2015/16) was 0.3%, which is the same level reported in the latest SCJS 
(2014/15) (see section 1.3.5). 
In Northern Ireland, 2.6% of clients presenting to treatment reported primary synthetic cathinone 
use in 2015; in England, this proportion was 1.4%. The proportion of synthetic cathinone 
clients presenting to treatment in Northern Ireland in 2015 was more than double that of 
crack, amphetamines, methamphetamines and MDMA combined (see accompanying table 
Treatment 1).
1.5.4 Nitrous oxide 
In recent years, use of nitrous oxide has increased in the UK, in particular among young people. 
In the 2013/14 CSEW, 2.3% of 16-59 year-olds and 7.6% of 16-24 year-olds reported using 
nitrous oxide in the past year (Home Office, 2014). Nitrous oxide use appears to be less common 
in Scotland, with 0.5% of adults aged 16 and over reporting use of this gas in the last year 
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(Scottish Government, 2016c). Among the UK respondents to the 2016 GDS, 34% reported 
that they had used nitrous oxide in the past year, with 48% of UK clubbers reporting last year 
use (up from 34% in 2014) (Global Drug Survey, 2016). This made nitrous oxide, according to 
the GDS, the fourth most common drug used by clubbers in the UK (excluding alcohol, tobacco 
and caffeine). 
1.5.5 GHB/GBL
Prevalence of GHB/GBL use was first asked about in the CSEW in 2009/10, and was removed 
from the CSEW in 2012/13 (Home Office, 2013). Prevalence has been low among all respondents 
to the CSEW, with the overall last year use recorded as between 0.0% and 0.1% in the 2009/10, 
2010/11 and 2011/12 surveys (when GHB/GBL was included in the CSEW) (Home Office, 2010a, 
2012). However, use of GHB/GBL is believed to be higher among MSM, who use this substance 
during chemsex (Abdulrahim, Whiteley, Moncrieff, & Bowden-Jones, 2016).
Data from Euro-DEN suggests that London has greater use of GHB/GBL than other European 
cities included in the study (Dines et al., 2015). Of the 711 GHB/GBL presentations to the 
16 participating EDs across Europe between October 2013 and September 2014, more than 
half (380; 53%) were to St Thomas’ Hospital or King’s College Hospital in London. GHB/GBL 
was the most common drug seen on presentation to St Thomas’ Hospital, and was involved 
in almost one-third of all drug-related presentations to this ED (293/956; 31%). By comparison, 
GHB/GBL was not seen in any of the 202 presentations to York Hospital.
Deaths involving GHB/GBL in England and Wales increased in the late 2000s, going from four 
deaths in 2005 to 20 deaths in 2008. However, the number of deaths has fluctuated around 20 
in the years since. There were 26 deaths where GHB was recorded on the death certificate in 
2015 (Office for National Statistics, 2016c).
1.5.6 Image and performance enhancing drugs
Limited information exists regarding the prevalence of image and performance enhancing drugs 
(IPEDs). The latest CSEW estimated that in 2015/16 lifetime prevalence among 16-59 year-olds 
was 0.8%, a slight decrease from 2014/15, with last year prevalence at 0.2%, the same as 
2014/15 (Home Office, 2016a). IPED use was less prevalent in the 16-24 age group, with lifetime 
and last year prevalence at 0.7% and 0.1%, respectively, among these respondents.
1.6 Drug use in the school population
1.6.1 Scottish Schools Adolescent Lifestyle and Substance Use Survey
The Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) was last 
carried out in 2015 and results were published in October 2016 (Scottish Government, 2016d). 
Following long-term decreases in lifetime and last month use of drugs by both 13-year-olds and 
15-year-olds, there were small increases in use reported in the 2015 SALSUS (see Figure 1.6). 
Eleven per cent of 15-year-olds and three per cent of 13-year-olds stated they had used drugs 
in the month prior to the survey, with 19% of 15-year-olds and five per cent of 13-year-olds 
reporting lifetime use. Cannabis was the most commonly reported drug, used by 17% of 
15-year-olds ever and 10% in the past month. Ecstasy and NPS had ever been used by five 
per cent of 15-year-old respondents (three per cent and two per cent, respectively, in the past 
month); cocaine had been used by four per cent of 15-year-olds in their lifetime (two per cent 
in the past month).
Overview of illicit drug use in the UK
13
Figure 1.6: Percentage of 13-year-olds and 15-year-olds reporting last month and lifetime 
use of drugs in the Scottish Schools Adolescent Lifestyle and Substance Use Survey, 
1998 to 2015
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Source: (Information Services Division, 2014b; Scottish Government, 2016d)
1.6.2 Smoking, drinking and drug use amongst young people in England
Data from the Smoking, drinking and drug use among young people in England survey (SDD) 
showed that the prevalence of drug use among 11 to 15 year-olds in England is continuing to 
decline, although at a slower rate than in the period between 2001 and 2010 (see Figure 1.7) 
(Health and Social Care Information Centre, 2015).
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Figure 1.7: Percentage of pupils aged 11 to 15 years who have taken drugs ever, in the last 
year and in the last month, 2001-2014
 
Ever taken drugs Taken drugs in the last year
Taken drugs in the last month
0%
5%
10%
15%
20%
25%
30%
35%
20
06
20
04
20
03
20
02
20
01
20
05
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
Source: (Health and Social Care Information Centre, 2015)
In 2014, 15% of pupils aged 11 to 15 years old had ever taken drugs, 10% had used drugs in 
the last year (recently), and 6.1% had used drugs in the last month. Cannabis was the most 
prevalent drug, with 6.7% of pupils using it in the last year. Volatile substances4 were the second 
most common, with 2.9% of pupils having used them recently. 
The proportion of pupils (aged 11-15) reporting use of stimulants in the last year has come down 
from 6.9% in 2007 to 2.1% in 2014. The decline in prevalence rates over this period was most 
prominent for poppers which had been the most commonly reported stimulant in the SDD in 
2007, with 4.9% reporting use in the last 12 months compared with 1.8% for cocaine (the next 
most prevalent stimulant) (Health and Social Care Information Centre, 2015). Only 0.7% reported 
using poppers in the last 12 months in the 2014 SDD compared with 0.9% reporting cocaine.
4 Glue, gas, aerosols or solvents.
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2 Drug policy 
2.1 Introduction
The UK government is responsible for setting the overall strategic approach to reducing drug 
harms and for its delivery in the devolved administrations in matters where it has reserved 
power. As such, policies concerning health, education, housing and social care are confined to 
England; those for policing and the criminal justice system cover England and Wales; and the 
work of the Department for Work and Pensions (DWP) applies to England, Scotland and Wales. 
The Drug Strategy 2010, Reducing demand, restricting supply, building recovery: supporting 
people to live a drug-free life (Her Majesty’s Government, 2010) emphasises supporting those 
who are drug dependent to achieve recovery and includes dependence to prescription and 
over the counter medicines as well as tackling new psychoactive substances (NPS). In addition 
to the drug strategy produced by the UK government, each of the devolved administrations 
has produced their own drug strategy, which reflects their ideology and the devolution of 
responsibilities to the national government.
The Scottish government and Welsh government’s national drug strategies were published in 
2008 (Scottish Government, 2008d; Welsh Assembly Government, 2008a), the latter combining 
drugs, alcohol, and addiction to prescription drugs and over the counter medicines. Each 
strategy aims to make further progress on reducing harm and helping individuals recover from 
their drug problems. The Scottish and Welsh strategy documents are also accompanied by an 
action or implementation plan, providing a detailed set of objectives, actions and responsibilities, 
expected outcomes, and a corresponding timescale for delivery (Scottish Government, 2008d; 
Welsh Assembly Government, 2008b). 
Northern Ireland’s strategy for reducing the harm related to alcohol and drug misuse, the New 
Strategic Direction for Alcohol and Drugs (NSD), was launched in 2006 (Department of Health 
Northern Ireland, 2006). The strategy contained actions and outcomes, at both regional and 
local level, to achieve its overarching aims. A review of the strategy was conducted in 2010, and, 
after consultation, a revised strategy, the New Strategic Direction for Alcohol and Drugs Phase 
2, 2011-2016, was launched in January 2012 (Department of Health Northern Ireland, 2011).
The drug strategies in Wales and Northern Ireland are underpinned by performance management 
frameworks, including Public Service Agreements and associated sets of performance 
indicators, against which progress is measured.
2.2 Current national drug strategies and action plans
A summary of the UK and devolved administrations’ drug strategies is given below. While none 
of these strategies have yet been formally evaluated, outlines of the most recent reviews have 
been included. 
2.2.1 United Kingdom
The UK Drug Strategy 2010, Reducing demand, restricting supply, building recovery: supporting 
people to live a drug free life (Her Majesty’s Government, 2010) was published in December 
2010. This strategy places greater emphasis than preceding strategies on supporting those 
United Kingdom Drug Situation 2016 – UK Focal Point on Drugs
16
who are drug dependent to achieve recovery and on the provision of the integrated support 
necessary to enable this, such as housing and employment. 
The 2010 drug strategy widened its focus to include dependence on all drugs, including 
prescription and over the counter drugs, as well as tackling the emergence of NPS. It highlighted 
a shift in responsibility away from central government to locally led treatment plans. New legal 
powers aimed at restricting the supply of drugs were also introduced, including Temporary 
Class Drug Orders for NPS (see section 8.2) and new powers to seize cutting agents and 
precursor chemicals. 
The Home Office currently leads on the implementation of the strategy within England, and with 
regard to reserved matters elsewhere. 
Drug strategy annual review 
In February 2015, the Home Office published the Drug Strategy Annual Review: A balanced 
approach (Home Office, 2015b), highlighting both key achievements and future priorities for all 
three strands of the drug strategy (reducing demand, restricting supply and building recovery). 
Key achievements included: 
 • the continued expansion of the Troubled Families programme (see section 3.5.2) 
 • the 2015 launch of the ‘Rise Above’ online resource (see section 3.4.1)
 • implementation of new legislation including the Serious Crime Act (Her Majesty’s 
Government, 2015c) and the introduction of a drug-driving offence
 • the addition of a new condition to the Public Health Grant to encourage local authorities 
(LAs) to invest in the provision of high quality drug and alcohol treatment services
 • the provision of £5 million to the Health Premium Incentive Scheme for 2015/16, to 
be distributed to LAs who can show a two per cent improvement in the number of 
successful completions for treatment 
The review also included progress made towards meeting other potential needs of those in 
treatment for substance misuse, such as statutory guidance on social housing and improvement 
of training packages at Jobcentre Plus. 
Recommendations/priorities cited for the next year included: 
 • the promotion of evidence-based practice in schools, the continuation of funding 
for the Alcohol and Drug Education and Prevention Information Service (ADEPIS) 
and addressing wider aspects associated with potential substance misuse such as 
reducing the number of youths who are not in education, employment or training
 • increased collaboration between police, festival organisers, night time economy 
stakeholders and LAs, the implementation of the National Institute for Health and Care 
Excellence (NICE) NSP guidance and the continued roll-out of Liaison and Diversion 
(L&D)5 schemes (see section 8.5.1)
5 L&D schemes are designed to identify, assess, screen and refer offenders who have mental health, learning disability, 
substance misuse or other vulnerabilities to an appropriate treatment or support service. See: https://www.england.
nhs.uk/commissioning/health-just/liaison-and-diversion/ld-about/ 
Drug policy
17
Future work will also include:
 • a crackdown on UK-based websites in violation of the Misuse of Drugs Act 1971 
(Her Majesty’s Government, 1971); and increased access to centralised data on drug 
testing on arrest to enable the identification of local trends.
2.2.2 Scotland
The Scottish government’s national long-term drug strategy, The Road to Recovery: A new 
approach to tackling Scotland’s drug problem, was published in 2008 (Scottish Government, 
2008d). Central to the strategy is the concept of recovery and supporting people to live a 
drug-free life as active and engaged members of society. It has received cross-party support 
from the Scottish Parliament. The strategy includes multiple objectives across five principal 
action areas: promoting recovery; delivering the recovery model; prevention; enforcement; and 
children affected by substance misusing families. 
The key priorities of the strategy are:
 • better prevention of drug problems, with improved life chances for children and young 
people, especially those at particular risk of developing a drug problem, allowing them 
to realise their full potential in all areas of life
 • to see more people recover from problem drug use so that they can live longer, 
healthier lives, realising their potential and making a positive contribution to society and 
the economy
 • having communities that are safer and stronger places to live and work because crime, 
disorder and danger related to drug use have been reduced
 • ensuring that children affected by parental drug problems are safer and more able to 
achieve their potential
 • improving the effectiveness of delivery at a national and local level
To help achieve these priorities, the Scottish government has developed an alcohol and drugs 
quality improvement framework to ensure quality in the provision of care, treatment and recovery 
services, as well as quality in the data that will show the outcomes people are achieving (Scottish 
Government, 2014) (see section 4.2.2).
In Scotland, the 2015/16 Updated Guidance for Alcohol and Drug Partnerships (ADPs) on 
Planning and Reporting Arrangements (Scottish Government, 2015b) identifies nationally 
agreed core outcomes and indicators that all ADPs are expected to deliver against. The Scottish 
government has developed a Recovery Outcomes Web tool, which will form part of the new 
national Drug & Alcohol Information System (DAISy), which aims to support the tracking of 
progress towards recovery for individuals in drug (and alcohol) services. 
2.2.3 Wales
The Welsh government also published its long term substance misuse strategy, Working 
together to reduce harm 2008-2018, in 2008 (Welsh Assembly Government, 2008a). The 
strategy combines drugs, alcohol, and addiction to prescription drugs and over the counter 
medications. It has a clear focus on reducing the harms associated with substance misuse, 
citing its four aims as:
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 • reducing the harm to individuals (particularly young people), their families and wider 
communities from the misuse of drugs and alcohol, while not stigmatising substance 
misuse
 • improving the availability and quality of education, prevention and treatment services 
and related support, with a greater priority given than under the previous strategy to 
those related to alcohol
 • making better use of resources – supporting evidence based decision making, 
improving treatment outcomes, developing the skills base of partners and service 
providers by giving a greater focus to workforce development and joining up agencies 
and services more effectively
 • embedding the core Welsh Assembly government values of sustainability, equality and 
diversity, support for the Welsh language, and developing user-focused services and a 
rights base for children and young people in both the development and delivery of the 
strategy
Since the launch of the strategy several accompanying shorter term delivery plans have also been 
published, most recently the Substance misuse delivery plan 2016-2018 (Welsh Government, 
2016). These delivery plans set out performance measures for each of the strategy’s key action 
areas: preventing harm; supporting substance misusers to improve their health and aid and 
maintain recovery; supporting and protecting families; and tackling availability and protecting 
individuals and communities via enforcement activity. Progress of the delivery plan is monitored 
through an internal cross-government Substance Misuse Programme Board and an external 
Substance Misuse National Partnership Board which meets three times a year. The current 
plan highlights the importance of the substance misuse agenda in relation to the Well-Being 
of Future Generations (Wales) Act 2015 (National Assembly for Wales, 2015). There is also a 
greater emphasis on prevention and early intervention. 
2.2.4 Northern Ireland
Northern Ireland’s strategy, the New Strategic Direction for Alcohol and Drugs (Department 
of Health Northern Ireland, 2006), was launched in 2006 with a focus on reducing the harms 
related to alcohol and drug misuse. The NSD emphasised five supporting pillars for the strategy: 
prevention and early intervention; treatment and support; law and criminal justice; harm reduction 
and monitoring; and evaluation and research. It identified two themes: children, young people 
and families; and adults, carers and the general public, to be addressed across the five pillars 
as well as the three cross-sectional threads of workforce development, stakeholder involvement 
and vulnerable groups to run throughout the strategy.
The strategy was reviewed and revised before being relaunched in 2011 as the New Strategic 
Direction for Alcohol and Drugs Phase 2, 2011-2016 (Department of Health Northern Ireland, 2011). 
A number of key priorities were identified including: 
 • developing a regional commissioning framework for treatment
 • targeting those at risk and vulnerable
 • alcohol and drug-related crime including anti-social behaviour and tackling underage 
drinking
 • reduced availability of illicit drugs
 • addressing community issues
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 • promoting good practice in respect of alcohol and drug-related education and 
prevention
 • developing harm reduction approaches
 • workforce development
In July 2016 the fourth annual report of progress towards outcomes contained within the 
drug strategy was published, showing that the majority of the 141 outcomes are on track for 
achievement within the timescale expected (Department of Health Northern Ireland, 2016a).6 
It is anticipated that a final review and evaluation of NSD Phase 2 will be conducted in 2017 with 
consideration being given to developing a new strategy after this. The ongoing development 
and implementation of the drug strategy is overseen by the NSD Steering Group.
2.3 Drug policy co-ordination
2.3.1 England
Figure 2.1 shows a summary graphic of drug treatment commissioning bodies in England.
Inter-Ministerial Group on Drugs
The Inter-Ministerial Group on Drugs, chaired by the Home Office, includes ministerial 
representation from across several key government departments and oversees the delivery of 
the UK drug strategy.
Home Office 
The Home Office has lead responsibility for the co-ordination of the delivery of the UK drug 
strategy on behalf of the government, and publishes annual reviews detailing the progress made 
towards the strategy’s objectives. The Home Office is supported by various departments and 
organisations including the DWP, Department of Health (DH), the Department for Communities 
and Local Government, the Department for Education (DfE), the National Crime Agency (NCA) 
and the Ministry of Justice (MoJ).
Advisory Council on the Misuse of Drugs 
The Advisory Council on the Misuse of Drugs (ACMD) is an independent expert body responsible 
for, among other things, making recommendations on the control of dangerous or otherwise 
harmful drugs, including classifications and scheduling under the Misuse of Drugs Act 1971, 
and carrying out in-depth inquiries which focus on emerging threats and challenges that are 
causing concern. 
6 These include outcomes relating to both drugs and alcohol
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Figure 2.1: Commissioning structure for drug treatment in England
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National Crime Agency
The NCA is a non-ministerial government department, accountable to the Home Secretary. 
They work with the police, Border Force and international collaborators to lead the UK law 
enforcement’s fight to cut serious and organised crime, including restricting the supply of drugs 
into the UK. 
Local authorities
LAs are accountable for meeting the needs of their local drug using population under the Health 
and Social Care Act 2012 (Her Majesty’s Government, 2012b). This includes tendering and 
commissioning the drug and alcohol treatment services they feel will provide the most suitable 
support for the needs of their constituents. The director of public health (DPH) is appointed 
jointly by Public Health England (PHE) and the LA, and as officer champion for health within 
each upper tier and unitary authority has the responsibility of delivering public health outcomes 
in their local area. 
Health and wellbeing boards 
Health and wellbeing boards (HWB) were established under the Health and Social Care Act 
2012 (Her Majesty’s Government, 2012b) and assumed responsibility for providing the overall 
strategic direction for improving wellbeing in their area. There are a number of statutory members 
each HWB must contain, including: at least one local elected representative; a Healthwatch 
representative; a representative of each local clinical commissioning group (CCG); the LA 
director for adult social services; the LA director for children’s services; and the LA DPH.
Each HWB is required to produce a Joint Strategic Needs Assessment which outlines the 
current and future health and social care needs of their area, and a plan to meet these needs 
in the Joint Health and Wellbeing Strategy.
Healthwatch
Local Healthwatch organisations are commissioned directly by LAs and together with the 
nationally-focused Healthwatch England form the Healthwatch network. Their role is to represent 
the users of health and care services at the HWB, providing feedback to service providers and 
commissioners on how and why people use local services and their experience when doing so. 
Department of Health
The DH is responsible for developing the statute and policy underpinning the health and care 
system. It leads on the ‘Building Recovery’ strand and jointly manages the ‘Reducing Demand’ 
strand of the 2010 strategy with the Home Office. It is supported by key agencies such as NHS 
England, the Care Quality Commission (CQC) and PHE.
NHS England
NHS England is involved in the provision of pharmacological treatments including opioid 
substitution therapy; the implementation of L&D programmes; and is responsible for 
commissioning health services within prisons, including drug and alcohol treatment services. 
NHS England also oversees CCGs, which are clinically led groups that commission local 
healthcare services within their geographical boundaries. CCGs do not commission drug and 
alcohol treatment services directly, although it is mandatory that a representative from the local 
CCG sits on each HWB. 
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Public Health England 
PHE is an executive agency of the DH. PHE supports LAs to commission and deliver alcohol 
and drug services by providing evidence-based guidance and advice, and by collating and 
analysing alcohol and drug treatment performance data via the National Drug Treatment 
Monitoring System. 
Care Quality Commission 
The CQC is an independent body charged with monitoring, inspecting and regulating health 
and social care services in England. Services must be registered with the CQC who then 
ensures that they are meeting core standards of care (see section 4.2.2). 
National Institute for Health and Care Excellence 
NICE is an executive non-departmental public body of the DH. Their role is to develop guidance, 
standards and information to improve health and social care. NICE directions are used by 
the NHS, LAs and anyone else involved in the delivering of care. NICE products are based 
on the best available evidence and are developed by multi-disciplinary teams of healthcare 
professionals and consumers or guideline development groups with particular expertise or 
experience in the topic. 
Ministry of Justice 
The MoJ is charged with protecting the public, reducing offending and overseeing courts, 
prisons, probation services and the secure youth estate. They are therefore involved in the 
hearing of criminal cases concerning drug-related offences and the rehabilitation of offenders. 
National Offender Management Service
The National Offender Management Service (NOMS) is an executive agency sponsored by 
the MoJ. Through Her Majesty’s Prison Service and the National Probation Service, NOMS is 
accountable for ensuring that both prison and community sentences in England and Wales are 
carried out. 
The National Partnership Agreement for the Co-Commissioning and Delivery of Healthcare in 
Prisons in England (NHS England, Public Health England, & National Offender Management 
Service, 2015), is a tripartite agreement between NHS England, NOMS and PHE, which sets out 
respective roles for the co-commissioning and delivery of services in England (see section 5.3.2). 
Department for Work and Pensions
Given the emphasis placed in the drug strategy on integrated working, the DWP plays an 
important role in ensuring that those accessing treatment are receiving the full range of benefits 
which they are entitled to and supporting those recovering from addiction back into work. 
Universal Credit7 is currently being rolled out across the UK, and is a new single payment for 
people who are looking for work or on a low income, which brings together a range of working-
age benefits into a single payment, replacing the employment benefits, income support benefit, 
tax credits and housing benefit.
7 As part of Universal Credit, the Department for Work and Pensions introduced ‘tailored conditionality’ where work 
search and work availability requirements can be suspended for a period of up to six months in any 12 month period 
for claimants actively participating in structured recovery-orientated treatment. This is to give claimants the time and 
space to engage in treatment, and begin their recovery journey. After the end of the period of ‘tailored conditionality’, 
on-going treatment commitments are still taken into account when an individual is looking for employment. This is 
recognised as a critical step in enabling people with dependencies to become ready for sustainable employment.
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Department for Communities and Local Government
The DCLG supports local governments to help ensure that their areas are working efficiently 
and effectively. They publish annual reports based on fiscal data provided by LAs on their 
revenue expenditure and financing, including that spent under the Public Health Grant. 
Department for Education 
The DfE is responsible for education and children’s services in England. In 2013 drug education 
became a statutory part of the science curriculum for schools in England.
2.3.2 Scotland
See Figure 2.2 for an accompanying summary structure graphic.
Figure 2.2: Overview of planning and reporting arrangements for Alcohol and Drug 
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Scottish government 
The Scottish government has devolved powers for policies concerning health, education, 
housing, social care, policing and the criminal justice system. It provides annual funding, in the 
region of £70 million, across drugs and alcohol to the ADPs, via NHS Boards, to enable them 
to implement their local delivery plans (LDPs). LDPs are guided by ministerial priorities and ADP 
core outcomes, informed by a robust assessment of local need and developed and delivered 
in line with the recognised evidence base. 
In April 2016 responsibility for drugs policy in Scotland transferred from the Justice portfolio 
to the Health portfolio. At the same time, the Drugs Policy Unit also took on responsibility for 
alcohol interests for ADPs, and has since been renamed the Substance Misuse Unit. 
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Convention of Scottish Local Authorities
The Convention of Scottish Local Authorities represents local governments in Scotland and 
was involved, along with NHS Scotland and the Scottish government, in producing the updated 
guidance for ADPs.
Alcohol and Drug Partnerships
There are 30 ADPs in Scotland and each is responsible for designing and implementing a 
comprehensive evidence-based local alcohol and drug strategy, as well as for the commissioning 
of treatment services most suitable for their local resident population. The partnerships include 
representatives from local NHS Boards, LAs and other key partners such as Police Scotland, 
the Scottish Prison Service, Housing and Social Services. 
Community Planning Partnerships 
The Community Planning Partnerships hold the ADPs to account and are involved in the 
generation of Single Outcome Agreements. 
NHS boards 
NHS boards develop annual LDPs which contain designated Health improvement, Efficiency 
and Access Treatment (HEAT) targets, including those relating to drugs and alcohol, and 
strategies for how they will be achieved. For 2015/16 the HEAT targets for drugs and alcohol 
(around reducing waiting times to treatment and delivery of Alcohol Brief Interventions) have 
evolved to become LDP Standard to support sustained performance. 
Information Services Division 
The Information Services Division (ISD) is part of NHS Scotland and provides health data, 
information and advice services, enabling NHS Scotland to make informed decisions regarding 
health and care facilities. The Scottish government has commissioned ISD to lead on the 
development of the new national combined drugs and alcohol data system, DAISy, which will 
eventually replace the current Scottish Drug Misuse Database.
Partnership for Action on Drugs in Scotland 
The Partnership for Action on Drugs in Scotland, which replaces the work of the former Drug 
Strategy Delivery Commission, advises, leads, and collaborates with partners, directly delivering 
on areas of work including: harm reduction and drug deaths; quality of standards; education 
and prevention; communities and stigma; and research.
2.3.3 Wales 
See Figure 2.3 for an accompanying summary structure graphic.
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Figure 2.3: Commissioning and reporting structure of substance misuse services in Wales 
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Welsh government 
The Welsh government has devolved powers for policies concerning health, education, housing 
and social care.
Substance Misuse National Partnership Board
The role of the Substance Misuse National Partnership Board is to guide and monitor progress 
and to facilitate co-ordination between the Welsh government, statutory agencies and the third 
and independent sectors. 
Community Safety Partnerships 
Established in each of the 22 LA areas with the aim to reduce substance misuse and crime, 
Community Safety Partnerships contain representatives from local stakeholders including the 
police, LAs, the NHS, fire and rescue services and voluntary organisations. They are responsible 
for the commissioning and delivery of substance misuse services in their area.
Area Planning Boards 
Seven Area Planning Boards (APBs) support the planning, commissioning and performance 
management of substance misuse services at a regional level. The boards include representatives 
from local health boards, LAs, police, prison, probation, housing, social services, service 
providers and service users.
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Local health boards 
Local health boards commission healthcare services in public sector prisons, including drug 
treatment services. 
Advisory Panel on Substance Misuse
The Advisory Panel on Substance Misuse is a Welsh government-sponsored body established 
under general executive powers of the Welsh Ministers. The panel is an independent expert 
advisory body whose remit is to advise the Minister on measures to prevent or reduce substance 
misuse and the associated health and social harms.
2.3.4 Northern Ireland
See Figure 2.4 for an accompanying summary structure graphic. 
Figure 2.4: Commissioning and reporting structure of substance misuse services in 
Northern Ireland
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Department of Health 
The Northern Ireland Department of Health (DoH) was responsible for the development and 
launch of the Northern Ireland drug strategies in 2006 and 2011, and will be responsible for the 
evaluation of the strategy. 
Public Health Agency 
The Public Health Agency (PHA) provides expert advice and commissions a range of alcohol 
and drug services under the NSD Phase 2. They also support the work of the Drug and Alcohol 
Co-ordination Teams (DACTs). 
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New Strategic Direction Steering Group
Established in 2006, the NSD Steering Group is chaired by the Chief Medical Officer. Its primary 
role is to oversee the ongoing policy development, delivery of the strategy and the achievement 
of outcomes. The steering group includes all key government departments, including the 
Department of Justice and the Department for Communities, and ensures a cross-sectoral 
approach to developing policy and implementing the strategy. The group monitors progress 
towards NSD targets and outcomes.
Drug and Alcohol Co-ordination Teams 
DACTs generate local action plans and priorities to implement the drug strategy and guide the 
expenditure of PHA funding, including the commissioning of drug treatment services. They 
work closely with other local groups and partnerships, including Policing and Community Safety 
Partnerships.
2.4 Funding for drug treatment
2.4.1 England
LAs in England received a ring-fenced Public Health Grant of £3.4 billion for public health 
services in the 2016/17 financial year.8 Funding for drug and alcohol treatment is not ring-fenced 
within the Public Health Grant and expenditure on services is determined by an assessment of 
the local population’s needs by local HWBs. LAs are required to report their annual forecasted 
and actual expenditure on each public health intervention making up the grant. The categories 
for reporting this data include: adult drugs, adult alcohol and young people’s drug and alcohol 
spend. The public health grant for 2017/18 has been announced as £3.3 billion. From 2016/17 to 
2020/21, £16 billion will be invested to support LAs’ public health responsibilities which include 
prevention reduction and treatment for drugs, alcohol and tobacco.9
2.4.2 Scotland
The Scottish government has invested over £630 million to tackle problem alcohol and drug use 
since 2008, with £574 million of this funding being provided via NHS health boards to ADPs for 
investment in local prevention, treatment and recovery support services.
2.4.3 Wales
The Welsh government invests almost £50 million annually to deliver the commitments within its 
substance misuse strategy and its associated delivery plan (Welsh Government, 2016). As well 
as the £17.1 million ring-fenced funding within the health board budget for substance misuse 
services, the Substance Misuse Action Fund budget for 2014/15 stands at £32 million. Over 
£22 million of this funding goes directly to the seven APBs in Wales supporting a number of 
projects ranging from education and prevention to treatment services. 
8 See: https://www.gov.uk/government/publications/public-health-grants-to-local-authorities-2016-to-2017
9 See: http://www.parliament.uk/business/publications/written-questions-answers-statements/written-statement/
Lords/2016-12-15/HLWS360
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2.4.4 Northern Ireland
Expenditure on alcohol and drugs services has remained broadly consistent in Northern Ireland: 
around £8 million per year is allocated to the implementation of NSD Phase 2, and a further £8 
million is allocated to statutory addiction services through the mental health budget.
2.5 New developments
2.5.1 Psychoactive Substances Act 2016
The Psychoactive Substances Act 2016 (Her Majesty’s Government, 2016f) came into force on 
26 May 2016. It is now an offence to produce, supply, possess with intent to supply, import or 
export substances which cause a psychoactive effect in those who consume them. There are 
a number of exempt substances, including nicotine, alcohol, caffeine, drugs already controlled 
under the Misuse of Drugs Act 1971 and medicines as defined by the Human Medicines 
Regulations 2012 (see section 8.3.1). 
2.5.2 Public Health England inquiry into drug-related deaths
In September 2016 PHE published the report of an expert working group convened as part of 
an inquiry to investigate the causes of the recent rises in drug-related deaths (DRDs) in England, 
and what could be done to prevent future premature deaths (Public Health England, 2016i). 
The report includes some key principles, recommendations for action by national and local 
stakeholders who can directly impact on DRDs, and stresses the need for continued research 
and investigation to better understand DRDs and their prevention. PHE will provide additional 
drug-related deaths data to LAs to benchmark their performance and encourage improvement 
through the Public Health Outcomes Framework (see section 4.2.1).
2.5.3 Dame Carol Black review
In December 2016 An independent review into the impact on employment outcomes of drug or 
alcohol addiction, and obesity was published (Black, 2016). Chaired by Dame Carol Black, the 
review made a number of recommendations: that the measure of a client’s recovery includes 
work and meaningful activity alongside successful treatment completion; that the government 
trials Individual Placement and Support approaches for those receiving treatment; that 
Jobcentre Plus trials the use of peer mentors; and that the government develops guidance on 
best practice in recruiting alcohol- and drug-dependent people. Significantly, the review did not 
advocate the mandatory attendance at treatment services for people with substance misuse 
problems; rather it recommended that those making a claim should be required to attend a 
structured discussion with a healthcare professional on the impact of their health condition on 
their ability to work. 
2.5.4 Modern Crime Prevention Strategy
In March 2016, the Modern Crime Prevention Strategy was published (Home Office, 2016b), 
which aims to tackle six key drivers of crime, namely: opportunity; character; the effectiveness 
of the criminal justice system; profit; drugs; and alcohol. The strategy asserts that reducing 
drug-related crime should focus on three areas: treatment of users; preventing people from 
starting to use drugs in the first place; and enforcement of drug laws. A new drug strategy is 
due to be launched in 2017 which will build on these themes.
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3 Prevention
3.1 Introduction
The UK government’s Drug Strategy 2010 – Reducing demand, restricting supply, building 
recovery (Her Majesty’s Government, 2010) has been refreshed to mix universal actions aimed 
at all young people with targeted actions for those most at risk of using drugs or who have 
already started using drugs. It tackles the risk factors that make people vulnerable to substance 
misuse, which includes investing in a range of evidence-based programmes that have a positive 
impact on young people and adults, giving them the confidence, resilience and risk management 
skills to resist drug use.
Prevention initiatives are also covered in each of the drug strategies of the devolved 
administrations. In Wales this is through Rights of Children and Young Persons (Wales) Measure 
2011 (Welsh Government, 2011). The Welsh government in the Working Together to Reduce 
Harm Substance Misuse Strategy Annual Report – 2015 (Welsh Government, 2015b) also 
emphasises the importance of delivering prevention messages within the workplace, and 
that the early identification of young people at risk of engaging in risky behaviours can be an 
important aspect of prevention.
The Getting It Right For Every Child programme10 provides the methodology for delivering the 
Scottish government’s three social policy frameworks (the Early Years Framework; Achieving our 
Potential; and Equally Well (Scottish Government, 2008a, 2008b, 2008c)), which aim to develop 
the prevention and early intervention agenda. More recently updated practice guidance, Getting 
Our Priorities Right (Scottish Government, 2013), was developed for agencies and practitioners 
working with children, young people and families affected by substance use in Scotland.
In Northern Ireland, Our Children and Young People – Our Pledge: A 10 year strategy for children 
and young people in Northern Ireland, 2006-2016 (Office of the First Minister and Deputy First 
Minister for Northern Ireland, 2006) sets a framework for addressing the needs of young people. 
Improved education and early interventions for young people and families (especially those 
most at risk) and improved public information about drugs are priority areas. 
3.2 The evolution of prevention approaches
Evaluations of drug prevention programmes have shown that the impact of drug education 
alone is unlikely to prevent young people from using drugs, and that ‘scare’ approaches are 
likely to be ineffective, if not counterproductive. Therefore, in recent years the focus of prevention 
policy has shifted away from interventions aimed specifically at drugs, to strengthening general 
resilience factors with the aim of reducing the desire to explore risky behaviours including drug 
use (Faggiano, Minozzi, Versino, & Buscemi, 2014; James, 2011; UK Drug Policy Commission, 
2012). A stronger emphasis has also been put on the importance of parent/carers and 
family influence on children’s substance misuse and associated behaviours, and how early 
life interventions, which should include prenatal family support, can reduce risk factors and 
strengthen the associated protective factors. Such interventions can include parenting skills 
education, support to families from pregnancy, for example the Family Nurse Partnership 
(see section 3.5.2), and parent and family skills training such as the Strengthening Families 
Programme (UK Focal Point, 2014).
10 See: http://www.scotland.gov.uk/Topics/People/Young-People/gettingitright/publications/practice-guide 
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Modern education and prevention programmes take into account the concept that young 
people’s behaviour is affected by the perceived behaviour of their peers, in particular their 
tendency to overestimate the prevalence of risky behaviours among their peers. Therefore, 
providing them with information about the real prevalence of such risky behaviours might 
reduce their participation in such actions (such as the ‘social norm’ approach (Chowdry, Kelly, 
& Rasul, 2013)). Some of these programmes tend to focus on relationships between individual 
behaviours and a range of social and environmental influences they are subject to, and the inter-
relationship between individual behaviours as ‘lifestyles’. Such programmes put an emphasis 
on the need to communicate effectively with young people through a range of networks (such 
as web-based activity) and through the media, as well as through traditional school health 
education. These approaches have increasingly used social marketing methodologies, which 
advocate an integrated ‘whole person’ approach, to disseminate their message and to support 
behaviour change in young people.
3.3 Environmental prevention
Environmental prevention strategies aim to alter the immediate cultural, social, physical and 
economical environments in which people make their choices about drug use.
Across the UK there are a number of policies and strategy documents concerned with illicit and 
licit substances (such as tobacco and alcohol) (see Table 3.1). 
Table 3.1: United Kingdom strategy documents for alcohol, tobacco and illicit drugs
Country Substance(s) covered Reference
UK
Illicit drugs
The Drug Strategy 2010, ‘Reducing demand, restricting supply, 
building recovery: supporting people to live a drug-free life’ 
(Her Majesty’s Government, 2010)
Alcohol The Government’s Alcohol Strategy (Her Majesty’s Government, 2012a)
England Tobacco Healthy Lives, Healthy People: A Tobacco Control Plan for 
England (Her Majesty’s Government, 2011a)
Wales
Illicit drugs 
and alcohol 
Working Together to Reduce Harm: The Substance Misuse 
Strategy for Wales 2008-2018 (Welsh Assembly Government, 
2008a)
Tobacco Tobacco Control Action Plan for Wales (Welsh Government, 2012)
Scotland
Illicit drugs Road to Recovery: A New Approach to Tackling Scotland’s 
Drug Problem (Scottish Government, 2008d)
Alcohol
Changing Scotland’s Relationship with Alcohol: A Framework 
for Action (Scottish Government, 2009a)
Changing Scotland’s Relationship with Alcohol: A Framework 
for Action – Progress Report (Scottish Government, 2012)
Tobacco Scotland’s Future is Drug Free: A Smoking Prevention Action 
Plan (Scottish Government, 2008e)
Northern 
Ireland
Illicit drugs 
and alcohol
New Strategic Direction for Alcohol and Drugs Phase 2 
2011-2016 (Department of Health Northern Ireland, 2011)
Tobacco Ten-Year Tobacco Control Study of Northern Ireland (Department of Health Northern Ireland, 2012)
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3.3.1 Legislation 
Drug driving legislation 
England and Wales
In March 2015 levels for the maximum blood concentration allowed for a selection of legal and 
illegal drugs for drivers were introduced in England and Wales under the Drug Driving (Specified 
Limits) (England and Wales) Regulations 2014 (Her Majesty’s Government, 2014a). Limits are 
specified for eight illicit drugs such as cannabis, heroin and cocaine,11 and eight medicines 
which may be abused (the limits for these compounds are higher to reflect their medical use).12
Following the implementation of drug driving limits in 2015, the Department for Transport 
launched an anti-drug driving campaign called “Think” which includes a TV campaign aiming to 
deter people from using drugs and driving under the influence. 
Northern Ireland
Under the new Road Traffic (Amendment) Act (Northern Ireland) (Her Majesty’s Government, 
2016g), the legal alcohol limit for drivers has been lowered from 80mg in 100ml of blood to 
50mg. The limit for learner and professional drivers is lower at 20mg. The recent drug driving 
laws introduced in England and Wales do not extend to Northern Ireland; however, individuals 
may still be arrested if they are unfit to drive.
Psychoactive Substances Act 2016
The Psychoactive Substances Act 2016 (Her Majesty’s Government, 2016f) places a blanket 
ban on psychoactive substances (with some exemptions) in the UK, prohibiting the production, 
distribution, sale and supply of substances capable of producing a psychoactive effect within 
the country. Exempted substances are: those substances already controlled under the Misuse 
of Drugs Act 1971; medicinal products listed under the Human Medicines Regulations 2012; 
alcohol; tobacco and nicotine products; caffeine; and food and drink. The main aim of the 
Psychoactive Substances Act 2016 is to halt the sale and supply of psychoactive substances 
through retail premises (such as headshops) and online retailers based in the UK (see section 
8.3.1). 
Smoking legislation
Scotland
The Smoking Prohibition (Children in Vehicles) Bill (Scottish Parliament, 2016) received Royal 
Assent on 21 January 2016. It is now an offence for an adult to smoke in a private motor vehicle 
when there is a child in the vehicle and the vehicle is in a public place. 
Northern Ireland
The Tobacco Retailers Act (Northern Ireland) 2014 (Her Majesty’s Government, 2014d) 
strengthened existing age of sale legislation by requiring all tobacco retailers in Northern Ireland 
to register centrally from April 2016. The act also introduces banning orders for retailers; fixed 
penalties for a number of tobacco-control offences; and a new offence of proxy purchasing 
(buying tobacco on behalf of a minor). 
11 Illegal drugs and limits in the new legislation: benzoylecgonine (cocaine), 50µg/L; cocaine, 10µg/L; delta-9-
tetrahydrocannabinol (cannabis), 2µg/L; ketamine, 20µg/L; LSD, 1µg/L; methylamphetamine, 10µg/L; MDMA, 10µg/L 
and 6-monoacetylmorphine (heroin), 5µg/L.
12 Medicines and limits in the new legislation: clonazepam, 50µg/L; diazepam, 550µg/L; flunitrazepam, 300µg/L; 
lorazepam, 100µg/L; methadone, 500µg/L; morphine, 80µg/L; oxazepam, 300µg/L and temazepam, 1,000µg/L.
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The Health (Miscellaneous Provisions) Act (Northern Ireland) 2016 (Her Majesty’s Government, 
2016b) was passed in May 2016. It places a ban on smoking in cars where children are present, 
and it makes provision in relation to age of sale restrictions for e-cigarettes. The Department of 
Health expects to consult on the regulations in the autumn and for the regulations to be in force 
in the first half of 2017.
Alcohol minimum unit pricing
Minimum unit pricing (MUP) for alcohol sales is yet to be implemented anywhere in the UK, 
although there are moves towards doing so in Scotland, Northern Ireland and Wales (UK Focal 
Point, 2016).
Scotland
The Alcohol (Minimum Pricing) (Scotland) Bill was passed and received Royal Assent in 2012 
(Scottish Parliament, 2012). The Scotch Whisky Association (SWA) (in conjunction with the 
European Spirits Organisation and the Comitée Européen Des Entreprises Vins) sought a judicial 
review of the act, which was held in January 2013 and found comprehensively in favour of the 
policy. The SWA et al appealed that decision, and following a hearing in February 2014 the case 
was referred to the Court of Justice of the European Union (CJEU) to clarify points of EU law. 
In September 2015, the Advocate General of the European Court of Justice stated that in their 
opinion, Scotland’s alcohol MUP legislation does not contravene European law.13 In December 
2015, the CJEU ruled that the plans to impose a blanket minimum price per unit would breach 
EU free-trade laws unless the policy was found to be more effective than just using general 
taxation. It ruled that the judgement on its effectiveness was to be made by national courts.
In October 2016, the Scottish Court of Session ruled that MUP of alcohol is lawful. The SWA 
has since successfully applied to appeal in the UK Supreme Court. 
NHS Scotland reported in May 2016 that more than half (51%) of alcohol sold in supermarkets 
and off-licences was sold at less than 50p per unit,14 the MUP threshold previously suggested 
by NHS Scotland.
3.3.2 Tobacco control
Standardised packaging of tobacco
In May 2016, the High Court dismissed a legal challenge brought forward by tobacco companies 
against the standardisation of tobacco packaging, and the Standardised Packaging of Tobacco 
Products Regulations 2015 (Her Majesty’s Government, 2015d) came into effect the following 
day as planned. Tobacco companies have been given one year to comply with new regulations 
which include a ban on packs of ten cigarettes and a ruling that all tobacco packaging must be 
uniformly olive green and display large health warnings. This includes both packets of cigarettes 
and hand rolling tobacco. 
E-cigarettes
Since May 2016 all e-cigarettes and e-liquids sold in the UK must either meet the provisions of 
the Tobacco Products Directive (TPD) (2014/40/EU)15 or be licensed as a medicine or medicinal 
13 See: http://curia.europa.eu/juris/document/document.
jsf?text=&docid=166846&pageIndex=0&doclang=en&mode=req&dir=&occ=first&part=1&cid=203295 
14 See: http://www.healthscotland.com/uploads/documents/27345-00.%20Alcohol%20consumption%20and%20
price%20in%20Scotland%202015%20-%20May2016.pdf 
15 See: http://ec.europa.eu/health/sites/health/files/tobacco/docs/dir_201440_en.pdf 
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device by the Medicines and Healthcare products Regulatory Agency. In areas outside of the 
harmonised rules set out in the TPD the countries of the UK may, within the scope of their 
devolved powers, make their own policy on e-cigarettes. 
Smoke free prisons
England and Wales
Since January 2016, all prisons in Wales are smoke free. This has been trialled in four early 
adopter sites in England, extended to seven further establishments by January 2017, with a view 
to the entire prison estate being smoke free in future. E-cigarettes and nicotine replacement 
therapies are now available to purchase by prisoners and access to stop smoking support is 
increasing throughout the estate. For further information, (see section 5.8.3). 
Scotland
The current position in Scotland is that prisoners are only permitted to smoke in their own 
cells and during outdoor recreation. Staff, visitors and contractors are not permitted to smoke 
anywhere on Scottish Prison Service (SPS) property. The Cabinet Secretary for Justice in 
Scotland has accepted recommendations that all Scottish prisons should be smoke free within 
a timescale of up to five years. SPS will be working closely with NHS health boards and the 
Scottish government, as well as other partner agencies, to develop comprehensive plans in 
preparation for the change. A decision has still to be made on whether e-cigarettes should 
be introduced to prisons in Scotland as part of moves towards smoke free prisons. A working 
group is in place to consider the options available.
3.4 Universal prevention
Universal prevention targets the entire population, regardless of individual levels of risk, with 
programmes, initiatives and messages aimed at preventing or delaying the onset of illicit 
drug use. 
3.4.1 England
Universal drug education is included in the national curriculum in England, where it is a statutory 
part of the science curriculum for schools. Pupils are required to be taught “the effects of 
‘recreational’ drugs (including substance misuse) on behaviour, health and life processes.” Drug 
education can be expanded through the non-statutory Personal Social and Health Education 
(PSHE) programme; however, there is no standardised approach for doing so. Guidelines do 
state that teaching should draw on good practice (Department for Education, 2014). Evidence 
suggests that well-delivered PSHE can have a positive effect on young people, and that 
interventions that help build confidence and resilience can prevent drug use (Home Office, 
2016b). In 2015, four House of Commons committees requested that PSHE be made mandatory 
in schools; however this proposal was rejected and is still under review. 
Alcohol and drug prevention briefing papers
As part of a series of briefing papers for teachers and practitioners, Mentor-ADEPIS (Alcohol 
and Drug Education and Prevention Service) published a document in 2016 that looks at how 
building resilience and preventing children and young people’s mental ill health can prevent 
substance abuse. It aims to provide teachers, educators and the wider school workforce with 
practical guidelines on how to prevent children and young people from developing mental health 
problems as a result of alcohol and drug misuse (Mentor-ADEPIS, 2016).
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In 2016 the Association for Young People’s Health in conjunction with Public Health England 
(PHE) published a resource, A public health approach to promoting young people’s resilience, 
on building resilience in young people (Association for Young People’s Health, 2016). This 
document is aimed at policy makers, commissioners and service planners and providers, and 
builds on previous work such as the PHE framework for young people’s health, and resources 
such as Rise Above which is focused on resilience and helping young people to make positive 
health decisions.
Sources of support and information about drugs
There are several universal prevention communication programmes in England. For example, 
‘Talk to FRANK’,16 a campaign from PHE, provides information about drugs to young people 
(under 16) and their families. Advice can be accessed through a number of channels including a 
24-hour helpline operated by trained advisors, the FRANK website, SMS, email and a live online 
chat service. There have been increases in the number of website visits and emails to FRANK 
in recent years (2.2 million in 2009/10 to 4.2 million in 2014/15).
Rise Above is another prevention communication programme, which was launched by PHE in 
November 2014. It is an interactive resource where young people can find material aimed at 
encouraging them to build resilience, encourage empowerment and talk about important issues 
in their life, including drugs, alcohol, smoking, body confidence, relationships and exam stress. 
Rather than providing information only, a range of situational tools and skills-based resources 
are available on the website. Since Rise Above was launched, there have been almost 350,000 
unique visits to the website, 1.09 million views of Buzzfeed posts, 4.9 million video views of Rise 
Above content across vloggers and the Rise Above channel on YouTube and 52,429 unique 
visits to the MTV Rise Above Wall. 
PHE has also developed its role in supporting local areas: sharing evidence to support 
commissioning and the delivery of effective public health prevention activities; and launching 
toolkits to support local areas’ responses on specific issues around new psychoactive 
substances (NPS) and other drug groups.
3.4.2 Scotland
In Scotland, education has developed to encapsulate broader life learning for children and 
young people through the Curriculum for Excellence,17 where traditional education is integrated 
with wider life learning for three to 18-year-olds. In the Curriculum for Excellence, learning in 
health and wellbeing is designed to promote confidence, independent thinking and positive 
attitudes. This learning helps enable children and young people to become resilient to risk taking 
behaviours and understand the wider impacts of staying safe and making positive choices.
In December 2016, the Scottish government produced a literature review examining drug 
education and prevention (Scottish Government, 2016f). The report argued that drug prevention 
is better provided through holistic strategies that promote healthy development and wellbeing, 
with targeted drug-specific interventions provided for those at most risk of harm or already 
misusing drugs.
16 See: http://www.talktofrank.com/
17 See: https://education.gov.scot/scottish-education-system/policy-for-scottish-education/policy-drivers/cfe-(building-
from-the-statement-appendix-incl-btc1-5)/What%20is%20Curriculum%20for%20Excellence
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Know the Score
‘Know the Score’18 provides factual information and advice to young people, their families 
and professionals. It is supported by the Scottish government and provides an online 24-hour 
information service and a telephone helpline on drugs information and advice from 8am to 
11pm, seven days a week.
Choices for Life
The Scottish government funds the ‘Choices for Life’ schools-based substance misuse 
education programme, delivered in partnership with Young Scot and Police Scotland. This 
programme provides education on drugs, alcohol and tobacco through an information website 
for young people and their parents, teachers and carers. It also provides a series of community 
events to engage young people directly and provide credible information to help them make 
the right health choices. The Choices for Life website hosts a series of interactive short films 
to educate teenagers on a wide range of topics including the dangers of NPS, peer pressure, 
alcohol, smoking, cannabis, substance misuse and drug driving.
In 2015/16, Choices for Life aligned itself with an existing successful event, Rock Challenge. 
This performing arts initiative delivers positive healthy lifestyle messages to young people. It 
raises awareness of social issues affecting young people including smoking, drugs, alcohol and 
anti-social behaviour, and encourages them to make informed lifestyle choices. Police Scotland 
allocated a support officer to the participating schools and made funding available to help with 
their projects.
In light of the findings of the literature review ‘What works’ in drugs education and prevention 
(Scottish Government, 2016f), the Scottish government is currently reviewing the education and 
prevention activities that it supports directly, to ensure that these are in line with the evidence 
base on what works. It is proposed that in the 2017/18 financial year, a review of the Choices for 
Life programme will be undertaken.
3.4.3 Wales
In Wales, in line with the goal laid out by Working Together to Reduce Harm: The Substance 
Misuse Strategy for Wales 2008-18 (Welsh Assembly Government, 2008a), the All Wales 
School Liaison Core Programme has been developed to deliver drugs education in primary and 
secondary schools.19 The Steroids and Image Enhancing Drugs Educational Toolkit for Young 
People (11-16 years) has been developed and issued for all schools and youth groups across 
Wales (Public Health Wales, 2014b).20 
Welsh Network of Healthy School Schemes 
The Welsh Network of Healthy School Schemes (WNHSS)21 is an initiative to ensure schools 
adopt a holistic approach to health with a focus on substance use (both licit and illicit). Each 
local authority employs healthy schools practitioners to support schools in the areas. Once 
schools have been involved in the scheme for nine years, they can apply for a National Quality 
Award (NQA). This award assesses the school on its approach to the seven key topic areas 
of food and fitness, mental and emotional health and wellbeing, personal development and 
18 See: http://knowthescore.info/ 
19 The All Wales School Liaison Core Programme is jointly funded by the Welsh Government and the four Welsh 
police forces and targets pupils aged between five and 16. See: https://www.schoolbeat.org/en/parents/know-the-
programme/national-events/what-is-the-all-wales-school-liaison-core-programme/ 
20 See: http://www.wales.nhs.uk/sitesplus/documents/888/SIEDS%20Toolkit%20English.pdf
21 See: http://www.wales.nhs.uk/sitesplus/888/page/82249
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relationships, substance use and misuse, environment, safety and hygiene. In August 2015, 87 
schools across Wales had achieved the NQA, an increase from 65 in August 2014. A further 
266 are working towards being assessed.
Healthy and sustainable further education and higher education settings
The Healthy Colleges and Healthy Universities framework22 was launched in Wales in 2015 as 
an extension of the WNHSS into Higher Education and Further Education settings. One of the 
six health topics detailed in the framework is substance use and misuse. The framework sets 
out criteria for various aspects of college and university life, covering: governance, leadership 
and management; facilities, environment and service provision; community and communication; 
and academic, personal, social and professional development. It aims to create a healthy and 
sustainable further education environment for both staff and students and provides guidance 
on how this may be achieved. 
DAN 24/7
Dan 24/723 is a bilingual (Welsh and English) 24-hour information and telephone helpline service, 
which frequently runs targeted campaigns. Traffic to the website increased by 29% from 2013/14 
to 2014/15. It has been updated to reflect current issues such as NPS and a recent campaign to 
raise awareness of hepatitis C in Wales. The service has also increased its presence on social 
media platforms in the past year. It is hosted by the Betsi Cadwaladr University Health Board with 
funding provided by the Welsh government. The helpline is aimed at assisting individuals, their 
families, carers, and support workers within the drug and alcohol field to access appropriate 
local and regional services. 
3.4.4 Northern Ireland
The school curriculum places a specific focus on the development of relevant ‘life skills’ among 
pupils. In particular, through Personal Development and Mutual Understanding24 in primary 
schools, pupils are provided with opportunities to develop strategies and skills for keeping 
themselves healthy and safe. Post-primary school pupils, through Learning for Life and Work,25 
are provided with opportunities to investigate the effects on the body of licit and illicit substances 
and the risks and consequences of their misuse.
During the 2014/15 financial year the Council for Curriculum, Examinations and Assessment 
(CCEA) updated the CCEA/Department of Education guidance on drugs and alcohol. The new 
guidance was published on the CCEA website in August 2015.26 In Northern Ireland, the Public 
Health Agency27 develops public information campaigns for various target groups and settings. 
In addition, Northern Ireland buys into the telephone helpline element of the FRANK campaign. 
A new community support and local awareness raising service, called ‘Connections’, was put 
in place in July 2015 to raise awareness of the harm alcohol and drug misuse can cause, work 
with local communities to address their priorities, and raise awareness of local services.
22 See: http://www.wales.nhs.uk/sitesplus/888/document/270938 
23 See: http://www.dan247.org.uk
24 See: http://ccea.org.uk/curriculum/key_stage_1_2/areas_learning/personal_development_mutual_understanding 
25 See: http://www.nicurriculum.org.uk/docs/learning_for_life_and_work/training/LLW-Guidance.pdf 
26 See: http://ccea.org.uk/curriculum/drugs_guidance 
27 See: http://www.publichealth.hscni.net/ 
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Thingyapp
In Northern Ireland, the Police Service of Northern Ireland, Big Lottery Fund, Youth Justice 
Agency and Family Support Northern Ireland have funded an app, designed by young people, 
called Thingyapp. Thingyapp offers young people health advice, including advice on drugs 
and alcohol, and signposts individuals to agencies where they can receive further help and 
information. 
3.4.5 UK-wide
Good Behaviour Game
The Good Behaviour Game is a classroom-based approach that has been trialled in a number 
of countries around the world. A trial is ongoing in UK primary schools funded by the Education 
Endowment Fund and led by Mentor. The programme is an approach to classroom management 
and aims to develop life skills in young people to build resilience and confidence in dealing with 
challenges. Evaluations in other countries have shown long term benefits including a reduction 
of risk-taking behaviour, including substance abuse, later in life. An evaluation report will be 
published in August 2017. 
Unplugged
Unplugged is an intervention aimed at 12-14 year-olds and is delivered through a series of 
12 one-hour modules in schools. The programme has been trialled in a number of European 
countries and has been shown to be effective in preventing and reducing alcohol misuse and 
smoking. It aims to give young people the skills they need to resist influences from peers and 
information regarding the negative health consequences of drug use.
3.5 Selective prevention in at-risk groups and settings
Selective prevention initiatives target subsets of the total population that are deemed to be at 
greater risk of substance misuse or risky behaviour, such as truants or young offenders.
3.5.1 Young people
Substance misuse services for young people
Specialist substance misuse treatment for young people is recognised as a form of prevention 
in the UK, as it aims to stop drug and alcohol use escalating, to reduce harm to young people or 
others and to prevent them becoming drug or alcohol-dependent adults. The Young People’s 
Statistics from the National Drug Treatment Monitoring System (NDTMS) showed that in 2014/15 
18,349 young people (under 18 years) accessed specialist substance misuse services (see 
section 4.5.1). The majority presented with cannabis (73%) or alcohol (17%) as their primary 
problem substance, followed by amphetamine (three per cent), NPS (two per cent) and ecstasy 
(one per cent) (Public Health England, 2015i).
The Drug Treatment Database in Northern Ireland shows that in 2015/16 149 clients aged under 
18 were in treatment for drug misuse – just under seven per cent of all those in treatment.
Young people with multiple vulnerabilities
Young people presenting to specialist substance misuse services frequently have multiple 
vulnerability factors such as being a looked after child, being involved in child sex exploitation, 
having a history of self-harm or offending behaviour. The Young People’s Statistics from NDTMS 
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identify 17 of these vulnerability factors.28 Of the 13,127 new presentations in 2014/15, 83% had 
two or more of these vulnerability factors (Public Health England, 2015i).
RisKit
The RisKit programme has been developed by the University of Kent and Kent County Council 
following a review of existing research and consultations with young people. The school-based 
programme screens those aged 14-16 and offers interventions to those who are deemed at risk. 
The interventions include drug and alcohol awareness sessions, motivational interviewing and 
life skills training sessions. Following an evaluation (Stevens et al., 2014), it was found that the 
programme is positively viewed by both pupils and those delivering the programme. Information 
on how to implement the programme has been made freely available on a Creative Commons 
licence.
3.5.2 At-risk families
Troubled Families Programme
The first phase of the Troubled Families Programme was launched by the UK government 
in 2012 and aimed to turn around the lives of 120,000 ‘troubled families’ across England by 
May 2015 (Department for Communities and Local Government, 2012). Delivery of the Troubled 
Families programme was unprecedented for an initiative of its kind in the UK in terms of the 
scale and pace required. Families taken on to the programme had multiple problems: children 
not in school; children committing crime; anti-social behaviour; parents not working; and other 
high cost problems, such as drug abuse and domestic violence.
In 2013 the government announced an expansion of the programme (phase two) to reach up 
to an additional 400,000 families from 2015/16. Funding totalling £720 million has been made 
available to meet these commitments by 2020 (Bate, 2016). The new programme retains the 
focus on families with multiple high cost problems and continues to include families affected by 
poor school attendance, youth crime, anti-social behaviour and unemployment. 
In 2016 an independent evaluation of phase one was published (Department for Communities 
and Local Government, 2016). Local authorities reported monitoring data which recorded 
problems being experienced by families, including assessments of drug and alcohol dependency 
in adults and young people. Where completed information was available at entry and exit to the 
programme, the monitoring data indicated a reduction in these issues for around one-third of 
families at exit from the programme.
The evaluation also included a family survey which contained self-reported drug and alcohol 
misuse questions. It compared responses from families starting the intervention with those 
nine months from the start of the intervention. There were no significant differences identified 
between the responses of these two groups in relation to their self-reported drug and alcohol 
use. However, a majority of the families at nine months after the intervention were identified 
subsequently as still receiving the intervention at the time of interview, so limited conclusions 
can be drawn from these findings. 
Emerging findings from the expanded programme evaluation are expected in 2017.
28 The 17 vulnerability factors are: began using primary substance aged under 15; has been involved in antisocial 
behaviour; reports self-harming behaviour; is a looked after child; is subject to a child protection plan; is a child in 
need; reports using opioids and/or crack; has ever injected; is not in education, employment or training; reports 
unsettled accommodation status or has no fixed abode; reports using two or more substances in combination 
(poly substance use); is pregnant or a parent; is a high risk alcohol user; is affected by others’ substance misuse in 
their close family and/or members of the household; has been affected by domestic abuse; reports a mental health 
problem; and reports sexual exploitation.
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Family Drug and Alcohol Courts
Family drug and alcohol courts (FDACs) are specialised courts designed to work with parents 
who abuse substances and are involved with the child welfare system. They aim to improve 
children’s outcomes by addressing their parents’ difficulties, and parents and children are able 
to remain together safely during the court proceedings. The courts are able to make quick 
alternative placement decisions for the child if parents are unable to successfully address their 
substance misuse problems. A dedicated judge will usually preside over all hearings in a given 
case, and families are supported by a multi-disciplinary specialist support team which reports 
back to the judge on their progress. 
A two-stage independent evaluation of pilots in 2008-2012 provided evidence that FDACs 
were more successful than ordinary care proceedings in helping parents overcome substance 
misuse in order to be reunited with their children (Harwin, Alrouh, Ryan, & Tunnard, 2014). It also 
found that FDACs enable parents to access and stay in treatment. These findings have been 
confirmed by the recently published report on the five year outcomes of FDACs. The study 
showed that a significantly higher proportion of mothers from FDACs than in the comparison 
group had ceased to misuse drugs, which led to a higher rate of family reunification (Harwin et 
al., 2016).
There are currently FDACs in England, in London, Gloucestershire, Milton Keynes & 
Buckinghamshire, East Sussex, Coventry, the South West Peninsula, Southampton, West 
Yorkshire and Kent & Medway.29 Further FDACs are expected to open, with plans to open four 
more per year over the next five year period.
The Family Nurse Partnership
Since 2007, the Family Nurse Partnership30 has provided support to young mothers in the UK 
from pregnancy to the baby reaching two years old, with structured home visits by trained 
nurses. A randomised controlled trial looking at its effectiveness was conducted in the UK and 
its findings were published in October 2015. Results showed the programme had no effect 
on pre-natal tobacco use, birth weight, emergency department attendance and subsequent 
pregnancy by 24 months, which were the study’s four main short term outcomes. There were 
small positive impacts on some of the secondary outcomes of the study, such as maternally 
reported child cognitive development, language development, levels of social support and 
partner-relationship quality (Robling et al., 2015).
3.5.3 Other at-risk groups
Vulnerable women
Following research carried out by the Stella Young Women’s initiative, the Against Violence 
and Abuse project produced guidelines in 2013 for engaging young women who experience 
domestic and sexual violence, substance misuse and mental ill-health (Against Violence and 
Abuse, 2013). The guidelines promote a holistic model of support. 
Published in March 2016, the Ending Violence against Women and Girls Strategy 2016-2020 
(Her Majesty’s Government, 2016a) sets out plans to tackle harm and exploitation associated 
with prostitution, including substance misuse. 
29 See: http://fdac.org.uk/locations/existing-sites/
30 The Family Nurse Partnership provides support to young families (mothers aged 19 years or younger);  
see: http://fnp.nhs.uk/
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Chemsex
PHE have published a briefing for commissioners and providers of services who work with people 
who engage in chemsex (Public Health England, 2015g). This includes targeted interventions, 
and also encourages collaboration between sexual health services and community groups. The 
2015/16 PHE action plan to promote the health and wellbeing of gay, bisexual and other men 
who have sex with men aims to increase intelligence on the prevalence of chemsex, provide 
support to services and reduce the availability of drugs associated with chemsex (Public Health 
England, 2014).
The Mental Health Taskforce
The independent Mental Health Taskforce published the Five Year Forward View in March 2016 
and set out the NHS commitments towards improving mental health care (Mental Health 
Taskforce, 2016). One of the key recommendations focused on the need for better integration 
between physical and mental health care services; for example ensuring those with severe 
mental illness, who are twice as likely to smoke, are signposted to smoking cessation services. 
It also highlighted the importance of early intervention for children and young people. 
The taskforce noted the change in commissioning of alcohol and substance misuse services 
from the NHS to local authorities. This led to the closure of specialist NHS inpatient addiction 
units. As a result, referral pathways have become more complex and this may have affected the 
provision of holistic care for those people with mental health and co-morbid substance misuse 
problems.
Every line counts
The National Crime Agency launched a campaign, #EveryLineCounts, in December 2015 to 
highlight the harm caused by the production and distribution of cocaine. Alongside their work 
on targeting organised crime groups, this campaign aims to target recreational users to highlight 
the social justice issues related to cocaine use. The campaign uses various social media outlets 
to share graphic images related to cocaine production and a video documenting the harm that 
is caused from production to when the product arrives on the street in the UK.
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4 Treatment
4.1 Introduction
UK drug strategies identify treatment as being effective in tackling problem drug use and seek 
to improve its quality and effectiveness. Co-ordination and integration across a range of service 
providers is seen as key in helping problem drug users integrate into society, and all recent 
UK drug strategies focus on this area. Substance misuse services are commissioned by local 
authorities (LAs) in England; by local NHS health boards in Scotland; by community safety 
partnerships in Wales; and by drug and alcohol co-ordination teams in Northern Ireland. Each 
of these commissioning bodies receives advice and input from a number of other organisations, 
including Public Health England (PHE), the Public Health Agency in Northern Ireland, voluntary 
organisations and the police.
In terms of quality assurance, the Drug Misuse and Dependence: UK Guidelines on Clinical 
Management (Department of Health England and the devolved administrations, 2007) provide 
guidance for clinicians delivering drug treatment in the UK. The Care Quality Commission 
(CQC) is responsible for monitoring, inspecting and regulating health and social care services in 
England, including the majority of substance misuse services.
Community-based specialist drug treatment centres are the most common providers of 
substance misuse services in the UK. Treatment interventions in any given area are expected 
to include: advice and information, care planning, psychosocial interventions, community 
prescribing, inpatient drug treatment and residential rehabilitation.
Treatment Demand Indicator (TDI) data on numbers presenting to treatment are from four 
separate systems: the National Drug Treatment Monitoring System (NDTMS) in England; the 
Scottish Drug Misuse Database (SDMD); the Welsh National Database for Substance Misuse; 
and the Northern Ireland Drug Misuse Database. Data from the four systems is combined 
into UK totals for reporting to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). Continuous national data are available from 2003/04.
In 2015 there were approximately 250,000 individuals recorded as being in drug treatment 
in England and Wales, with around 140,000 in continuous treatment at the start of the year, 
and 110,000 presenting to treatment during the year. More than 80% of clients in continuous 
treatment in England and Wales (n=112,000) cited opioids as their primary substance, and 
100,000 clients were receiving opioid substitution treatment (OST). Fifteen thousand clients 
presented to treatment in Scotland and Northern Ireland in 2015. Of those presenting to 
treatment in the UK in 2015 approximately half reported primary use of opioids, and one-quarter 
reported cannabis as their primary substance. In England, around 15,000 people aged under 
18 years old were in contact with drug misuse services in 2014/15, with almost 90% of these 
clients citing cannabis as their primary substance.
Since 2008/09 there has been a steady decline in the number of new treatment presentations 
across the UK, from a peak of almost 140,000 clients to just over 100,000 in 2015. Between 
2003/04 and 2015, the percentage of new presentations citing cannabis more than doubled, 
while the proportion citing heroin and other opioids decreased from over 70% to just over half 
of all presentations. The number of opioid users in prescribing treatment in England increased 
steadily between 2005 and 2010; however, the heroin drought that began in late 2010 saw the 
number of clients receiving OST decrease in 2011, and level off since then. The opioid treatment 
seeking population is ageing, with over one-third of those presenting for treatment in 2015 aged 
40 and over.
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4.2 Policy, strategy and quality assurance
4.2.1 Strategy and policy
United Kingdom
The UK Drug Strategy 2010, Reducing demand, restricting supply, building recovery: supporting 
people to live a drug free life (Her Majesty’s Government, 2010) emphasises supporting those 
who are drug dependent to achieve recovery, and the provision of the integrated support 
necessary to enable this (see section 2.2.1).
The ‘building recovery’ strand of the strategy includes a number of objectives relating to 
treatment. These include: 
 • ensure that all those on a substitute prescription engage in recovery activities
 • support services to draw on a client’s ‘recovery capital’
 • commission drug treatment and recovery services which are locally led, transparent 
about performance and delivered in line with best practice 
 • launch PHE, whose role is to support LAs on commissioning services most suitable for 
their area and population
 • encourage local areas to jointly commission services to deliver ‘end-to-end’ support
 • enable people to successfully reintegrate into their communities following treatment by 
tackling housing needs and helping them find sustained employment
 • launch six Payment by Results pilots to investigate affordability and value for money in 
drugs recovery for adults.
England
The Public Health Outcomes Framework (PHOF)31 (Department of Health, 2012) set out the 
government’s strategic direction in meeting two high level objectives: to increase health life 
expectancy; and to reduce differences in life expectancy and health life expectancy between 
communities.
The framework includes an indicator and sub-indicators which are explicitly related to drugs: 
reporting successful completions of treatment for opioid and non-opioid users who do not 
return within six months. In response to the rising trend in drug-related deaths in recent years, a 
further sub-indicator reporting the number of deaths from drug misuse was added to the PHOF 
in April 2016 (Department of Health, 2016).
Scotland
The concept of recovery and supporting people to live a drug-free life as active and engaged 
members of society is central to the Scottish government’s drug strategy, The Road to 
Recovery: A new approach to tackling Scotland’s drug problem (Scottish Government, 2008d) 
(see section 2.2.2). 
The key treatment-related priorities of the strategy are: to see more people recover from problem 
drug use so that they can live longer, healthier lives, realising their potential and making a 
positive contribution to society and the economy; and to improve the effectiveness of delivery 
at a national and local level.
31 See: http://www.phoutcomes.info/
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The Scottish government has developed a Recovery Outcomes Web tool32 for use by local 
services to record and monitor people affected by problem drug and alcohol use. This is an 
independently validated, peer-reviewed tool which has been developed through consultation 
with Alcohol and Drug Partnerships (ADPs), drug and alcohol frontline staff, managers, service 
users and research groups.
The key aim of the tool is to measure changes in a person’s life as a result of an intervention 
received when they access specialist support from drug and/or alcohol services in Scotland. 
This tool will help to provide a better understanding of an individual’s recovery journey, related 
needs and motivation for change. Secondary benefits of the outcomes measurement tool are to 
inform workforce development, service improvement and future service provision for managers, 
ADPs, funding bodies and the Scottish government.
Wales
The Welsh Assembly government’s substance misuse strategy, Working together to reduce 
harms 2008-2018 (Welsh Assembly Government, 2008a), predominantly focuses on reducing the 
harms associated with substance misuse (see section 2.2.3). Their treatment-related objectives 
include: improving the availability of treatment services and related support; making better 
use of resources (for example, utilising evidence-based decision making, improving treatment 
outcomes, developing the skills of those working in the treatment sector and promoting joined 
up working across agencies); and developing user-focused services.
The strategy has been accompanied by shorter term implementation plans which outline 
performance measures for each of the key action areas, including supporting substance 
misusers to improve their health and aid and maintain recovery. Establishing recovery-oriented 
systems of care, peer-led recovery community support, and implementing best practice across 
Wales continue to be prioritised. 
The most recent three year delivery plan was launched in September 2016 (Welsh Government, 
2016), and captures the final three years of the strategy. The plan was developed in close 
collaboration with a wide range of stakeholders, including service users, and is clear about the 
contribution the substance misuse agenda can make to achieve the goals set out in the Well-
being of Future Generations (Wales) Act 2015 (National Assembly for Wales, 2015). The plan 
covers both mental and physical wellbeing.
Northern Ireland 
The current Northern Irish strategy, New Strategic Direction for Alcohol and Drugs (NSD) Phase 2, 
2011-2016 (Department of Health Northern Ireland, 2011), has a number of treatment-related 
priorities including: developing a regional commissioning framework for treatment; targeting 
those at risk and vulnerable; and workforce development. 
4.2.2 Quality standards
England
Care Quality Commission 
The CQC is an independent body charged with monitoring, inspecting and regulating health 
and social care services, including substance misuse treatment services based in hospitals, 
communities and residential rehabilitation. Five key questions are asked of all services during 
inspection to ascertain whether they are: safe; effective; caring; responsive to people’s needs; 
and well-led. 
32 See: http://www.ssks.org.uk/media/134321/ro%20web%20tool%20-%20pdf.pdf
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At present, the CQC generally only provides ratings for substance misuse services delivered 
by an NHS trust. Such services are not always included in trust ratings: their inclusion is based 
on specific criteria, such as whether the service represents a large proportion of a provider’s 
activity or expenditure. These services are rated on a four point scale (outstanding, good, 
requires improvement and inadequate) for each of the five key questions. Ratings will be shared 
with service users and their families and carers, the public, treatment providers, commissioners 
and other stakeholders.
Local quality governance
While the CQC is responsible for regulating the majority of substance misuse services, a 
significant minority of locally commissioned services do not fall within the scope of their remit, 
for example community-based services where care is not provided by a listed professional. 
To assist LA commissioners, in July 2015, PHE provided guidance describing what quality 
governance is, its importance, and setting out the responsibilities of provider organisations, 
commissioners and national and regional bodies to ensure that quality and safety are not 
jeopardised (Public Health England, 2015f).
Scotland
Local delivery plans
The Local Delivery Plan (LDP) standard (formerly Health, Efficiency, Access and Treatment 
standard) for drug and alcohol treatment waiting times expects that 90% of people receive 
access to appropriate drug and/or alcohol treatment within three weeks of referral to support 
their recovery (Information Services Division, 2015). Getting people into treatment quickly for 
drug-related problems is a priority for the Scottish government, as evidence suggests this is 
likely to result in improved client outcomes.
Data is published on a quarterly basis at national, health board and ADP level. The most recent 
statistics, published in December 2016, indicate that in July – September 2016, 93.9% of the 
11,438 people who started their first drug or alcohol treatment waited three weeks or less (LDP 
standard) (Information Services Division, 2016d). This ambitious standard therefore continues to 
be exceeded at national level.
Quality principles
The Scottish government has developed an alcohol and drugs quality improvement framework 
to ensure quality in the provision of care, treatment and recovery services, as well as quality in 
the data that will show the outcomes people are achieving (Scottish Government, 2014). There 
are eight overarching principles, each with a set of supporting statements and all underpinned 
by a recovery philosophy. The broad ethos of the principles being:
 • an emphasis on high-quality, evidence-informed interventions
 • workers who are appropriately trained and supervised
 • comprehensive strengths-based assessments
 • person-centred recovery plans that are agreed and regularly reviewed
 • the opportunity for family members to be involved in recovery (if this is helpful to the 
individual).
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4.2.3 Guidelines for treatment
UK guidelines on clinical management
In September 2007 the Drug Misuse and Dependence: UK Guidelines on Clinical Management 
(Department of Health England and the devolved administrations, 2007) were published, to be 
used as a guide by all clinicians working in drug misuse treatment, particularly those providing 
pharmacological interventions. 
The guidelines include the following key principles underlying appropriate care of drug misusers:
 • drug misusers have the same entitlement as other patients to the services provided by 
the NHS
 • the General Medical Council’s statement that: “The investigations or treatment you 
provide or arrange must be based on the assessment you and the patient make of their 
needs and priorities, and on your clinical judgement about the likely effectiveness of the 
treatment options. You must not refuse or delay treatment because you believe that a 
patient’s actions have contributed to their condition. You must treat your patients with 
respect whatever their life choices and beliefs”
 • it is the responsibility of GPs to provide general medical services for drug misusers. 
Health authorities, Primary Care Trusts in England, local health boards in Wales and 
health boards in Northern Ireland and Scotland all have a duty to provide treatment 
for drug misusers, to meet local population needs. This should include interventions 
to reduce drug-related harm such as hepatitis B vaccinations and needle exchange 
provision, together with evidence-based drug treatment
 • every doctor must provide medical care to a standard which could reasonably be 
expected of a clinician in their position. An increasing number of clinicians are trained 
and supported to provide drug treatment under the terms of a contract negotiated with 
their local commissioners
 • the focus for the clinician treating a drug misuser is on patients themselves. However, 
the impact of their drug misuse on other individuals and on communities should be 
taken into consideration.
Following a consultation carried out by PHE (on behalf of the departments of health in England, 
Scotland, Wales and Northern Ireland) in 2014, an independent expert working group conducted 
a review of the evidence on drug treatment since the 2007 guidelines were published. The 
guidelines are being updated in accordance with the group’s findings, and are expected to be 
published in 2017.
National Institute for Health and Care Excellence
The National Institute for Health and Care Excellence (NICE) has produced a range of guidelines, 
technical appraisals and pathways relating to best practice and standards of care in the 
treatment of substance misuse. Interventional procedures apply to all countries of the UK. 
Clinical guidelines and technology appraisals apply to those using the NHS in England and Wales 
only and are usually disseminated after local review in Northern Ireland. Public health guidance 
applies to those using the NHS in England only and is often disseminated after local review in 
other UK countries. New guidelines for drug misuse prevention are currently in development, 
and are expected to be published in February 2017.
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The key NICE guidelines relating to substance misuse treatment are: 
 • CG51 (2007) Drug misuse in over 16s: psychosocial interventions (National Institute for 
Health and Care Excellence, 2007b)
 • CG52 (2007) Drug misuse in over 16s: opioid detoxification (National Institute for Health 
and Care Excellence, 2007a)
 • CG120 (2011) Co-existing severe mental illness (psychosis) and substance misuse: 
assessment and management in healthcare settings (National Institute for Health and 
Care Excellence, 2011)
 • NG58 (2016) Co-existing severe mental illness and substance misuse: community 
health and social care services (National Institute for Health and Care Excellence, 2016)
 • PH4 (2007): Substance misuse interventions for vulnerable under 25s (National Institute 
for Health and Care Excellence, 2007d)
 • PH52 (2014): Needle and syringe programmes (National Institute for Health and Care 
Excellence, 2014b)
 • PH49 (2014) Behaviour change: individual approaches (National Institute for Health and 
Care Excellence, 2014a)
 • QS23 (2012) Drug use disorders in adults (National Institute for Health and Care 
Excellence, 2012)
 • TA114 (2007) Methadone and buprenorphine for the management of opioid 
dependence (National Institute for Health and Care Excellence, 2007c).
Project NEPTUNE
The Novel Psychoactive Treatment UK Network (NEPTUNE), an independent charity funded 
by the Health Foundation, conducted a systematic review of the evidence on club drugs,33 
focusing particularly on their acute and long-term harms and convened a group of UK experts 
to provide clinical consensus on their treatment. This evidence was used to develop Guidance 
on the clinical management of acute and chronic harms of club drugs and novel psychoactive 
substances (Abdulrahim & Bowden-Jones, 2015), published in March 2015. The guidance is 
now being translated into a number of free-to-access e-learning modules for clinicians and 
other practitioners, which will be available online in 2017.
4.3 Organisation and provision of drug treatment
4.3.1 Outpatient drug treatment system
Main providers
In the UK, community-based specialist drug treatment centres are the most common providers 
of substance misuse services. Specialist services account for 92% of community-based 
treatment units reporting to the NDTMS in England (n=786). GPs prescribing OST medications 
in a shared care arrangement report to NDTMS through the specialist service providing the 
shared care component. Some GPs prescribing in isolation do not report to NDTMS; therefore 
there is some under-reporting from these services. 
33 The term ‘club drugs’ is used here to refer to a group of psychoactive substances typically used in dance venues, 
house parties, music festivals and sometimes in a sexual context.
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Specialist drug treatment centres are predominantly public services, commissioned and funded 
by local government. The contracts to deliver drug treatment services commissioned by LAs 
are often held by registered charities. Some organisations specialise solely in substance misuse, 
while others deliver contracts for mental health services and services for people with learning 
disabilities. Specialist drug treatment services are also provided by the NHS by Mental Health 
Trusts.
Client utilisation
Almost all clients treated in the UK receive treatment in a community setting, including some who 
receive treatment in the community before or after attending a residential unit. The majority of all 
clients in the UK (both outpatient and inpatient) cite heroin as a problematic drug (see section 
4.4.3). Comparisons with Problem Drug Use estimates suggest that in England around half of 
the problem opioid and/or crack using population access community treatment services.34 
However, the most recent problem drug use estimates cover 2011/12, therefore this figure 
should be considered an approximation. 
4.3.2 Inpatient drug treatment system 
Main providers
Inpatient and residential facilities account for 11% (n=128) of all substance misuse treatment 
units reporting data to the NDTMS in England. 
Inpatient units are for those alcohol or drug users whose needs require supervision in a 
controlled medical environment. These units provide assessment, stabilisation and/or assisted 
withdrawal, with 24-hour cover from a multidisciplinary clinical team who have had specialist 
training in managing addictive behaviours. In addition, the clinical lead is a consultant in addiction 
psychiatry or another substance misuse medical specialist. The multi-disciplinary team may 
include psychologists, nurses, occupational therapists, pharmacists and social workers. 
Inpatient units are often based within hospitals, but can be attached to residential rehabilitation 
services or standalone. Inpatient detoxification interventions may also be delivered on a general 
ward within a hospital. 
Residential rehabilitation services are primarily run by voluntary and private sector organisations. 
They offer structured programmes that may include psychosocial interventions, individual and 
group therapy, education and training, and social and domestic skills. There is a wide range of 
different types of residential rehabilitation available, and services differ widely in terms of their 
philosophy, intensity, inclusion criteria, programme content and duration. 
Another non-hospital based residential setting in the UK is a recovery house. This is a residential 
living environment, in which integrated peer support and/or integrated recovery support 
interventions are provided for residents who were previously, or are currently, engaged in 
treatment to overcome their drug and alcohol dependence. The residences are also referred to 
as dry-houses, third-stage accommodation or quasi-residential.
Client utilisation
The proportion of the overall treatment population who receive treatment in inpatient/residential 
settings is low compared to those who receive it on an outpatient basis. In England in 2015/16, 
5.2% of the total treatment population were reported as having been treated in an inpatient unit; 
34 Based on the most recent estimates for prevalence of opioid use and/or crack cocaine use: 293,879 from 2011/12 
(Hay et al., 2014).
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2.6% were treated in a residential service;35 and 0.2% were treated in a recovery house (with 
some clients having been treated in more than one setting).
The average cost of inpatient treatment is £160.42 daily compared with £100.86 for residential 
rehabilitation.36 Given the average time spent in residential rehabilitation is 11 weeks, this 
equates to an average of over £7,750 for every treatment episode commissioned by LAs. As 
such, clients accessing rehabilitation will usually be required to meet certain admission criteria, 
including: being abstinent from drugs and alcohol following detoxification; a commitment to 
becoming substance free; a desire to leave treatment; and having been assessed as capable of 
achieving abstinence and being prepared to do so. Clients are usually also required to complete 
a period of community treatment prior to rehabilitation and may return to community services 
for further support after exiting inpatient facilities. 
The NICE guideline CG51 (National Institute for Health and Care Excellence, 2007b) recommends 
that residential rehabilitation be used for the “most complex” clients. As such, those accessing 
residential rehabilitation will usually have: 
 • not benefited from previous community-based psychosocial treatment 
 • longer and more entrenched drug and alcohol misusing careers
 • a range of problem substances
 • more significant housing problems
 • co-morbid physical and/or mental health problems.
In addition, residential rehabilitation services treat a higher proportion of clients who are using 
both heroin and crack, injecting drugs, polydrug users, and offenders. 
In 2015/16, in England 5,217 clients accessed support through residential rehabilitation, as 
reported by the NDTMS (Public Health England, 2015a). 
4.3.3 Prisons
There are 138 prisons across the UK (120 in England and Wales, 15 in Scotland and three in 
Northern Ireland), and the majority offer some form of treatment for substance misuse. Prison 
drug treatment reporting is not yet fully integrated with community datasets, and until 2014 
only Northern Irish prison treatment data was included in TDI figures. However, from 2015 data 
from prisons in England will also be included. The provision of treatment in prisons is covered 
in section 5.
4.4 Data from the Treatment Demand Indicators
4.4.1 Changes to the treatment demand indicator and reporting
The TDI records the number of clients presenting to a treatment centre in a particular year, 
but does not provide information on clients who remain in treatment without starting a new 
treatment episode. Data is presented for the UK as a whole unless otherwise stated.37 Due to 
35 These figures do not include private clients as they are not reported to the NDTMS.
36 Based on the New Economy Unit Cost Database, see: http://neweconomymanchester.com/stories/832-unit_cost_
database 
37 Percentages quoted are valid percentages.
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changes in the TDI protocol, data from 2013 are not directly comparable to previous national 
reports. Further information is available in accompanying tables Treatment 1, 2 and 3.
In 2015, 124,234 clients presented to treatment in the UK. This figure includes data from NHS 
Greater Glasgow and Clyde and NHS Tayside health boards, which was not included last year, 
and (for the first time) data from clients receiving treatment in prison in England. 
For the reporting year 2015, the EMCDDA began to collect data not only on those presenting 
to treatment in the given year, but also on clients that were in treatment at the beginning of the 
year (treatment prevalence). The data collected on these individuals is not as comprehensive as 
that for TDI cases; however, information available includes age, primary substance, duration in 
treatment and OST status. Treatment prevalence data is available for England and Wales only. 
As with TDI, English prisons data is included in these figures. 
4.4.2 Treatment centres
A total of 1,086 treatment centres reported TDI data through national treatment monitoring 
systems in the UK during 2015. Of these, 71% provided outpatient services (n=775), 10% 
provided inpatient services (n=110), 12% were treatment services in prison (n=131) and 4.5% 
were GP services (n=49). 
Table 4.1 shows that 72% of all clients presenting to drug treatment in the UK during 2015 were 
treated in outpatient centres. Opioid users make up a larger proportion of clients within inpatient 
and GP services than within outpatient services.
Table 4.1: Primary drug by centre type in the United Kingdom, 2015
Outpatients Inpatients Prison* GP† Other Total
n % n % n % n % n % n %
Amphetamines 2,301 2.9 29 2.3 609 2.1 10 1.0 0 0 3,122 2.6
Benzodiazepines 1,294 1.6 20 1.6 712 2.5 157 15.3 45 7.5 3,205 2.7
Cannabis 22,841 28.4 55 4.5 6,047 21.3 65 6.3 351 58.4 31,129 25.9
Cocaine powder 8,208 10.2 127 10.3 2,951 10.4 24 2.3 72 12.0 11,858 9.9
Crack cocaine 2,556 3.2 116 9.4 2,073 7.3 12 1.2 0 0 4,815 4.0
Opioids 38,861 48.4 835 67.6 14,516 51.2 663 64.6 45 7.5 59,763 49.7
Other 4,241 5.3 53 4.3 1,457 5.1 95 9.3 88 14.6 6,402 5.3
Sub-total 80,302 100 1,235 100 28,365 100 1,026 100 601 100 120,294 100
Not known 144 3 35 5 0 3,940
Total 80,446 72.0 1,238 1.1 28,400 25.4 1,031 0.9 601 0.5 124,234 100
*Data are for England and Northern Ireland only
†Data are for England only
Source: TDI
4.4.3 Characteristics of treated clients
The following data outlines the characteristics of clients seeking treatment in the UK and is 
based on data from TDI and TDI Prevalence tables. Similarly to previous years, 78% of clients 
presenting to treatment were male, and 33% had never received treatment previously.
Source of referral
As in previous years, the most common source of referral among clients starting a new episode 
of treatment in 2015 was self-referral (46%), with the criminal justice system (CJS) the next most 
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common referral source (20%). Despite the association between opioid use and crime, the 
proportion of opioid clients referred to treatment through the CJS was actually slightly lower 
than the proportion of primary cannabis and cocaine users (19%, 22% and 23% respectively). 
Previously treated clients were more likely to self-refer than those who were new to treatment 
(50% and 38%, respectively) (TDI).
Primary drug
Primary drugs reported through the treatment demand indicator
In 2015 half of all treatment presentations in the UK were for primary opioid use (50%; a small 
decrease from 52% in 2014), with just over one-quarter (26%) for primary cannabis use (see 
accompanying table Treatment 1). However, the pattern is markedly different between those 
reporting that they have been previously treated and those who have not, with cannabis being 
the most frequently reported primary drug among first ever presentations (46% compared to 
16% of those reporting previous treatment). The proportion of previously treated clients reporting 
primary opioid use was approximately three times that of those new to treatment (64% and 
22%, respectively). This is indicative of heroin clients being more likely to drop out of treatment 
and to subsequently re-present, or to relapse after completing a treatment episode and to seek 
treatment again as a result. 
While new treatment entrants were around twice as likely to report a primary substance of 
powder cocaine as previously treated clients (14% and 7.6% respectively), they were less likely to 
report a primary substance of crack cocaine (2.8% and 4.6% respectively), indicating that crack 
users are also more likely to have multiple episodes. First time treatment entrants were more 
likely to report the primary use of stimulants other than cocaine (7.0%), and benzodiazepines 
(3.5%), compared to those who had been previously treated (3.8% and 2.2% respectively).
Comparisons of clients accessing treatment across the United Kingdom
Due to its greater population size, data from the treatment system in England has a substantial 
influence on primary drugs reported for the UK; however, there are a number of differences 
between the countries of the UK in the primary drugs cited by clients, shown in Figure 4.1. 
While primary opioid use was reported by around half of all treatment entrants in England, 
Wales and Scotland (49%, 55% and 55%, respectively), only 20% of clients starting treatment 
in Northern Ireland in 2015 reported primary use of these drugs. England had almost twice the 
proportion of treatment entrants citing primary use of powder cocaine in comparison to Wales 
and Scotland (10%, 6.1% and 5.4%, respectively), and more than five times the proportion of 
treatment entrants citing primary crack use (4.6%, 0.8% and 0.7%, respectively). 
Northern Ireland reported a relatively large proportion of its treatment entrants as seeking help 
for drugs that are commonly prescribed as medicines. ‘Other opioids’ represented 10% of 
treatment entrants (compared to 3.3% in the UK overall), and 18% of clients reported primary 
benzodiazepine use in this country, compared to 1.6% in England and 2.0% in Wales. These 
values are high even when taking into account the differences caused by the smaller proportion 
of opioid treatment seekers in Northern Ireland. Scotland also reported a high proportion of 
primary benzodiazepine users, with 11% of treatment entrants citing these substances.
There were also differences between the countries of the UK with respect to stimulants other 
than cocaine reported upon treatment entry. Wales reported the greatest proportion of these 
clients in 2015, with 8.9% of all treatment entrants reporting primary use of amphetamines 
(compared to 2.2% in England, 2.0% in Scotland and 0.3% in Northern Ireland). Synthetic 
cathinones were reported by 1.4% of clients in England and 2.6% of clients in Northern Ireland; 
primary synthetic cathinone use was reported by more clients in Northern Ireland than primary 
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use of amphetamines, methamphetamine and MDMA combined. Scotland and Wales did not 
provide information on synthetic cathinone use.
Figure 4.1: Proportion of clients presenting to treatment in the United Kingdom in 2015, by 
country and primary drug
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Primary drug breakdown for continuous treatment clients (England and Wales)
The length of time that clients spend in drug treatment differs greatly depending on the nature 
of the drug for which they are seeking help; in particular, opioid clients are typically in treatment 
for much longer than non-opioid clients. As such, the distribution of primary drug for just those 
clients who commence treatment in a year (ie TDI cases) does not take into account those 
(mostly opioid) clients in continuous treatment from the previous year. Of the 137,409 clients 
in continuous treatment in England and Wales in 2015, 82% were in treatment due to primary 
opioid use, with 72% of all clients citing heroin. This is a much greater proportion than for those 
commencing treatment in 2015 (see above). At nine per cent, cannabis was the only other 
primary drug cited by more than five per cent of those in continuous treatment. Methadone use 
was cited by 4.6% of clients, and powder cocaine was cited by 3.2% (TDI Prevalence). 
Secondary substances
Alcohol was the most common secondary substance reported by those entering treatment 
in 2015, with 22% of all clients (n=25,789) reporting a secondary alcohol problem. Secondary 
alcohol use was most common among those reporting primary powder cocaine (40%), MDMA 
(30%), crack cocaine (29%) and cannabis (29%) (TDI).
Crack cocaine was the next most common secondary substance, reported by 23,540 clients 
(20%). The vast majority (n=22,207; 94%) of these clients were primary opioid users. The 
number of primary heroin clients entering treatment in the UK reporting secondary use of crack 
cocaine has been increasing since 2003/04, and in 2015 accounted for 45% of all primary 
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heroin presentations (a rise from 38% in 2013 and 41% in 2014). In England, crack use was 
reported by 43% of primary opioid users, whereas in Scotland and Northern Ireland, only 3.3% 
and 1.6% of primary opioid users reported secondary crack cocaine (TDI).38
The number of clients presenting to treatment in the UK in 2015 reporting a secondary 
benzodiazepine problem (n=9,384) was over three times the number of presentations reporting 
a primary benzodiazepine problem (n=3,079). Heroin users accounted for more than two-thirds 
(67%) of these secondary benzodiazepine users. As with primary use, secondary benzodiazepine 
use was high in Northern Ireland and Scotland, with 40% and 30%, respectively, of primary 
opioid users in these countries reporting secondary use, whereas 11%  of opioid users in 
England reported secondary benzodiazepine use (TDI).
Age 
Age of treatment presentations
The mean age of all treatment presentations in 2015 was 32.4 years. However, those who had 
never previously received treatment tended to be younger (28.2 years). Of all clients accessing 
treatment, males tended to be slightly older than females (32.6 years and 31.8 years respectively), 
but the ages across genders were more similar in new treatment entrants (28.1 years in males 
and 28.2 years in females) (TDI). 
Of all clients accessing treatment in 2015, those accessing treatment for heroin, methadone, 
crack cocaine and benzodiazepines tended to be older (36.6 years, 37.3 years, 35.9 years 
and 36.6 years, respectively) than those accessing treatment for cannabis, MDMA and volatile 
substances (24.3 years, 22.1 years and 25.0 years, respectively). Among users of stimulants other 
than cocaine, those who presented for treatment of amphetamine or methamphetamine use 
were almost ten years older than those who required treatment for use of synthetic cathinones 
(35.0 years, 35.8 years and 26.1 years, respectively). These patterns of age differences were 
seen irrespective of gender or treatment history, except for volatile inhalant users, where those 
new to treatment were approximately ten years younger than those who have received treatment 
previously (21.0 years and 30.4 years, respectively). 
Since 2003/04 the percentage of primary heroin users entering treatment who were over the 
age of 40 years has more than trebled, increasing from 10% to 35% in 2015; this is reflective of 
the static population of an ageing cohort. 
Age of those in continuous treatment (England and Wales)
Age breakdowns of those in continuous treatment are available for clients in England and 
Wales (see accompanying table Treatment 2). Nearly two-thirds (64%) of the 137,409 clients in 
continuous treatment in 2015 were aged 35 and over. However, as clients in treatment for opioid 
use make up more than three-quarters (82%) of all those in continuous treatment, they heavily 
influence age breakdowns. Excluding primary opioid clients, the majority of service users in 
continuous treatment were aged under 35 years (68%), with 38% aged under 25.
Of the 98,811 clients in treatment for heroin use in 2015, the greatest proportion (44%) were in 
the 35-44 years age bracket, with 71% aged 35 and over. Crack cocaine also showed a similar 
age split, with 65% of these clients aged 35 and over, whereas cocaine powder users were 
more likely to be younger, with 67% of clients aged under 35. Benzodiazepine and amphetamine 
clients were mostly aged 35 and over (61% and 59%, respectively).
38 Data from Wales has not been included, as data on secondary substance use was not known for 87% (n=6,385) of 
the 7,345 Welsh treatment clients.
Treatment
53
Three-fifths (60%) of those in continuous treatment for cannabis use were aged under 25, and 
83% were under 35. More than four-fifths of clients in treatment for primary use of MDMA, 
hallucinogens and synthetic cathinones were aged under 35 (80%, 82% and 86%, respectively).
Age at first use among treatment entrants (England and Northern Ireland)
Data on the age at first use of the primary drug cited is only available for England and Northern 
Ireland (TDI). The ages at first use of cannabis, volatile substances and MDMA were lower than 
for other drugs (14.7 years, 15.9 years and 17.1 years, respectively). This was similar regardless 
of gender and history of previous treatment.
Injecting status
The majority (62%) of clients presenting to treatment reported that they had never injected 
drugs, with 16% reporting current injecting. Previously treated clients were three times more 
likely to report currently injecting than new treatment clients (see Table 4.2). Primary opioid 
users accounted for 90% of current injectors, with amphetamine users accounting for 2.4%. 
Heroin users were most likely to inject, with over one-third (37%) of treatment entrants citing 
injecting as their primary route of administration. Although accounting for small numbers, a high 
proportion of methamphetamine users (69/207; 33%) were recorded as current injectors. Clients 
in Northern Ireland were much less likely to have ever injected, or be currently injecting, than 
those in the rest of the UK: 12% of Northern Irish clients had ever injected, with 3.6% currently 
injecting (see accompanying table Treatment 1).
Table 4.2: Injecting status among all clients entering treatment in the United Kingdom, 2015
Injecting status New treatment clients
Previously treated 
clients All clients
n % n % n %
Ever injected, but not 
currently 2,711 7.9 21,938 28.2 24,733 22.0
Currently injecting (in last 
month) 2,215 6.5 16,241 20.9 18,515 16.5
Never injected 29,347 85.6 39,714 51.0 69,254 61.6
Sub Total 34,273 100 77,893 100 112,502 100
Not known/missing/don’t 
want to answer 6,117 5,017 11,732
Total 40,390 32.8 82,910 67.2 124,234 100
Source: TDI.
4.4.4 Treatment demand indicator trends
As mentioned above, TDI data for 2015 includes data collected in prisons in England for the first 
time; previously only Northern Ireland had provided data for clients in treatment in prison. For 
the sake of continuity, the English prison data has been removed for the trends section of this 
annual report.
Due to the introduction of a new methodology for calculating TDI, differences between 2013 
data and previous years should be interpreted with caution. Both the increase in proportion of 
cannabis presentations and the decrease in opioid presentations from 2011/12 to 2013 will have 
been exaggerated by the introduction of the new TDI protocol and should not be treated as one 
time series.
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All treatment entrants
From 2003/04, the percentage of primary cannabis presentations steadily increased from 11% 
of all presentations through to 22% in 2011/12 (the last year of the previous protocol) (see Figure 
4.2). After the change in TDI protocol in 2011/12, the proportion of treatment entrants with 
primary cannabis use increased to 27%; however, this has fallen to 26% in 2015.
There has been a decrease in the percentage of all clients accessing treatment for primary 
opioids, from a peak of 71% in 2003/04 to 56% in 2011/12 (see Figure 4.2). This proportion has 
remained at just over half of all treatment entrants in 2015 (51%). 
Presentations for primary crack cocaine have halved from a peak of 6.0% in 2008/09 to 
3.0% of the treatment cohort in 2015. The proportion of treatment entrants who are being 
treated for primary use of benzodiazepines has steadily increased since 2005/06, and in 2015 
was 2.7% of the treatment entrants (up from 1.9% in 2005/06).
Figure 4.2: Percentage of all drug treatment presentations by primary drug in the United 
Kingdom, 2005/06 to 2015
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New treatment entrants
After recent rises in the percentage of first ever treatment presentations for cannabis, this proportion 
appears to have stabilised at just under 50% of the new to treatment population (48% in 2015). 
The overall percentage of primary opioid clients has decreased from a peak of 58% in 2003/04 
to 21% in 2015/16 (see Figure 4.3). The long-term fall in the proportion of opioid cases among first 
presentations towards the beginning of the series will be partly an artefact of the methodology 
used prior to 2013. Additionally, the drop from 2010/11 to 2011/12 in opioid presentations may 
reflect reduced demand for treatment as a result of reduced supply of heroin at that time. 
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Figure 4.3: Percentage of first drug treatment presentations by primary drug in the United 
Kingdom, 2005/06 to 2015
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4.5 Published statistics from national treatment reporting systems
Aside from TDI data, which is generated from national treatment reporting systems for the UK 
Focal Point/EMCDDA, statistics on clients in treatment are published by England, Wales and 
Scotland. In Northern Ireland, a census of those in treatment on a certain day is carried out 
every two years, with the most recent carried out in 2014.
4.5.1 Data from the National Drug Treatment Monitoring System in England
Adults in treatment
Due to a change in the methodology used by the NDTMS in England, it is not possible to 
compare previously reported figures of adult clients in treatment with those from 2014/15. Drug 
and alcohol treatment clients are now reported together, meaning that those who had drug 
use treatment needs who might previously have been seen by alcohol services (and so not 
included in drug treatment statistics) are now reported. Therefore, the total number will appear 
to have increased. NDTMS has, however, reanalysed previous data using the new methodology, 
allowing for some comparisons. Historical figures will not match those previously reported.
In 2015/16 there were 203,808 individuals over the age of 18 in drug treatment in England; a 
slight decrease from the previous year (n=206,117) and a continuation of the decreasing trend 
in numbers in treatment that started in 2009/10 (Public Health England, 2016a).
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This reduction is principally driven by decreases in the numbers of new treatment journeys 
for opioids and/or crack cocaine. Between 2005/06 and 2015/16, decreases in treatment 
presentations for opioids and/or crack have occurred in all age groups except those aged 40 
and over (see Figure 4.4). However, in recent years, the number in the 35-39 years age group 
has levelled out. These decreases mirror reductions in estimates of the prevalence of problem 
drug use (PDU) and suggest an ageing cohort of opioid and/or crack cocaine users. 
Figure 4.4: Number of adult new treatment presentations for opioids and/or crack cocaine by 
age group in England, 2009/10 to 2015/16
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Young people in treatment in England
The number of young people (aged nine to seventeen) attending specialist drug misuse services 
during 2014/15 was 15,216, down from 15,350 in 2013/14 (a 0.9% decrease) (Public Health 
England, 2015i). This decrease is in line with decreases in self-reported drug use among young 
people (Health and Social Care Information Centre, 2015). Young people waited an average of 
two days to start treatment and 98% waited less than three weeks from the point of referral to 
the first appointment (Public Health England, 2015i).
Cannabis remains the most cited primary drug for which young people present to treatment in 
England. Although there has been a decline in self-reported use of cannabis, the number of young 
people entering treatment for primary cannabis use has been increasing steadily. In 2007/08 
there were just over 9,000 young treatment entrants citing cannabis as a primary substance and 
in 2014/15 this had increased to 13,454 (88% of all young drug treatment entrants). However, 
the number of cannabis entrants seems to have stabilised between 13,000 and 14,000 within 
the last three years (Public Health England, 2015i).
In 2014/15, the number of young people citing heroin as their primary substance fell to a historic 
low of 97, continuing the decreasing trend since 2005/06 and mirroring adult treatment data. 
Following five years of decreasing presentations for powder cocaine (806 in 2007/08 to 245 in 
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2012/13), the figure has remained stable for the past two years, and was 250 in 2014/15 (see 
Figure 4.5). The number of presentations for amphetamine use has decreased over the past 
two years, nonetheless the number in 2014/15 was nearly double that seen in 2005/06.
Figure 4.5: Number of young people in treatment for the primary problematic use of selected 
drugs in England, 2005/06 to 2014/15
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4.5.2 Data from the Scottish Drug Misuse Database
In 2014/15, 12,402 individuals in Scotland had an initial assessment for specialist drug treatment 
(Information Services Division, 2016f). As has been found previously, and observed in data from 
England, since 2006/07 an increasing proportion of individuals from older age groups have 
been assessed for specialist drug treatment each year. In 2006/07, under one-third (30%) of the 
assessed individuals were aged 35 and over, which has increased to just under half (48%) of 
clients in 2014/15.
While heroin was still the most common drug for which individuals sought treatment in 2014/15, 
the proportion of clients reporting this drug as their main substance has decreased over time, 
from 64% (n=6,357) in 2006/07 to 46% (n=3,955) in 2014/15; this proportion varied between 
health boards, from 35% to 64%. Cannabis was the second most common primary drug, 
with 20% of individuals reporting use of this substance, followed by diazepam (10%). Use of 
these two substances has increased over time, up from 14% and six per cent, respectively, 
in 2006/07. The proportion of individuals reporting ‘other opiates’ (ie those other than heroin, 
methadone and dihydrocodeine) has also increased, from 0.6% in 2006/07 to 5.2% in 2014/15. 
In line with the trend reported over recent years, fewer young people are reporting heroin use 
upon initial assessment. In 2006/07, 58% of those under the age of 25 reported using heroin 
at their initial assessment; this fell to 23% in 2014/15. The percentage of individuals currently 
United Kingdom Drug Situation 2016 – UK Focal Point on Drugs
58
injecting fell between 2006/07 and 2012/13, from 28% to 21%; this proportion appears to have 
stabilised, and was 20% in 2014/15, with a range between health boards of 11% and 31%.
4.5.3 Data from the Welsh National Database for Substance Misuse
In 2015/16, the number of new referrals to treatment citing drugs (including those with a primary 
substance of alcohol)39 in Wales was 9,561, a decrease from 10,392 in 2014/15 (NHS Wales 
Informatics Service & Welsh Government, 2016).40 The distribution of males/females has 
remained broadly consistent across the years; 72% of all clients referred were male and 28% 
female in 2015/16. Following an increase in 2012/13, the number of clients citing an opioid 
as their main problematic substance on referral has decreased every year since then, and 
in 2015/16 was 4,309, down from 4,871 in 2014/15. Heroin remains the most cited drug at 
treatment referral, accounting for 42% of all referrals for which drugs were specified as the main 
problematic substance, a slight decrease from 44% in 2014/15. Cannabis (n=1,943; 24%) was 
the second most common primary drug cited at referral. Amphetamines remained the third 
most common substance (n=677; eight per cent) in 2015/16, ahead of cocaine (n=536; six per 
cent). 
4.5.4 Data from the Northern Ireland Drug Misuse Database
In Northern Ireland in 2015/16, a total of 2,229 clients presented to services for problem drug 
misuse, a similar number to 2014/15 (n=2,262), but 21% lower than the number that presented 
in 2012/13 (n=2,824) (Department of Health Northern Ireland, 2016b). However, the number 
of clients presenting to treatment has increased from 1,409 in 2003/04. Unlike treatment 
presentations in England, Wales and Scotland, heroin was the fourth most common main 
drug, with eight per cent of individuals citing it upon presentation. Cannabis, benzodiazepines 
and cocaine were more common than heroin, with 40%, 17% and 11% of clients citing these 
substances as their main drugs. Tramadol was reported as the main drug by 4.8% of clients, 
and 2.3% reported primary use of NPS.
4.5.5 Treatment outcomes
The Treatment Outcomes Profile (TOP) is a clinical tool that enables clinicians and drug workers 
to keep track of the progress individuals make through their treatment journey.41 It measures 
drug use and gives an early indication about a client’s progress in overcoming problems with 
work, education or housing through a set of 20 questions. TOP was introduced in England in 
2007 and has been used in Wales since 2009. In Scotland, from 2008 an enhanced, web-
based SDMD follow-up reporting system was introduced to collect information on individuals 
throughout their treatment, not just at initial assessment. TOP data from England and Wales is 
not comparable due to differences in reporting methodologies.
39 Where there is a known substance type.
40 Figures will not match referenced figures as they exclude alcohol (used without other drugs) as a primary substance 
type.
41 A TOP assessment is completed at treatment entry and then should be completed every three months and on 
treatment exit. See: http://www.nta.nhs.uk/healthcare-TOP.aspx
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Treatment outcomes profile data in England
Table 4.3 shows the mean number of days’ use of a drug reported at treatment start and review, 
and the percentage of clients reporting abstinence of that drug at the six month treatment 
review in England in 2015/16 (Public Health England, 2016a). As with other NDTMS data, the 
reporting methodology changed in 2014/15, and so those using non-opioid drugs are divided 
into those also using alcohol and those not also using alcohol. In 2015/16 the mean days’ use42 
of a drug at treatment start was highest for opioids (all opioid clients) and cannabis (without 
alcohol) (22 days). This was followed by amphetamines (without alcohol) and crack cocaine (in 
those also using opioids) (both 14 days) and then cocaine powder (without alcohol; 10 days). 
For cannabis, powder cocaine and amphetamine users, those who also used alcohol all had a 
lower mean days’ use at treatment start, a lower mean days’ use at six month review, and were 
more likely to be abstinent at six month review.
Table 4.3: Self-reported drug use by Treatment Outcome Profiles at treatment start and six 
month review, and the percentage of abstinent clients at six month review in England, 2015/16
Mean days’ 
use of drug 
at treatment 
start
Mean days’ 
use of drug 
at six month 
review
Percentage 
of clients 
abstinent at 
six month 
review
Opioids (all opioid clients) 21.6 8.3 39%
Crack (in those also using opioids) 13.7 6.7 43%
Powder cocaine (without alcohol) 9.9 2.5 65%
Powder cocaine (with alcohol) 8.9 2.2 67%
Amphetamines (without alcohol) 14.2 5.6 60%
Amphetamines (with alcohol) 11.6 4.5 67%
Cannabis (without alcohol) 22.0 11.3 38%
Cannabis (with alcohol) 19.0 9.0 50%
Source: (Public Health England, 2016a)
Users of both opioids and crack cocaine reduced their days of illicit opioid use by less than 
opioid only users (mean days’ use of drug at six month treatment review was ten days compared 
to seven days out of the last 28 days) (Public Health England, 2016a). 
Treatment outcomes profile data in Wales
Based on TOP data in Wales, for those with a main problematic substance of heroin the average 
number of days of heroin use fell from 22.4 at the start TOP to 8.5 at the exit TOP (a 62% 
reduction), with 56% having not used heroin at all in the 28 days prior to the exit TOP (NHS 
Wales Informatics Service & Welsh Government, 2016). Reductions were greater in clients citing 
use of powder cocaine, where the average number of days of powder cocaine use fell from 9.4 
to 2.6 (a 72% reduction). Reductions were also seen in clients who used cannabis from 22.7 
days to 14.0 (a 38% reduction), with 28% not having used cannabis at all in the 28 days prior 
to the exit TOP. Finally, the change in frequency in the use of amphetamines between start and 
exit TOPs fell from 17.6 to 8.8 days (a 50% reduction), with 47% having not used amphetamines 
at all in the 28 days prior to the exit TOP.
42 Self-reported use in the 28 days prior to starting treatment.
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4.5.6 Clients leaving treatment successfully in England 
Adult clients
The number of opioid clients leaving treatment successfully in England was 10,463 in 2015/16. 
This represented 28% of those exiting treatment. Slightly fewer clients who cited non-opioid 
drugs with or without alcohol left treatment successfully (n=9,955 and n=10,545, respectively); 
however, these successful completions represented 56% and 60% of the total treatment exits 
for these two groups of clients, respectively (see Figure 4.6). 
Figure 4.6: Proportion of clients leaving treatment free from dependency in England, 2009/10 
to 2015/16
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Young people
In 2014/15 12,074 individuals under the age of 18 exited treatment, 80% of whom did so in a 
planned way and no longer required specialist treatment (Public Health England, 2015i).
4.6 Opioid substitution treatment
In the UK OST can be prescribed and managed by any GP, although the vast majority is 
received through structured treatment services where clients are encouraged to also engage 
in other forms of treatment such as psychosocial intervention, counselling and/or groups. Both 
methadone and buprenorphine are recommended in NICE guideline TA114 as treatment options 
for people who are opioid dependent (National Institute for Health and Care Excellence, 2007c). 
Methadone currently remains the most commonly prescribed drug for OST overall in the UK; 
however, in Northern Ireland methadone and buprenorphine are prescribed at similar levels.
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4.6.1 England
Data from the NDTMS shows that the number of opioid users in prescribing treatment increased 
from 99,149 in 2005 to a peak of 153,939 in 2010. It has decreased slightly from this point, 
and in 2015 treatment was prescribed to 139,937 clients in England, a fall from the 144,038 
recorded in 2014 (see Figure 4.7). 
Figure 4.7: Trends in numbers of clients in England receiving opioid substitution treatment, 
2005 to 2015
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4.6.2 Wales
In Wales there was a steep increase in the total number of OST clients between 2005 and 2011, 
from 522 to 2,308.43 Following a fall in 2012 to 2,013, the number increased again to 2,450 
in 2014; however, the number decreased in 2015 to 2,148 (see Figure 4.8). This pattern was 
largely driven by the number of clients being prescribed methadone. The number of clients 
receiving buprenorphine steadily increased from 75 in 2005 to 865 in 2014; however, the number 
decreased slightly in 2015 to 772 (see accompanying table Treatment 3).
43 Due to changes in the Welsh dataset these figures will not match those reported in previous years.
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Figure 4.8: Trends in numbers of clients in Wales receiving opioid substitution treatment, 2005 
to 2015
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4.6.3 Scotland
In Scotland in 2015/16, methadone 1mg/ml solution was prescribed at least once to 
25,569 individuals, based on prescriptions with a valid Community Health Index (CHI) number. 
Due to less than optimal CHI capture rates, this number should be treated as a minimum. In 
2015/16, 112,480 (or 26%) of prescriptions did not have a valid CHI number, and it is not possible 
to determine how many additional individuals prescribed methadone would have been identified 
had this data been complete. The number of individuals prescribed methadone appears to have 
reduced from 26,197 in 2011/12, but this change should be treated with caution given the above 
caveats (Information Services Division, 2016b).
4.6.4 Northern Ireland
A total of 865 patients received substitute prescribing treatment across Northern Ireland in 
2014/15, a five per cent increase on the previous year. Just under half (46%) of OST clients 
were prescribed methadone, while a further 46% were prescribed buprenorphine (personal 
communication – Department of Health Northern Ireland).
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4.6.5 Prescription cost analysis
The Health and Social Care Information Centre publishes annual data on the number of 
prescriptions, quantity prescribed and cost of all medications (in their individual formulations) 
that have been dispensed by pharmacies in England (Health and Social Care Information Centre, 
2016). The UK Focal Point have used this published data to calculate totals for methadone 
and buprenorphine prescribed for substance misuse going back to 2004. The number of 
methadone prescriptions rose by 75% between 2004 and 2010 as more people accessed 
OST, and retention improved. Buprenorphine prescriptions also rose over this time period, but 
the proportion of OST prescribing accounted for by buprenorphine fell from 21% to 20% as the 
increase in methadone prescribing was larger.
Figure 4.9: Number of prescriptions for methadone and buprenorphine dispensed in England, 
2004 to 2015
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After 2010 the total number of people receiving OST fell, and there was a corresponding fall in 
the number of methadone prescriptions dispensed. Despite this overall fall in OST prevalence, 
buprenorphine prescriptions continued to rise until 2014, lifting the proportion of OST 
prescriptions accounted for by buprenorphine to 30%. Buprenorphine prescriptions dropped 
for the first time in 2015, although the corresponding drop seen for methadone was similar, so 
the balance of OST medications prescribed in the English treatment system remained stable 
at 71% methadone to 29% buprenorphine in 2015. One possible contributing factor to the 
increase in the proportion of OST prescriptions accounted for by buprenorphine is the reduction 
in cost (see Figure 4.10).
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Figure 4.10: Price per mg of buprenorphine prescribed in England, 2004 to 2015
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4.7 New developments
4.7.1 New psychoactive substances in prison
In January 2016, PHE published a toolkit in response to increasing use of NPS in prisons. The 
toolkit is designed for prison custodial, healthcare and substance misuse staff and provides 
information on the effects of various NPS and how to manage the problems they cause in prison. 
The toolkit was supported by a national training programme undertaken between September 
2015 and June 2016 (Public Health England, 2015d). 
4.7.2 Chemsex
New guidance has been published by PHE to support those who commission and deliver 
services for MSM involved in chemsex. The briefing includes information on prevalence and 
guidance for local teams in recognising and engaging with clients (Public Health England, 
2015g). 
4.7.3 Project NEPTUNE
Building on its previous work project NEPTUNE is currently developing a series of clinical tools 
and an e-learning44 package for clinicians who come into contact with people who use club 
drugs and NPS.
44 See: http://neptune-clinical-guidance.co.uk/e-learning/
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4.7.4 Treatment funding in Scotland
In April 2016 responsibility for drugs policy in Scotland transferred from the Justice portfolio 
to the Health portfolio. At the same time, the Drugs Policy Unit also took on responsibility for 
alcohol interests for ADPs, and has since been renamed the Substance Misuse Unit. An alcohol 
team remains in Scottish government with responsibility for all other aspects of alcohol policy, 
including Minimum Unit Pricing and Alcohol Brief Interventions. 
4.7.5 Social impact bonds
In July 2016 the UK government launched the Life Chances Fund, representing £80 million of 
funding directed towards a range of entrenched, complex social issues. The fund is structured 
around six key themes, one of which is drug and alcohol dependency, and £30 million of 
funding is allocated specifically for this area. The Life Chances Fund aims to encourage the 
use of social impact bonds, whereby treatment providers are given start-up funding by social 
investors to deliver a service. Upon successful achievement of the predetermined outcomes, the 
Life Chances money will be used to pay the social investor. Providers were asked to submit an 
expression of interest in this scheme by 30 September 2016, with the final application decisions 
to be made in July 2017.45
4.7.6 Recovery Partnership quality standards frameworks
The Recovery Partnership, formed in 2011 and funded by the Department of Health, published 
a set of quality standards frameworks for community drug and alcohol treatment services in 
October 2016. There are separate frameworks for community substance misuse services and 
residential rehabilitation (Recovery Partnership, 2016a, 2016b).
45 See: https://www.gov.uk/government/publications/life-chances-fund 
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5 Drug users in prison
5.1 Introduction
The link between substance misuse and crime is strong and represents a major challenge to 
the efforts to turn prisoners away from further criminal activity. Offenders do not necessarily 
want to stop taking drugs just because they have been imprisoned and so the demand for 
drugs in prisons is strong. For many prisoners they form a ‘lifestyle’ as well as a physical and 
psychological dependency. As such, there is an unwelcome but deeply held desire for drugs 
in prisons: to maintain dependency; as recreation; to continue the ‘lifestyle’; or to make money 
out of their supply. Drugs can have a number of different impacts in prisons. In addition to 
making rehabilitation more difficult, they can present significant health risks as well as cause 
unpredictable and violent behaviour. They can also put pressure on families and staff to supply 
them and form the basis of a trade which involves debt, intimidation and violence.
The Department of Health (DH) funds clinical and non-clinical substance use treatment in all 
prisons and the community in England. As part of the new health and care changes set out in 
the Health and Social Care Act 2012 (Her Majesty’s Government, 2012b), NHS England became 
responsible for commissioning health services in prisons and other secure accommodation 
in England. In Wales, health services are under the control of the Welsh government, with 
commissioning carried out by local health boards. The National Offender Management Service 
(NOMS) Wales retains responsibility for non-clinical substance misuse services for sentenced 
offenders. In Scotland, the NHS is responsible for the provision of health care services in prisons, 
with a range of health and substance misuse services now being provided within Scottish 
prisons by the respective local health boards. In Northern Ireland the South Eastern Health and 
Social Care Trust (SEHSCT) provides prison healthcare services.
One of the key elements of Transforming Rehabilitation: A strategy for reform (Ministry of Justice, 
2013) was to provide offenders with the support they need ‘through the gate’, offering continuous 
support, including treatment for substance misuse, from custody into the community. 
Those in prison have access to a range of treatment services for substance misuse including 
clinical services such as detoxification and opioid substitution treatment (OST), structured 
psychosocial interventions, case management and structured counselling. Testing for HIV and 
hepatitis, and the vaccination against hepatitis B, are also available. In Scotland, Take Home 
Naloxone (THN) is widely available for prisoners at risk of opioid overdose on release, and is 
becoming increasingly available in England, Wales and Northern Ireland. 
5.2 Prison service overview
5.2.1 England and Wales
Custodial estate
There are 120 prisons currently in use in England and Wales. The majority (106) are run by Her 
Majesty’s Prison Service, while the remaining 14 are contracted out to private companies. Twelve 
establishments out of the 120 are predominantly for female prisoners, five are young offender 
institutions (YOIs), and two are immigration removal centres (National Offender Management 
Service, Her Majesty’s Prison Service, & National Probation Service, 2017). 
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When sentenced, adult male prisoners are assigned to a security category and allocated to 
the appropriate prison. Categorisation is based on the level of risk a prisoner might pose to 
the public or national security should they escape and the likelihood of their making attempts 
to do so. 
Community
Under rehabilitation reforms which commenced operation in early 2015, Community Rehabilitation 
Companies (CRCs) are required to ensure that all sentence requirements or licence conditions/
supervision requirements are delivered for the offenders they manage, which may include 
specific licence conditions such as drug testing. CRCs oversee the sentence of the court for 
each offender allocated to them to manage, and in doing so seek to rehabilitate offenders and 
reduce reoffending. CRCs are paid a fixed fee to ensure the sentence requirements and licence 
conditions are delivered, with further payment by results payments available for CRCs achieving 
reductions in offending. An essential aspect of these reforms is the creation of a nationwide 
‘through the gate’ resettlement service, meaning most offenders are given continuous support 
by one provider from custody into the community (see section 5.3.2). 
Young offenders
Offenders under the age of 18 can be held in a secure children’s home (SCH), a secure 
training centre (STC) or a YOI. STCs accommodate males and females aged 12-17, while SCHs 
accommodate those aged 10-17 who are assessed as being particularly vulnerable. YOIs 
accommodate only 15-17 year-old male juveniles. There are five YOIs in England and Wales, 
which are distinct from young adult YOIs which cater for 18-21 year-olds and form part of the 
adult estate. Between April 2014 and March 2015 most young people under the age of 18 held 
in custody were in YOIs (69%), with 21% in STCs and the remaining 10% in SCHs (Ministry of 
Justice & Youth Justice Board, 2016). 
Inmate profile England and Wales
On 30 September 2016, the prison population was 85,639, with 81,796 male and 3,843 female 
inmates (Ministry of Justice, 2016c). On the same date, the YOI population aged under 18 
years was 652 (all male). The number of young people in custody is now almost one-quarter 
of the number in custody in 2008: in June 2008 the under 18 population in custody was 2,527 
(Ministry of Justice, 2016c).
5.2.2 Scotland
The Scottish Prison Service (SPS) is an executive agency of the Scottish government established 
in 1993, and delivers custodial and rehabilitation services to those offenders sent to it by the 
courts. 
There are currently 15 prisons within the Scottish prison system. Thirteen are publicly managed, 
and two prisons (HMPs Addiewell and Kilmarnock) are operated by private sector companies 
under contract to the SPS. There are ten male prisons, one female prison (HMP Cornton Vale), 
and four prisons that hold prisoners of both gender. Ten prisons hold adults, one prison is 
designated for young offenders (HMYOI Polmont), and four prisons house both adult and young 
offenders. Scotland has one open prison, HMP Castle Huntly, and HMP Addiewell is designated 
as a learning prison.
United Kingdom Drug Situation 2016 – UK Focal Point on Drugs
68
The available design capacity for prisons in Scotland is for 8,158 prisoners (personal 
communication – Scottish Prison Service). The average daily adult prisoner population during 
2015/16 was 6,785 male and 385 female prisoners. In 2015/16, the average YOI population 
(aged under 21) was 505 inmates (486 males, 19 females). In total, the average daily prisoner 
population in Scotland in 2015/16 was 7,675 (Scottish Prison Service, 2016a). 
5.2.3 Northern Ireland
In Northern Ireland there are three publicly run prison establishments: HMP Maghaberry, a 
modern high security prison holding adult male prisoners; HMP Magilligan, a medium-to-low 
security institution also holding adult male offenders; and HMP and Young Offenders’ Centre 
Hydebank Wood College and Women’s Prison, which holds male young offenders and female 
prisoners of all ages. 
In December 2016 the prison population of Northern Ireland consisted of 1,415 inmates: 44 adult 
females, 1,277 adult males and 94 young offenders (four female and 90 male) (Northern Ireland 
Prison Service, 2017).
5.3 Strategy and co-ordination
5.3.1 Prison drug strategies
England and Wales
The Drug Strategy 2010, Reducing Demand, Restricting Supply, Building Recovery: supporting 
people to live a drug free life (Her Majesty’s Government, 2010) notes that prison may not always 
be the best place for drug users to overcome their dependence and offending. Reference is 
made to the importance of encouraging offenders to seek treatment at every stage of contact 
with the criminal justice system (CJS) (see section 8.5.1). The strategy also covers reducing drug 
supply in prisons through increased security measures.
In the same year, The Patel Report (Department of Health, 2010) was published. Emphasising 
its role in reducing drug-related crime and in improving the health and rehabilitation of offenders, 
the report reviewed the provision of drug prison treatment in England at the time and made a 
number of recommendations for the future. These included recommendations to: develop a 
unified drug strategy for people in prisons, moving between prisons and on release; develop a 
national health and criminal justice outcomes model to help improve health outcomes; create 
an updated national drug treatment and interventions strategy that covers both community 
and prisons; and ensure that said drug treatment and interventions strategy is linked to other 
relevant initiatives and strategies as they develop.
In May 2013, the Ministry of Justice (MoJ) published a new strategy, Transforming Rehabilitation: 
A strategy for reform (Ministry of Justice, 2013), with the aim of reforming the CJS and reducing 
reoffending rates for prisoners. One of the proposed actions was to provide offenders with 
the support they need ‘through the gate’, offering continuous support, including treatment for 
substance misuse, from custody into the community. The strategy also called for new legislation 
which would make engagement with rehabilitation mandatory over a 12 month period for all 
prisoners released from short custodial sentences of up to two years. Upon release, offenders 
would be subject first to a standard licence period and then to an additional supervision period 
for the purpose of rehabilitation. Following release from prison, offenders would be supervised 
by either CRCs (who supervise low to medium risk offenders) or through the National Probation 
Service (which supervises the highest risk offenders).
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Another change to the prison estate made under Transforming Rehabilitation was the designation 
of a number of prisons as ‘resettlement prisons’, in 2015. These establishments hold category 
C prisoners46 who will engage with resettlement providers in the last three months of their 
sentence. Offenders released from these prisons are expected to leave with a package of 
support in place, delivered by their CRC, enabling better linkage with local settlement services 
and improved family contact.
In February 2015 two new licence conditions and supervision requirements (the drug 
appointment condition and the drug testing condition) became available to manage offenders 
in the community following their release, as part of the Offender Rehabilitation Act 2014 (Her 
Majesty’s Government, 2014c). These conditions make it mandatory for offenders whose use 
of illicit drugs (specific Class A or B drugs in the case of the drug testing condition) caused or 
contributed to them committing the offence for which they were convicted, or may cause or 
contribute to them committing an offence in the future, to attend treatment services or drug 
testing. 
The MoJ has recently published a white paper, Prison Safety and Reform (Ministry of Justice, 
2016d), outlining measures that the government intend to take in order to improve both the 
outcomes of prisoners released back into the community, and the conditions they experience 
while in prison. The government set out its intentions to introduce legislation to simplify the 
framework for testing for psychoactive substances, strengthen search capabilities within 
prisons, and reassess the approach taken to tackling the supply and demand for drugs in 
prison. Measures to be assessed include the substance misuse treatment pathway for prisoners; 
the relationship between substance misuse and issues such as mental health; drug treatment 
services to and from the community; and research to assess the methods currently used to 
tackle the supply of drugs. The government also set out its plan to employ a further 2,500 
prison officers by the end of 2018.
Scotland
The Scottish drug strategy, Road to Recovery: A new approach to tackling Scotland’s drug 
problems (Scottish Government, 2008d), focuses on recovery but also looks at prevention, 
treatment and rehabilitation, education, enforcement and protection of children. The role of 
prison-based drug treatment programmes is highlighted in the strategy as a means of assisting 
recovery. 
In the same year that the drug strategy was published, the Scottish government commissioned 
a task force to investigate health inequalities and published a new strategy, Equally Well (Scottish 
Government, 2008c). One of the key recommendations was for offenders who want to tackle 
their drug problems to be able to get access to addiction and health services within six weeks 
of release from prison. Improving the health and wellbeing of offenders was also cited as a 
means to reduce inequalities associated with violence and alcohol and drug problems. In 2010 
a review of the strategy was conducted and it was agreed to continue offering Throughcare 
Addiction Services, which offer wraparound support to offenders with addiction issues being 
released from prison (Scottish Government, 2010). 
The Strategy framework for the management of substance misuse in custody (Scottish 
Prison Service, 2010) reflects the aims and objectives of the Scottish government’s national 
drug strategy. Over the past decade prison policy on managing prisoners with problematic 
substance misuse has moved from a punitive response to a therapeutic approach, offering a 
comprehensive integrated treatment service to support recovery and community integration 
46 Category C prisoners are those who cannot be trusted in open conditions, but who do not have the resources and 
will to make a determined escape attempt.
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and to reduce reoffending. The strategy focuses on robust security systems to divert, disrupt, 
detect and deter the supply of illicit substances and to support the provision of treatment 
services to encourage prisoners to reject the illicit drug culture.
In 2011 the responsibility and accountability for the provision of health services in prison, including 
substance misuse and mental health services, transferred to NHS health boards. The health 
boards provide a range of health and substance misuse services broadly comparable to that 
available in the community, with the emphasis placed on recovery-focused treatment options, 
including naloxone provision and improved throughcare services. An independent expert review 
of OST in Scotland published in 2013 acknowledged the role that prison healthcare has to play 
in delivering OST to assist recovery (Drug Strategy Delivery Commission, 2013). 
Northern Ireland
The Northern Ireland Prison Service (NIPS) addresses substance misuse based around a three 
strand approach: to restrict supply; to reduce demand; and to assist recovery.
In March 2012 NIPS and SEHSCT, who assumed responsibility for providing healthcare 
(including addiction services) in prisons in 2008, jointly published a Strategic Framework for the 
Reduction and Management of Substance Misuse in Custody. The framework reinforced the 
two organisations’ commitment to working in partnership to address misuse.
The purpose of the framework is to provide strategic direction and guidance in the management 
of prisoners with substance problems. NIPS and SEHSCT will take all reasonable measures to 
reduce the availability of illicit substances to prisoners, and provide recovery-aiding services 
broadly equivalent to those available in the community, while recognising that prisoners require 
different routes to recovery.
The strategic aims are to reduce the availability and supply of illicit substances; reduce the 
levels of substance misuse through recovery-based treatment programmes; ensure treatment 
programmes are integrated with a wide range of related prison-based services; and develop 
substance misuse services to reflect the diverse needs of the prisoner population. 
NIPS also established a team to work in partnership with SEHSCT to address the 
recommendations from the Safety of Prisoners held by the Northern Ireland Prison Service 
report (Criminal Justice Inspection Northern Ireland, 2014). This includes an examination of the 
strategy to manage substance misuse in prisons. Both NIPS and SEHSCT are currently in the 
process of revising the substance misuse policy and strategy.
5.3.2 Co-ordination of drug-related prison health responses
England and Wales
In England, DH is responsible for determining the policy on substance misuse treatment and 
suitable approaches, including the balance between clinical treatment and psychosocial 
interventions. Substance misuse treatment services in custody are commissioned and funded 
by NHS England.
NOMS and NHS England have a co-commissioning responsibility to enable and support the 
efficient delivery of provision. The National Partnership Agreement for the Co-Commissioning 
and Delivery of Healthcare in Prisons in England (NHS England et al., 2015), a tripartite agreement 
between NHS England, NOMS and Public Health England (PHE), sets out respective roles, 
shared principles and development priorities as well as objectives to work together and address 
any issues arising from changes to the delivery environment. The agreement is overseen by the 
Prison Healthcare Board (England).
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In October 2014, the 35 former Probation Trusts were dissolved and their responsibilities were 
transferred to either the newly established National Probation Service within NOMS or CRCs. 
The National Probation Service is responsible for providing supervision to the highest risk 
offenders in the community while 21 CRCs supervise lower to medium risk offenders.
In Wales, health and delivery of its services within public sector prisons are the responsibility of 
the Welsh government, with responsibility for service provision devolved to local health boards. 
NOMS retains responsibility for its non-clinical substance misuse services for sentenced 
offenders.
Resettlement
Key to successful drug treatment outcomes is continuity of treatment following release. The 
MoJ has been working closely with partners in health to help extend the focus of substance 
misuse treatment and recovery services in prison to plan and operate through the gate into 
the community. ‘Through the gate’ resettlement services have been introduced and new 
legislation means that all sentenced prisoners will be supervised for a minimum of 12 months 
post-release, and extends powers to drug test prisoners on licence as well as introducing a 
new drug appointment licence condition. In addition, a comprehensive ‘end-to-end’ approach 
to tackling addiction from custody to the community is being developed and tested in a number 
of resettlement prisons. DH funding has enabled NOMS, NHS England and PHE to test new 
pathway arrangements, develop products which can be used across the country, and capture 
learning by working closely with 10 resettlement prisons as early adopters in the north-west. 
The emphasis has been on joining up services in prison and on release.
Scotland
In Scotland, responsibility for the provision of healthcare services in prisons transferred from 
the SPS to the NHS in November 2011. There are 14 NHS boards in Scotland responsible for 
the delivery of healthcare services to those within their geographical area. The 15 prisons in 
Scotland are located within nine of these boards, each of which has responsibility for providing 
substance misuse services to prisoners within these areas. NHS boards provide a range of 
health and substance misuse services through primary and secondary care practitioners to 
those in prison.
Northern Ireland
The provision of substance misuse services within Northern Ireland’s prisons has undergone 
significant change in recent years. The transfer of responsibility for prison healthcare services 
to the SEHSCT, and recommendations from a number of independent reviews, surveys and 
inspections, have influenced and reflected on a period of continued transition and change.
The provision of substance misuse services has seen progress regarding the implementation 
of a joint Prison Service and Trust substance misuse policy. Each of the prisons within Northern 
Ireland provides a range of treatment interventions through primary care, secondary care and 
specialist addiction services.
5.4 Drug use and problem drug use in prison
5.4.1 Drug use prior to imprisonment
Data regarding prevalence of drug use prior to imprisonment in England and Wales comes from 
self-reporting by prisoners as part of prison surveys (Her Majesty’s Inspectorate of Prisons, 2016). 
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More comprehensive information became available in 2015, with the publication of an in-depth 
report into substance use in prisons, which asked respondents about their substance use in the 
two months prior to imprisonment (Her Majesty’s Inspectorate of Prisons, 2015). In Scotland, as 
well as the biennial prisoner survey which asks about problem drug use before prison (Scottish 
Prison Service, 2015a), further information is available from addiction prevalence testing. This 
study, carried out during one month of the year (November 2015 for the 2015/16 results), tests 
offenders for a number of substances on reception to prison. Addiction prevalence test (APT) 
data and survey results from England and Wales suggest that the majority of prisoners used 
drugs in the period prior to coming to prison (see Table 5.1). A large proportion (around 30-40%) 
of prisoners report having a problem with drugs prior to imprisonment, with female prisoners 
apparently more likely to have a problem than male prisoners (Her Majesty’s Inspectorate of 
Prisons, 2016; Scottish Prison Service, 2016b). The proportion reporting problematic use of 
drugs prior to imprisonment appears to be similar for young (those aged under 21) and adult 
prisoners (Her Majesty’s Inspectorate of Prisons, 2016; Scottish Prison Service, 2016c). 
Table 5.1: Self-reported drug use prior to imprisonment or positive drug tests on reception to 
prison in England & Wales and Scotland, 2015
Illicit drug/medication use two 
months prior to prison
Problem drug use on arrival at 
prison
England & Wales 52% 28% (41% female; 27% male)
Illicit drug/
medication use on 
arrival at prison*
Problem drug use 
prior to prison
Receiving treatment 
for drug use prior to 
prison
Scotland 73% 38%
21% 
(30% female; 
20% male)
*APTs positive for any illegal drugs or medications in 2015/16
See: http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2015-2016.pdf
Source: (Her Majesty’s Inspectorate of Prisons, 2015; Scottish Prison Service, 2015a)
5.4.2 Drug use inside prison: drug testing and survey data
Prevalence of drug use inside prison is self-reported in surveys, and in-prison testing data 
is published for prisons in England, Wales and Scotland. Table 5.2 shows data from the in-
depth survey into drug use in prisons in England and Wales (Her Majesty’s Inspectorate of 
Prisons, 2015), the Scottish Prisoner Survey (Scottish Prison Service, 2015a), and APT. Levels 
of drug use in prisons are lower than in the community, with a marked decrease in the use of 
cocaine. Cannabis is the most prevalent drug both outside and inside prison, with around 40-
50% of prisoners reporting use prior to imprisonment, and 10-15% reporting use inside prison. 
Heroin use appears to halve, from around 20% to less than 10% in prison. Recent surveys 
have reported that synthetic cannabinoid receptor agonists (SCRAs) are now more prevalent 
than heroin, with around 10% of inmates reporting use of these substances. However, other 
surveys suggested that prevalence of SCRA use may be even higher. One study on SCRA use 
in prisons, which collected data between October 2015 and March 2016, reported that 33% 
of respondents had used ‘Spice’ in the last month, with prevalence in nine different institutions 
ranging from 15% to 71% (User Voice, 2016). Due to their recent emergence, and the large 
number of SCRA compounds that may be found in synthetic cannabis products, SCRAs have 
only recently been included in routine in-prison drug testing programmes in England and Wales.
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Table 5.2: Proportion of prisoners self-reporting or testing positive for use of selected drugs 
prior to and during imprisonment, in England & Wales and Scotland, 2015
England & Walesa Scottish Prisoner Surveyb APT (Scotland)
c
Used drugs in prison
18% (drugs) 
26% (inc. 
medications)
43% (ever in prison) 
24% (last month) –
Used 
prior to 
prison
Used in 
prison
Used 
prior to 
prison
Used in 
prison
Use on 
arrival
Use on 
release
Cannabis 38% 13% – 15% 52% 8%
Heroin 15% 7% – 8% 25% (opioids)
8% 
(opioids)
Buprenorphine – 9% – 9% 7% 12%
Benzodiazepines – 4% – 9% 35% 6%
Cocaine 29% 4% – 3% 15% 0%
‘Legal highs’ 5%d 5%d 27% 11% – –
SCRAs 6% 10% 16% 9% – –
a Used in the two months prior to imprisonment; or ever used in respondent’s current prison
b Ever used ‘legal highs’ or SCRAs prior to imprisonment; or used in the last month in prison
c Positive tests on arrival at prison; or on release from prison
d Does not include SCRAs
See: http://www.scotpho.org.uk/downloads/drugs/SPS-Addiction-Prevalence-Testing-Stats-Final-2015-2016.pdf
Source: (Her Majesty’s Inspectorate of Prisons, 2015; Scottish Prison Service, 2015a)
As well as reporting drug use via surveys, prisoners in England and Wales can be subject to 
mandatory drug testing (MDT). There are five ways in which drug testing can be undertaken: 
random testing; reasonable suspicion; risk assessment (where prisoners are being considered 
for a privilege or position of trust); frequent test programme (prisoners selected because of 
their previous history of drug misuse); or testing on reception to prison. During 2015/16 the 
proportion of prisoners undergoing random mandatory drug testing (RMDT) that tested positive 
was 7.7%, a 12% increase on the rate for the previous year of 6.9%, and the highest rate seen 
since 2009/10, when the RMDT rate was 7.8% (National Offender Management Service, 2010, 
2016).
5.4.3 Drug use inside prison: other indicators
England and Wales
Seizures of drugs inside prisons
In response to a question in the House of Commons, the Prisons Minister reported the number 
of prisoners in England and Wales that had been found in possession of drugs during a cell 
search, strip search or other searches (see Table 5.3). The number of prisoners found in 
possession has increased in recent years, from 1,556 in 2013 to 2,255 in the 10 months to the 
end of October 2015. 
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Table 5.3: Incidents where drugs were found in prisoners’ possession, England and Wales, 
2010 to 31 October 2015
2010 2011 2012 2013 2014 2015*
No. of incidents 1,248 1,217 1,565 1,556 2,289 2,255
*Data to October 2015
Source: http://www.theyworkforyou.com/wrans/?id=2015-11-25.17639.h&s=Alcohol+and+Drugs#g17639.r0
Research conducted within a category B local prison47 in England suggests that the type 
of drugs seized between 2005 and 2015 has altered dramatically (Ralphs, Williams, Askew, 
& Norton, 2016). In the first three months of 2015, 973g of SCRAs were seized, compared to 15g 
of cannabis and three grams of heroin. The mass of SCRAs seized in just this quarter of 2015 
outweighed the total recovered in the same prison in the whole of 2014 (969g). Comparison to 
data from 2005 demonstrated the marked decreases in the amounts of cannabis and heroin 
seized: in one month in 2005, seizures of cannabis totalled two kilograms, with 60g of heroin 
also recorded. 
Scotland
Scottish Prison Service report
The SPS 2015/16 annual report shows that 1,031 male and 102 female prisoners were disciplined 
for “administering, or allowing to be administered, a controlled drug to oneself”. This was an 
increase from 2013/14 when the figures were 901 and 102 respectively; the overall rate per 1,000 
prisoners has increased every year since 2012/13 (see Table 5.4) (Scottish Prison Service, 2016a).
Table 5.4: Incidents where an inmate was disciplined for administering, or allowing to be 
administered, a controlled drug to oneself, in Scottish prisons, 2012/13 to 2015/16
2012/13 2013/14 2014/15 2015/16
n
No. per 
1,000 
prisoners n
No. per 
1,000 
prisoners n
No. per 
1,000 
prisoners n
No. per 
1,000 
prisoners
Male 509 67.4 790 106.5 901 123.3 1,031 141.8
Female 125 273.5 79 183.3 102 240.0 102 252.5
Total 634 79.1 869 110.7 1,003 129.7 1,133 147.6
Sources: (Scottish Prison Service, 2013, 2014, 2015b, 2016a)
5.5 Drug–related problems in prisons
5.5.1 Problems associated with new psychoactive substance use
Violence and intimidation
Anecdotal evidence suggests that the growing level of SCRA use in prisons is linked to a 
number of negative outcomes, including an increase in disturbed and disruptive behaviour by 
prisoners, increasing levels of debt, and heightened levels of intimidation and violence towards 
both staff and prisoners (National Offender Management Service, 2015). Until May 2016, a large 
number of SCRAs were not controlled in the UK; therefore due to their relatively low price in 
47 Category B prisons house prisoners placed in the second highest of four security categories, ie for whom the very 
highest conditions of security are not necessary, but for whom escape must be made very difficult. Local prisons 
serve the courts and receive remand and post-conviction prisoners before their allocation to other establishments.
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the community and the lack of comprehensive testing capable of detecting the use of these 
substances, SCRAs have been smuggled into prisons to be sold at a high profit, reportedly for 
up to 30 times their price outside of prison (Ralphs et al., 2016; User Voice, 2016).
In their report Changing Patterns of Substance Misuse in Prisons and Service Responses, Her 
Majesty’s Inspectorate of Prisons described how debts accrued by prisoners could accumulate 
quickly, and be passed on to other prisoners (for example if a prisoner in debt left the prison, 
their debt can be passed on to friends or former cell mates) (Her Majesty’s Inspectorate of 
Prisons, 2015). Prisoners who were prescribed medication may sell this to pay off their debts, or 
to be able to buy other drugs; and others became involved in the selling or transporting of drugs 
within prison to pay off their debts. Debt accrued as a result of SCRA use has been associated 
with violence and intimidation. Prisoners in debt may be used as ‘spice pigs’, whereby they are 
forced by dealers to test new SCRA products to ascertain what quantities are safe and the 
effects caused by the product (Her Majesty’s Inspectorate of Prisons, 2015; User Voice, 2016).
Over the past two years, there has been a marked increase in the rate of assault incidents 
reported in prisons in England and Wales. The MoJ reported that in the 12 months to June 
2016, compared to 2015 there was a 32% increase in the number of prisoner on prisoner 
assault incidents (rate per 1,000 prisoners: 208/1,000 vs 158/1,000), and a 43%  increase in 
assaults on staff (rate per 1,000 prisoners: 70/1,000 versus 49/1,000). Over the same time 
period, serious prisoner on prisoner assaults increased from 1,926 to 2,462 (28% increase), and 
the number of serious assaults on staff rose from 579 to 697 (a 20% increase). The total number 
of serious assaults in prisons in England and Wales has more than doubled since 2013 (Ministry 
of Justice, 2016e). However, this increase has coincided with a reduction in prison staff, with the 
number of public sector prison officers48 falling from 24,831 in March 2010 to 21,505 in March 
2013, and to 18,003 in September 2016 (Ministry of Justice, 2016b). It is therefore possible that 
changes to staffing numbers may also have had an impact on violence levels within prisons.
Prisons in Scotland have also seen an increase in the number of assaults since 2012/13, although 
not to the same extent as those in England and Wales. In 2015/16 there were 83 serious assaults 
(both on prisoners and on staff), compared to 75 in 2012/13. There were also 2,173 minor 
assaults/assaults resulting in no injury on prisoners and staff in 2015/16, compared to 1,921 in 
2012/13 (Scottish Prison Service, 2013, 2016a).
Self-harm and death
As well as an increase in assaults, there has also been a recent increase in the number of 
self-harm incidents reported in prisons in England and Wales. The MoJ reported that in the 
12 months to June 2016, compared to the same time period in 2014/15, there had been a 
26% increase in the number of self-harm incidents (rate per 1,000 prisoners: 426/1,000 versus 
338/1,000). The number of deaths in prisons reported in the year ending September 2016 was 
324, compared to 267 in the same period in 2015, an increase of 21%. The rate of deaths per 
1,000 prisoners (now 3.8/1,000) has been rising since 2012.
In 2015, the Prisons and Probation Ombudsman (PPO) reported on 19 deaths which occurred 
between April 2012 and September 2014 where the deceased was known to be, or highly 
suspected of, using NPS prior to death (Prisons and Probation Ombudsman, 2015). In November 
2016 the PPO reported in a speech that there had been 64 deaths that had occurred in custody 
that were related to the use of NPS between June 2013 and April 2016 (Prisons and Probation 
Ombudsman, 2016). The PPO outlined five risk factors that played important roles in these deaths: 
 • mental health risks – the majority (44) of the 64 deaths were self-inflicted, with psychotic 
episodes believed to be responsible for some, and extreme and unpredictable 
behaviour also found
48 Operational staff at bands 3 to 5, including prison officers, supervising officers and custodial managers.
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 • physical health risks – NPS may exacerbate the effects of underlying medical problems, 
and nine deaths were due to natural causes in prisoners who used NPS
 • drug toxicity – six deaths were attributed to the toxicological effects of NPS or NPS in 
combination with other drugs
 • debt and bullying – prisoners in debt to dealers may be at increased risk of self-harm or 
suicide due to the bullying and violence they experience
 • behavioural problems – prisoners displaying aggressive or violent behaviour caused 
by their NPS use may not be identified to be using these substances, therefore 
opportunities for substance misuse and healthcare teams to intervene may be missed. 
The PPO also outlined five areas of learning for prison staff to help to decrease the adverse 
effects that NPS are having among prisoners: reducing the supply of NPS; increasing staff 
awareness of NPS-related problems; addressing bullying and debt problems robustly; treatment 
services addressing NPS use and offering appropriate monitoring and treatment; and reducing 
demand for NPS among prisoners.
5.5.2 Drug-related health problems
Blood-borne viruses
England 
One of the developmental priorities of the National Partnership Agreement for the 
Co-Commissioning and Delivery of Healthcare in Prisons in England between NHS England, 
PHE and NOMS was to improve the detection, surveillance and management of infectious 
diseases in prisons (NHS England et al., 2015). In April 2014 a new opt-out testing programme 
for blood-borne viruses (BBVs) was introduced in 11 prisons across England. In the first six 
months there was a doubling of BBV testing from 11% to 22% of new receptions being screened 
in the eight prisons that provided data (Public Health England, 2015b). The proportion of those 
testing positive remained stable, with 0.3% testing positive for HIV, 0.2% positive for hepatitis B 
virus (HBV) nine per cent testing positive for hepatitis C virus (HCV). Opt-out testing was initiated 
in a further 10 Phase 2 pathfinder prisons in April 2015. In September 2015 the third wave of 
eight prisons began implementing opt-out BBV testing, including HMP Pentonville, the first 
prison in London to participate in the programme. As of April 2016, NHS England estimated that 
63% of prisons in England and Wales were offering opt-out testing. Preliminary data from the 
health and justice indicators of performance (HJIPs) (see section 5.7.1) for the Phase 2 prisons 
indicates that 16,425 HBV tests, 18,967 HCV tests and 40,705 HIV tests were carried out in 
England in 2015/16 (Public Health England, 2016b). It is hoped that opt-out BBV testing will be 
fully implemented across all prisons in England by 2017. 
Wales
BBV testing programmes and access to treatment are available in each prison in Wales. In 
2015, 13% of prison receptions to Welsh prisons were tested for BBV (personal communication 
– Public Health Wales). This was a small decrease from 14% of prison receptions undergoing 
testing in 2014. 
Scotland
In 2009 the SPS commissioned a study into the prevalence and incidence of hepatitis C 
among a sample of 5,076 prisoners (Scottish Prison Service, 2012). Eight per cent (404/5,076) 
of respondents reported having ever injected drugs in prison, and 2.5% (127/5,076) reported 
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having injected during their current period of imprisonment. Of these 127 prisoners, 74 (58%) 
reported injecting with needles and syringes previously used by someone else. The HCV 
antibody prevalence among all prisoners who participated in the study was 19%; however, 
among injecting drug users (IDU) the prevalence rate was 53%. HCV antibody prevalence was 
higher in female IDU (65% versus 52% in male IDU) and older IDU (68% in those aged 40 years 
and over versus 14% in those aged under 20). Additionally, female IDU in prison had a significantly 
higher HCV positive rate than those in the community (65% versus 54%, respectively).
The Scottish government are working with NHS boards and the SPS to introduce opt-out 
testing for HBV, HCV and HIV for all new prisoners in Scotland during their induction period 
(Scottish Government, 2015a). As of November 2016, opt-out testing for these three viruses 
was available for new prisoners at eight prisons (out of the 15 in Scotland), with an additional 
three prisons conducting opt-out testing for HCV and HIV.49 
5.6 Drug-related health responses
5.6.1 England and Wales
Drug treatment in prisons is based on an assessment of local need and designed to meet 
the requirements of low, moderate and severe drug misusers within the prison population, 
including the many that spend a comparatively short time in prison. Local commissioners have 
the discretion to commission services that accord with national clinical guidelines and that 
they judge are best oriented towards recovery (and consequential reductions in re-offending). 
However, in general, available interventions are:
 • clinical services including clinical responses to immediate needs, such as detoxification 
or maintenance prescribing of methadone or buprenorphine
 • a range of accredited and non-accredited rehabilitative programmes, structured 
psychosocial interventions and other evidence-based approaches in prisons that are 
designed to address prisoners’ substance use, offending behaviour and contribute to 
their wellbeing. Offenders are often encouraged to learn and practise life skills that will 
help them on their recovery journey.
 • case management/continuity, structured talking therapies – including motivational 
therapy, coping/social skills training, behavioural self-control training, mutual aid (ie self-
help) such as Narcotics Anonymous, life skills and family work 
Drug treatment services in prison are commissioned on the basis of equivalence with community 
based treatment and underpinned by evidence-based clinical guidance. 
Treatment figures
From 2015, treatment demand indicator (TDI) data for England contains treatment presentation 
figures from prisons as well as from the community (see section 4.3.3). TDI records data from 
those presenting to treatment services during that year; those already in treatment at the 
beginning of the year are not included in this indicator. In 2015, 27,836 clients presented to 
treatment units in prison; this represented more than one-quarter (27%) of all clients presenting 
to treatment in England. The proportion presenting for opioid use was slightly higher in prison 
than in the community (52% in prison; 49% in the community), with greater proportions of clients 
presenting for primary misuse of methadone (2.7% in prison versus 1.6% in the community) 
49 See: http://www.parliament.scot/parliamentarybusiness/28877.aspx?SearchType=Advance&ReferenceNumbers=S
5W-04546&ResultsPerPage=10 
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and buprenorphine (4.3% in prison versus 1.4% in the community). The proportion of primary 
heroin clients was similar in prison (43%) to in the community (42%). Cannabis was the second 
most common reason for presentation in prison, with 21% of clients reporting primary use of 
this drug (compared to 28% in the community). Primary use of cocaine was more commonly 
reported in prison, with more than double the proportion of those entering treatment reporting 
primary use of crack cocaine in prison than in the community (7.5% and 3.5%, respectively). As 
may be expected, presentation for stimulant use (other than cocaine) was lower in prison (3.9%, 
compared to 5.0% in the community), whereas primary use of benzodiazepines was higher 
(2.1% in prison, compared to 1.5% in the community) (see accompanying table Treatment 1).
Naloxone
The availability of naloxone to prisoners in England has so far been limited. There are proposals 
to pilot its use as part of the end-to-end approach to tackling addiction from custody into the 
community, currently being tested in the north-west area (personal communication – Public 
Health England). Naloxone distribution remains sporadic across England and its distribution is 
not required under treatment guidelines. 
Sondhi et al (2016) conducted a study across ten prisons to analyse the perceptions of staff and 
prisoners regarding THN, and to assess the barriers preventing the training of prisoners and 
the effective and timely distribution of kits (Sondhi, Ryan & Day, 2016). They found confusion 
among staff and prisoners regarding the conflicting message that THN gave; concern regarding 
potential side effects and the consequences of being found in possession of THN; difficulties 
with identifying and encouraging these prisoners to take part in training; and logistical issues 
surrounding the training of prisoners and the distribution of kits at discharge. The study identified 
a need to reduce the loss of potential trainees through the complexity of the prison system, and 
that the beliefs and perceptions of prisoners needed to be given a more nuanced consideration, 
in order to ensure the effective distribution of THN in prison.
In comparison to England, THN is more widely available in Wales, and information is recorded 
regarding the number of prisoners being issued with this antidote on release (Public Health 
Wales, 2016b). Data from the Harm Reduction Database in Wales indicates that 17% of male 
unique individuals issued with THN between 1 April 2015 and 31 March 2016 were issued upon 
release from prison.50 This is a reduction in the proportion of individuals from 2014/15; however, 
the number of individuals increased from 128 in 2014/15 to 146 in 2015/16. As with data from 
previous years, when compared to national Area Planning Board provision, prisons are the 
second highest distributors of THN within Wales.
5.6.2 Scotland
In Scotland a national health improvement framework, Better Health, Better Lives, which was 
developed in collaboration with key partners and launched in 2012, supports the delivery of 
action to improve health and wellbeing in prisons (Brutus et al., 2012). The framework provides 
recommendations consistent with a ‘whole prison’ approach to health improvement and was 
built around health promotion pillars including tobacco, alcohol and illicit drugs. A national multi-
agency Prison Health and Wellbeing Group provides strategic support and direction to health 
improvement, and local multi-agency forums are implementing the framework across prisons 
in Scotland.
The Health Improvement Framework for Offenders in the Community is now being delivered by 
the National Health Improvement Agency, NHS Health Scotland, as part of their work supporting 
community justice. 
50 There are currently no female-only prisons in Wales, therefore comparisons are made for male individuals only.
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Throughcare Addiction Service
The Throughcare Addiction Service (TAS) forms part of the voluntary aftercare service. TAS is 
delivered by local authority criminal justice social work who will work with the offender in the six 
week period prior to release from custody through the six week period post-release, offering 
an intensive motivational service to help the offender address their addiction and link them to 
appropriate services. Data shows that 633 individuals received assistance from the TAS on 
release from prison in 2014/15, just over half the number seen in 2013/14, and a decrease to 
24% from 50% of all voluntary assistance cases (Scottish Government, 2016a).
Naloxone
The independent National Naloxone Advisory Group (NNAG) for Scotland was the body that 
engaged with the Scottish government to manage central funding of naloxone kits, allowing 
for continued service provision. The work of the NNAG ceased on 31 March 2016, when 
responsibility for kit reimbursement passed to NHS boards; however, the Harms Reduction 
sub-group of the Scottish government will monitor naloxone provision. The SPS and NHS health 
boards work in partnership to enable prisoners to undertake naloxone training while in custody 
and receive a naloxone kit on release.
There were 932 THN kits issued by NHS staff in prisons in Scotland in 2015/16 to persons at 
risk of opioid overdose upon release, which represented a six per cent increase on the number 
issued in 2014/15 (n=878) (Information Services Division, 2016e). Since 2011/12 there have been 
4,343 THN kits issued in prisons in Scotland in total. 
There has been a steady decline in the percentage of all opioid-related deaths occurring within 
four weeks of prison release, from the 2006-2010 baseline indicator of 9.8% to 3.1% in 2014. 
This percentage increased in 2015 to 4.7%; this was the same proportion that was seen in 
2013, and is still significantly lower than the baseline indicator value, although the authors 
noted the figures should be treated with caution given the low numbers involved (n=23 in 2015) 
(Information Services Division, 2016e). Performance against the baseline indicator will continue 
to be monitored to ensure that the percentage in the post-naloxone period is estimated with 
sufficient precision. 
The SPS has recently conducted a pilot in HMP Inverness which tested the effectiveness of 
a programme in naloxone administration to operational prison staff, which trained them to 
administer intra-muscular naloxone to prisoners in emergency ‘first on the scene’ situations. 
The SPS is now reviewing the options available to develop future training for front line staff 
responding to opioid overdoses (Scottish Prison Service, 2016a).
5.6.3 Northern Ireland
Treatment figures
In 2015, 564 individuals presented to drug treatment in prisons in Northern Ireland, a similar 
number of patients to 2014 (n=546). This represented one-quarter (25%) of all patients 
presenting to treatment in Northern Ireland in 2015. As in 2014, the most common primary 
drug on presentation was cannabis, which was reported by 26% of patients (n=148); however, 
this represented a decrease from 2014 (30%). Opioids were the most commonly used class of 
drugs, with 34% of prisoners reporting primary use of these substances. ‘Other opioids’ were 
the most common opioid reported (16% of all prisoners), followed by heroin (14%). Primary 
benzodiazepine use was reported by 23% of prisoners, an increase from 15% in 2014; and 13% 
of prisoners presented with primary use of cocaine (all powder). The percentage of treatment 
presentations for primary cannabis use was less than those presenting to treatment in the 
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community (43%), although there were more than double the proportion of primary heroin and 
opioid users seeking treatment in prison than in the community (community figures of 6.4% 
for heroin and 16% for opioids). Primary cocaine users accounted for a greater proportion of 
presentations in prison than in the community (13% versus 11%); however, stimulants other than 
cocaine were much more commonly reported in community treatment centres than prison 
(8.2% and 3.2% respectively) (TDI, 2016).
Opioid substitution treatment
SEHSCT is responsible for the provision of addiction services to NIPS, which comprise a clinical 
addiction team (for clinical treatments) and Alcohol and Drugs: Empowering People Through 
Therapy (AD:EPT) for all psychosocial interventions. The clinical team provides OST within the 
prison setting, adhering to the Northern Ireland Opioid Substitution Services Interface Protocol 
between Prisons and Health and Social Care Trust Community Addiction Services (April 2015). 
Psycho-social support / counselling / harm reduction
AD:EPT is a comprehensive drug and alcohol service delivered by Start360, a voluntary sector 
provider, across the three sites of the NIPS in partnership with SEHSCT. AD:EPT provides 
a range of services to people in custody who have problems associated with the misuse of 
substances. Interventions provided by AD:EPT include addiction severity index comprehensive 
assessment; one-to-one counselling; relapse prevention sessions; naloxone training; and pre-
release work. 
Naloxone
The New Strategic Direction for Alcohol and Drugs Phase 2 2011-16 (NSD Phase 2) (Department 
of Health Northern Ireland, 2011) requires the Public Health Agency (PHA) to pilot a scheme for 
THN and for this to be reviewed. The pilot is being undertaken by a partnership between the 
PHA and the Health and Social Care Trusts, and community addiction teams and NIPS began 
to give out THN kits in July 2012. THN training in prisons is jointly provided by AD:EPT and the 
SEHSCT clinical addiction team. Initially it was offered to those on substitution programmes, but 
has since been expanded to anyone at risk. 
The PHA service review highlighted some of the on-going challenges to the uptake of THN, 
which include consideration of how to increase the training and take-up for those leaving prison, 
and reducing the time between departure and receiving their naloxone (Shorter & Bingham, 
2016). To date the statistical data collected regarding the distribution of naloxone is limited. 
However, it is estimated that approximately 150 THN kits have been distributed to patients being 
discharged from prison health care.
5.7 Quality assurance of drug-related prison health responses
5.7.1 England
Public Health Outcomes Framework indicators
There are a number of indicators on the Public Health Outcomes Framework (see section 4.2.1) 
related to people in contact with the CJS. Until April 2016, the proportion of people assessed 
for substance dependence issues when entering prison who then require structured treatment 
and who had not previously received community treatment was one of these. This measure 
was designed to give local authorities an indication of the scale of treatment need unmet in 
the community; in 2012/13 the average proportion across England was 47% (Public Health 
England, 2015e).
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Following a consultation in 2015, this indicator was amended in May 2016 to report the 
proportion of adults with substance misuse treatment needs who successfully engaged in 
community-based structured treatment following release from prison (Department of Health, 
2016). Prisoners with substance misuse treatment needs are at increased risk immediately 
following their release from prison; this indicator will therefore directly measure their engagement 
with treatment services during this important period. 
Health and Justice Indicators of Performance
A set of HJIPs were developed by NHS England, PHE and NOMS to replace the previously 
used prison health performance and quality indicators (NHS England, 2014). These indicators 
are largely quantitative and include specific measures for drugs and alcohol. NHS England area 
teams will work with their commissioned providers to collect the HJIPs. 
Quality assurance of mental health services
In May 2015 the Royal College of Psychiatrists’ Centre for Quality Improvement established a 
Quality Network for Prison Mental Health Services, with the aim of promoting quality improvement 
in the field of prison mental health. This field is becoming increasingly important with regard to 
substance misuse with the increase in prevalence of SCRAs in prison, and the mental health 
issues that have been associated with their use (see section 5.5.1). The network published its first 
edition of standards for services in June 2015, which were updated in September 2016 (Royal 
College of Psychiatrists Centre for Quality Improvement, 2016b). Standards include requiring 
written policies in place for liaison and joint working with substance misuse services and primary 
care in cases of co-morbidity, and a joint working policy on the control and management of 
substance misuse and illegal substances. Eighteen prisons participated in the first year of the 
network, carrying out self- and peer-review of services in these establishments, the results of 
which were published in the annual report in September 2016 (Royal College of Psychiatrists 
Centre for Quality Improvement, 2016a). Forty-two services have been recruited to participate 
in the second year of the network.
5.7.2 Wales
Across the public sector prison estate in Wales, standards of treatment provision will be matched 
against those set out above. In addition, the practice standards issued by the Royal College of 
Psychiatrists in relation to Mental Health services for prisoners will also be adopted.
5.7.3 Scotland
In February 2016 NHS Scotland and the SPS published joint guidance for quality service 
delivery of drugs, alcohol and tobacco health services in Scottish prisons (NHS Scotland & 
Scottish Prison Service, 2016). The report discussed current best practice in substance use 
interventions, and made a number of recommendations covering: data capture and reporting; 
use of national standards (for example adhering to relevant local delivery plan standards) and the 
development of service quality indicators; provision of purposeful activity; capacity of treatment 
services; and the use of service user views in planning and delivery.
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5.8 New developments 
5.8.1 Reform prisons
In May 2016, in its Prisons and Courts Reform Bill,51 the government announced plans to 
convert six institutions in England and Wales to ‘reform’ prisons, in addition to the newly built 
reform prison HMP Berwyn (due to open in 2017). The institutions to be converted are HMPs 
Coldingley, Highdown, Holme House, Kirklevington, Ranby and Wandsworth. The governors of 
these institutions will be given full autonomy over their resource budget, with the ability to opt 
out of national contracts and services. Responsibility for commissioning health care services in 
the new prisons is to be shared between NHS England and the prison’s governor, with the aim 
for this co-commissioning model to be subsequently rolled out nationwide.
5.8.2 New psychoactive substances
As discussed above, the presence of SCRAs within prisons is now an established and significant 
problem (see section 5.5.1). In surveys carried out in England, Wales, and Scotland, SCRAs 
(or ‘Spice’/‘Black Mamba’) were the second most commonly reported illicit ‘drug’ used in 
prison, following closely behind cannabis (Her Majesty’s Inspectorate of Prisons, 2015; Scottish 
Prison Service, 2015a) (see section 5.4.2). Of the 23-25 prison-based treatment services that 
responded to the State of the Sector survey (Recovery Partnership, 2016c), 96% reported an 
increase or significant increase in the number of prisoners with treatment needs relating to 
SCRAs since September 2014. Sixty-two per cent and 58% of respondents also reported that 
there had been an increase or significant increase in the number of prisoners requiring support 
related to the use of new stimulants or new hallucinogens, respectively, since September 2014. 
The Psychoactive Substances Act 2016 came into force in the UK in May 2016, making it an 
offence to be in possession of a psychoactive substance in a custodial institution (Her Majesty’s 
Government, 2016f). See section 8.3.1 for further details.
England and Wales
In November 2016 the PPO reported that there had been 64 deaths in prisons between June 
2013 and April 2016 associated with the use of NPS (Prisons and Probation Ombudsman, 
2016); this came after a report in July 2015, where the PPO reported on 19 deaths under similar 
circumstances (Prisons and Probation Ombudsman, 2015) (see section 5.5.1).
NOMS has developed an innovative new drug testing programme, the first in the world to routinely 
test for NPS through MDT. This was implemented across the prison estate in September 2016.
In May 2016 the Justice Secretary announced that an extra £10 million was going to be made 
available to prison governors to help tackle increasing levels of violence and suicides within 
English and Welsh prison establishments; funding was made available for additional drug 
testing, including for NPS, as well as extra prison staff, training, and equipment.52 
Scotland
The SPS is currently developing a national strategy and action plan to respond to prisoners 
under the influence of NPS. This includes developing a protocol on the management of prisoners 
under the influence of NPS who are demonstrating challenging behaviour including ‘excited 
51 See: http://researchbriefings.files.parliament.uk/documents/CBP-7601/CBP-7601.pdf 
52 See: https://www.parliament.uk/documents/commons-committees/Justice/correspondence/letter-190516-michael-
gove-response-prison-safety-report.pdf 
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delirium’, and the roll out of a national NPS staff training programme. The SPS is also working 
collaboratively with NHS health boards to support the development of a clinical response in line 
with the Project NEPTUNE guidance (see section 4.2.3).
5.8.3 Legislation
Smoking ban
The Health Act 2006 (Her Majesty’s Government, 2006) brought in a total smoking ban in 
enclosed public places in England on 1 July 2007 (similar bans had already been implemented 
in Scotland, Wales and Northern Ireland). Prisons were exempt from this ban and prisoners 
remained able to smoke inside their cells. This has led to a number of legal challenges, resulting 
in the Welsh Assembly committing to a full smoke-free policy being implemented from January 
2016 in all prisons in Wales. In England, four early adopter sites (HMPs Exeter, Channing Wood, 
Dartmoor and Erlestoke) were chosen to become smoke-free as the first step of a phased 
approach to achieving an entirely smoke-free prison estate. Seven additional prisons in England 
have since become smoke-free. As of January 2017, all of these prisons are operating as entirely 
smoke-free, in both buildings and grounds. E-cigarettes and nicotine replacement therapies 
(NRT) are available to buy in prisons, and NRT can be obtained as part of a stop smoking 
service intervention through prison health services. In addition to this, access to stop smoking 
support is being increased throughout the estate and every prison now has voluntary smoke-
free accommodation. 
5.8.4 Guidelines
In response to the growing concerns over use of NPS in prisons, PHE developed a new toolkit 
designed to support prison custodial, healthcare and substance misuse staff. This provides 
information on the various categories of NPS, their prevalence within prisons, the effects seen 
after acute and chronic use of these substances, and advice on the management of prisoners 
who have taken them (Public Health England, 2015d). The toolkit was published in December 
2015, and was supported by a training programme delivered by PHE and NOMS staff within 35 
prisons, with over 500 prison staff attending these events (Public Health England, 2016f). 
Guidance on the clinical management of substance misuse in prisons is currently being reviewed 
and updated to reflect changing patterns of drug use and to keep pace with the learning from 
recent reviews of unclassified deaths in custody and emerging best practice, and is linked to the 
redrafting of the NICE guidance on managing substances misuse. This work will pick up issues 
around OST, including the use of methadone and buprenorphine, and the use of THN.
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6 Drug-related deaths
6.1 Introduction
Data on drug-related deaths (DRDs) submitted to the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) by the UK is based on three different definitions. The EMCDDA 
definition (Selection B) refers to deaths caused directly by the consumption of at least one illicit 
drug.53 The UK Drug Misuse Definition (DMD),54 originally adopted to measure the impact of 
the former UK drug strategy (Home Office, 2002), is where the underlying cause is drug abuse, 
drug dependence, or poisonings where any of the substances scheduled under the Misuse of 
Drugs Act 1971 (Her Majesty’s Government, 1971) are involved. The definition used by the Office 
for National Statistics (ONS) is much wider and includes legal drugs.55 
The UK DMD has been adopted by the general mortality registers (GMRs) across the UK and is 
a subset of the ONS definition. Information on deaths is also available from a Special Mortality 
Register.56
In 2014, 2,655 deaths which met the EMCDDA definition of drug misuse were recorded across 
the three GMRs. This is a record high and data available for other definitions covering 2015 
shows further increases. Heroin was involved in the majority of DRDs in the UK (46%), and 
86% involved heroin and/or other opioids. Other drugs commonly associated with drug misuse 
deaths included benzodiazepines (14%), cocaine (13%) and amphetamine (seven per cent). 
About three-quarters of DRDs were among men. The average age of those who died in 2014 
was 41.6 years. Women who died were on average about four years older than their male 
counterparts.
6.2 Changes to methodology
In England and Wales, there are significant delays in the registration of DRDs: for each year 
since 2007 the median delay was between five and six months. However, Scotland is subject to 
different legislation around the registration of deaths, and experiences only minimal delays. This 
is problematic for reporting figures based on registration year at UK level, as it combines up-to-
date data from Scotland with generally delayed data from England and Wales. Consequently, UK 
figures under the EMCDDA definition are, from 2015 reporting year onwards, counting deaths 
from England and Wales according to year of occurrence. As such, 2014 is the latest available 
reporting year by this definition, as this is the most recent year where it can be assumed the 
large majority of relevant deaths in England and Wales have now been registered (it is probable 
a substantial proportion occurring in 2015 were not registered by the end of that year). As there 
will be DRDs falling under the EMCDDA definition occurring in 2014 in England and Wales which 
were not registered by the end of 2015, the figure for 2014 is provisional and will be revised 
upwards slightly in the next report to reflect this. For the ONS and drug misuse definitions, the 
figures continue to represent registrations in the most recent year (2015).
53 These deaths are known as ‘overdoses’, ‘poisonings’ or ‘drug-induced deaths’. See: http://www.emcdda.europa.eu/
themes/key-indicators/drd
54 Formerly known as the Drug Strategy Definition.
55 See: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelat
edtodrugpoisoninginenglandandwales/2015registrations#things-you-need-to-know 
56 The National Programme on Substance Misuse Deaths (NPSAD) publishes data from inquests into DRDs reported by 
coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; Procurators Fiscal in Scotland 
and the Scottish Crime and Drug Enforcement Agency.
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A further methodological change from the 2015 reporting year is that causes of death recorded 
as the International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) codes X44, X64 and Y14 alongside relevant T-codes have been incorporated 
into UK figures using the EMCDDA definition. Due to historical coding practice in England and 
Wales, this has substantially increased the number of deaths counted under this definition. 
Because of a lack of specific drug information for some deaths in England and Wales, it is likely 
that some deaths relating to illicit use continue to fall outside the EMCDDA definition. Also, due 
to changes in reporting, a small number of deaths registered in England and Wales where the 
person was not resident in either country are no longer included. For each definition, the time 
series back to 2004 has been updated to take into account these changes (see accompanying 
table DRD2).
6.3 Overdose deaths
Using the EMCDDA definition, the total number of DRDs in the UK during 2014 was 2,655, at 
least a five per cent increase from 2013 (n=2,529) (see accompanying table DRD2), and the 
highest number reported to date. Using the slightly different definition of drug misuse, and 
reporting based on year of registration, there were 3,285 DRDs registered in the UK in 2015 (up 
from 2,936 in 2014). Using the much wider ONS definition, there were 4,609 DRDs registered in 
the UK in 2015 (up from 4,174 in 2014). 
6.3.1 Overdose deaths recorded in each General Mortality Register
In 2014, a total of 1,864 DRDs were reported under the EMCDDA definition for England – this 
is 70% of the UK total. In Scotland, 574 deaths (22%) were reported, with 140 (six per cent) in 
Wales and 77 (three per cent) in Northern Ireland. England saw a two per cent increase in the 
number of DRDs compared to 2013, while Scotland experienced an increase of 11%, Wales an 
increase of 15%, and Northern Ireland a rise of 18%. Figures for England and Wales will still be 
somewhat incomplete for 2014 so they may ultimately make up a greater proportion of the total.
6.3.2 Age and gender
Of the deaths occurring in 2014 meeting the EMCDDA definition, almost three-quarters 
(73%, n=1,948) were males and one-quarter (n=707) were females (see accompanying table 
DRD1). This proportion is similar across the UK, ranging from 68% males in Northern Ireland to 
75% males in Scotland. The number of deaths among males in the UK has increased by four 
per cent between 2013 and 2014, and among females by seven per cent.
In 2014, the average age of those dying was 41.6 years. Males tended to be about four years 
younger than females (40.3 years and 44.6 years respectively). The average age at death has 
increased from 37.6 years in 2004. The average age was lower in Scotland (40 years) than for 
the UK as a whole, particularly for women (40 years).
Overall, the largest proportion of deaths occurring in the UK in 2014 occurred in the 40 to 
44 years age group (467; 18% of deaths). Compared to 2008, the number of DRDs decreased 
for all age groups below the age of 35 and increased for all age groups above this point. An 
increase was seen in all age groups in 2014 compared to 2013, with the exception of the 25-29 
years cohort.
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6.3.3 Intentionality
Three-quarters of deaths reported in the UK using the EMCDDA definition for 2014 (78%, 
2,078 deaths) were accidental self-poisonings (see accompanying table DRD1). There were 219 
deaths reported as intentional self-poisonings and 216 deaths as poisonings of undetermined 
intent (eight per cent each). The remaining five per cent of deaths were reported as mental and 
behavioural disorders due to psychoactive substance use (‘F’ codes). A higher proportion of 
deaths were reported as ‘undetermined intent’ in Scotland than in England and Wales (11% 
versus five per cent each). Northern Ireland had a significantly higher proportion of deaths 
reported as ‘undetermined intent’ (60%), as well as a higher proportion of deaths reported using 
the ‘F’ codes than the UK as a whole (14%), with only 23% reported as accidental poisonings.
6.4 Toxicology of overdose deaths
6.4.1 Headline figures 
Across the UK under the EMCDDA definition, there were 2,304 deaths counted which featured 
an opioid in 2014. This was 87% of the UK total (see accompanying table DRD1). Eleven per 
cent involved non-opioid drugs without an opioid (n=291), while two per cent of the total did not 
have any drug specified (n=60). The large majority of cases with no drug specified (n=51) were 
in England. The proportion of cases with opioid use has remained broadly similar since 2004, 
while the proportion with non-opioid drugs without an opioid has risen from six per cent (see 
accompanying table DRD2). The proportion with no drug specified has fallen from six per cent. 
The proportion of deaths featuring an opioid reported through each GMR in 2014 was highest in 
Scotland (93%), followed by Wales (87%) and England (86%). Northern Ireland experienced the 
lowest proportion (69%); a fall from 91% in 2013, although numbers are lower than the rest of 
the UK (total n=77 in 2014), therefore this should be interpreted with caution. The fall in Northern 
Ireland was attributable to an increase in deaths not involving opioids rather than a substantial 
fall in opioid deaths.
6.4.2  Detail of substances mentioned/implicated General Mortality 
Registers
Each of the three GMRs in the UK are subject to annual reporting and provide a greater level of 
detail on substances mentioned or implicated in death than is currently available at UK level.
England and Wales
The most recent figures for England and Wales cover 2015 registrations reported using the 
DMD and the broader ONS definition (Office for National Statistics, 2016c). There were 1,201 
registrations of deaths where heroin/morphine was mentioned, which represented a 26% 
increase on registrations in 2014 and a 57% increase from 2013. The number of heroin/morphine 
deaths has more than doubled since 2012 (n=579). Although deaths registered in 2011 and 
2012 were notably lower than the preceding years, the rate of heroin/morphine deaths per 
million population in 2015 was the highest on record. Heroin/morphine deaths accounted for 
48% of the 2,479 deaths under the DMD, and heroin was the only drug mentioned in 24% of 
drug misuse deaths (603 deaths). Methadone was mentioned in 434 cases (18%), which was an 
increase from the 394 cases seen in 2014, but was a slight decrease in the proportion of deaths 
from 19%. Methadone was the only drug mentioned in 141 deaths (six per cent of the total). 
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Tramadol, which became a controlled drug in the UK in June 2014 (Her Majesty’s Government, 
2014b), accounted for 208 deaths (eight per cent); a decrease from the number (n=240) and 
proportion (11%) seen in 2014. This was the first decrease in tramadol deaths since the first 
registered death in 1996, and tramadol prescriptions have also fallen following a long-term 
rising trend. However, while early indications suggest that the control of tramadol may have 
led to a reduction in tramadol poisonings, registration delays in England and Wales mean that 
complete poisoning data after June 2014 remains limited and this relationship will continue to 
be monitored. In total, 1,989 deaths featured at least one opioid, disregarding those included 
as part of an analgesic compound. Just under one-third of deaths registered in 2015 where at 
least one opioid was mentioned also had a mention of alcohol (557 deaths, 28%), a proportion 
which has fallen over the last three years from 37% in 2012.
Benzodiazepines were mentioned in 366 deaths registered in 2015 in England and Wales, 15% 
of the total under the DMD. This represented a slight decrease from the 372 deaths registered in 
2014, but was still a greater number than the 2013 figure (n=342). However, as seen in previous 
years, only a small number (n=17) of these cases did not also mention another drug. There 
was also a decrease in the number of drug misuse deaths mentioning antidepressants in 
combination with other substances, from 517 in 2014 to 447 (18% of all drug misuse deaths) in 
2015. Conversely there were large increases in the numbers of deaths involving pregabalin and 
gabapentin, from 38 and 26 in 2014 to 90 and 49 in 2015, respectively.
Cocaine was mentioned in 320 deaths (13%), an increase of 30% on 2014 (n=247; the previous 
record number), and 89% on 2013 (n=169). It is believed that the increase in heroin deaths 
where cocaine was also present accounts for a large part of this increase in cocaine-related 
deaths. Eighty-eight cocaine deaths occurred without another substance present. 
The number of mentions of amphetamines rose slightly to 157 (six per cent of deaths); this was 
a stabilisation in numbers after increasing from 56 deaths in 2010 to 151 in 2014. The largest 
proportion of deaths relating to amphetamines involved amphetamine itself (n=90). MDMA was 
mentioned in 57 cases (two per cent), an increase from 50 deaths in 2014. This was the second 
highest number on record, and an increase from eight deaths in 2010; however, this number 
is around the same level seen between 2001 and 2008, before a decrease in the availability of 
MDMA in the late 2000s. Mentions of new psychoactive substances (NPS) continued to rise, 
increasing to 114 (five per cent of deaths), a 39% rise from 2014. The majority of NPS deaths, 
and the increase seen in 2014, were accounted for by mentions of cathinones, principally 
mephedrone (44 out of 49 cathinone deaths, up from 22 of 27 in 2014) and GHB/GBL (26 
deaths). 
When broken down by substance, there were distinct differences in the age profile among 
deaths registered in England and Wales in 2015. The majority of deaths where NPS, cocaine or 
amphetamine were mentioned occurred in people under 40 years of age, while the reverse was 
true for deaths where opioids or benzodiazepines were mentioned. Furthermore, over one-third 
of deaths involving amphetamines or NPS occurred in people aged under 30 years.
Scotland
Statistics for DRDs in Scotland registered in 2015 were published in August 2016 (National 
Records of Scotland, 2016). For this report, DRDs are identified by National Records of 
Scotland (NRS) requesting further information on all deaths involving drugs or persons known, 
or suspected, to be drug-dependent, or where the information on the death certificate is vague 
or suggests that there might be a background of drug abuse. This corresponds closely to the 
UK DMD. 
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There were 706 such deaths registered in Scotland in 2015, an increase of 15% from 2014 
(n=613). More than two-thirds (484 deaths; 69%) of the deaths were males. The largest 
proportions of deaths fell into the 35–44 years age category (n=249; 35%); however, as seen in 
the UK data, the proportion of deaths in the older age categories continued to increase. More 
than one-quarter of all deaths (n=183; 26%) were in the 45–54 years age category in 2015, 
compared to 5.5% of deaths in 2000. Almost three-quarters (n=513; 73%) of individuals were 
aged over 35, and more than one-third (n=264; 37%) were aged over 45 (increases from 67% 
and 32%, respectively, in 2013).
In 2015, there were 606 deaths in Scotland where an opioid was implicated, an increase of 
13% from 2014 (535 opioid deaths). These 606 cases represented 86% of all DRDs, similar to 
the proportion seen in 2014. In 197 of these cases, only opioids (and possibly alcohol) were 
implicated in the death, a decrease from 209 deaths in 2014. Within the opioid category, heroin/
morphine was the most commonly implicated drug, with 345 deaths (49% of all deaths), followed 
by methadone with 251 deaths (36%). There was a 40% increase in the number of cases where 
heroin/morphine was implicated in 2014. The implication figure for this substance has increased 
further for 2015, by 12%. Benzodiazepines were implicated in 191 deaths in 2015 (27%), which 
represented an increase of 58% on the 2014 figure, back to the level seen in 2011 and 2012 
(185 and 196 deaths, respectively). As elsewhere in the UK, deaths where benzodiazepines 
were the only drug implicated (and then possibly with alcohol) were rare (n=6). The number 
of cases where cocaine was implicated more than doubled, from 45 in 2014 to 93 (13% of 
all deaths), among which there were 14 deaths where cocaine was the only drug. Ecstasy 
and amphetamines, reported distinctly, were each implicated in two per cent of deaths. All 15 
ecstasy deaths were male. Alcohol was implicated in 107 DRDs (15%), a similar number to 2014 
but representing a fall in the proportion of all deaths. 
NPS were implicated in 74 cases, a 19% increase from 62 deaths in 2014. Benzodiazepine–
type NPS were the most commonly implicated class of substances, contributing to 57 (77%) of 
the NPS deaths, and etizolam was the most commonly implicated of these NPS, contributing 
to 43 cases. Heroin, methadone or both were implicated alongside the benzodiazepine-
type NPS in 50 cases (88% of benzodiazepine-type NPS deaths). In the remaining 17 cases 
involving non-benzodiazepine NPS, ethylphenidate (five deaths) and methiopropamine (four 
deaths) were the most commonly implicated substances. There were three cases where NPS 
were implicated without any other substance (two methiopropamine deaths and one where 
methylenedioxypyrovalerone (MDPV) was implicated).
Northern Ireland
Tables for DRDs registered in 2015 in Northern Ireland were published in September 2016 
(Northern Ireland Statistics and Research Agency, 2016). These are reported according to the 
DMD and ONS definitions. In 2015, there were 144 DRDs registered in Northern Ireland, with 
114 deaths reportedly due to drug misuse. As seen in the rest of the UK, opioids were the most 
commonly mentioned substance group, being mentioned in 88 deaths registered in 2015 (61% 
of DRDs) and 543 DRDs registered between 2005 and 2015 (53%). However, in contrast to the 
UK as a whole, tramadol was the most commonly mentioned opioid drug, mentioned in 28 
deaths registered in 2015 (19% of all DRDs), followed by heroin, mentioned in 27 deaths (19%). 
There was a sharp increase in the number of deaths involving fentanyl, from one death in 2014 
to 15 deaths in 2015 (10% of all DRDs). As seen in previous years, the number of deaths involving 
a benzodiazepine was high, with 63 deaths (44%) mentioning one of these substances on the 
death certificate. The number of deaths involving NPS (16; of which seven involved mephedrone) 
was more than the total involving cocaine and all amphetamines combined (15 deaths).
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6.5 Provision of naloxone 
In the UK, naloxone is used in hospitals and carried routinely on ambulances to treat patients 
suffering from severe respiratory depression following an opioid overdose. There are national 
naloxone programmes in Scotland, Wales and Northern Ireland which facilitate the distribution 
of naloxone in non-clinical settings such as hostels. These programmes also facilitate the 
distribution of naloxone kits to those at risk of overdose, including individuals at the point of 
release from prison, or to their families and carers. In October 2015 legislative changes came 
into force in the UK to increase the availability of naloxone. These changes made naloxone 
exempt from prescription-only medicine requirements when it is supplied by a drug service 
commissioned by a local authority or the NHS. 
6.5.1 Wales
Data from the Welsh Harm Reduction Database (HRD) showed that in Wales, 1,397 take-home 
naloxone (THN) kits were distributed to new THN clients in 2015/16, with a further 1,789 re-
supply kits being issued (Public Health Wales, 2016b). This represented a 14% increase in the 
total number of kits supplied in 2014/15 (2,785). Since 2009, 10,552 kits have been distributed 
within the country. THN was reported to have been used in 433 drug poisoning events in Wales 
in 2015/16; most commonly (n=368; 85%) to a third party. Death was reported in less than one 
per cent of cases where naloxone was administered.
6.5.2 Scotland
In October 2016, Information Services Division Scotland reported that 8,146 THN kits were issued 
in Scotland in 2015/16. This was an increase of 10% on the previous year. In the community, 
7,214 kits were issued in the same time period, an 11% increase compared to the previous year 
(Information Services Division, 2016e). Throughout the five year cycle of the programme (April 
2011 to March 2016), a total of 29,309 THN kits (including kits issued in the community and from 
prison) were issued in Scotland. 
For Scotland as a whole, supply of kits more than doubled, from 52 kits per 1,000 problem drug 
users in 2011/12 to 132 per 1,000 in 2015/16. The percentage of kits distributed as a repeat 
supply increased each year from 12% in 2011/12 to 38% in 2015/16. In addition, 748 repeat kit 
supplies were made in 2015/16 because the previous kit was reported as having been used to 
treat an opioid overdose. 
In Scotland, Take Home Naloxone (THN) is widely available for prisoners at risk of opioid 
overdose on release and is becoming increasingly available in England, Wales and Northern 
Ireland (see section 5.6).
6.6 Trends in drug-related deaths
6.6.1 Short-term trends
Using the revised figures under the EMCDDA definition, the figure of 2,655 DRDs in 2014 is the 
highest to date for the UK, exceeding the previous peak of 2,529 in 2013. Due to the registration 
delays in England and Wales, the 2014 figure will be revised slightly upwards when the UK 
reports to the EMCDDA in 2017. Following a previous peak in 2009, there was a sharp fall in 
DRDs in 2010 (to 2,058, a decrease of 15% from 2009), with a small rise in 2011, a stable figure 
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in 2012, and an increase of 12% in 2013. Table 6.1 shows the number of deaths recorded under 
the EMCDDA definition in England and Wales over the last decade.
Table 6.1: Mentions of selected drugs on death certificates in England and Wales, 
2005 to 2014
Date of death year
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total 1,739 1,684 1,911 1,788 1,865 1,537 1,597 1,586 1,948 2,004
Opioids 1,467 1,384 1,581 1,503 1,636 1,360 1,427 1,368 1,687 1,719
Heroin 782 777 894 798 909 609 559 608 819 967
Methadone 231 290 349 399 375 401 490 392 386 343
Tramadol 29 20 28 37 37 84 163 178 248 199
Cocaine 186 181 231 214 156 108 120 138 183 260
Amphetamines 96 92 102 94 48 57 78 114 137 134
Ecstasy 46 48 50 39 4 9 25 40 41 47
Benzodiazepines 125 128 164 184 245 216 248 244 296 286
Opioids % 84% 82% 83% 84% 88% 88% 89% 86% 87% 86%
Heroin % 45% 46% 47% 45% 49% 40% 35% 38% 42% 48%
Methadone % 13% 17% 18% 22% 20% 26% 31% 25% 20% 17%
Tramadol % 2% 1% 1% 2% 2% 5% 10% 11% 13% 10%
Cocaine % 11% 11% 12% 12% 8% 7% 8% 9% 9% 13%
Amphetamines % 6% 5% 5% 5% 3% 4% 5% 7% 7% 7%
Ecstasy % 3% 3% 3% 2% 0% 1% 2% 3% 2% 2%
Benzodiazepines % 7% 8% 9% 10% 13% 14% 16% 15% 15% 14%
Source: Internal analysis from ONS GMR
It should be noted that figures for 2015 based on year of registration indicate that the large increase 
in DRDs in the UK for 2014, which followed a much larger increase in 2013, is very likely to have 
been followed by a further significant increase in 2015. This is evident in the figures submitted 
for the UK for 2015 registrations using the DMD, which show a 12% increase in registrations 
from 2014, and a 44% total increase from 2012. Figures published by the ONS for England and 
Wales for 2015 registrations (Office for National Statistics, 2016c) show a 10% increase using 
the DMD from 2013 and a 52% increase from 2012. In Scotland, where the registration delays 
are minimal and therefore registration year essentially equates to year of death, there was a 
reported 15% rise in 2015, to 706 deaths (National Records of Scotland, 2016). There was also 
an increase of 23% in deaths registered in Northern Ireland using DMD in 2015, to 111 deaths. 
It is therefore safe to conclude, with all the available information, that the increases reported for 
the UK for 2013 and 2014 probably represents the start of an increasing trend.
6.6.2 Long-term trends
The GMR for England and Wales has reported the number of deaths registered going back to 
1993. Registrations increased steadily throughout the 1990s, reaching a peak of 1,851 in 2001 
before falling to 1,480 in 2003. Numbers rose to around 2,000 deaths registered each year in 
2008 and 2009, before falling to 1,636 in 2012 and rising again to the current peak of 2,479 
in 2015 (Figure 6.1). The increases reported between 2012 and 2015 represent the sharpest 
gradient of increase over the full time period.
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Figure 6.1: Number of deaths registered under drug misuse definition,  
England and Wales, 1993 to 2015
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The GMR in Scotland has reported figures going back to deaths registered in 1996. There has 
been a general increasing trend in DRDs since reporting began (National Records of Scotland, 
2016). Figure 6.2 shows the annual figures, along with three- and five-year moving averages, to 
provide a better indication of the overall long-term trend. The broken grey lines show the likely 
range of random statistical variation around the five-year moving average.
Figure 6.2: Drug-related deaths registered in Scotland, three- and five-year moving averages, 
and likely range of values around five-year moving average, 1996 to 2015
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Gender
Males account for around three-quarters of DRDs in the UK. The number of deaths by gender 
in England and Wales is shown in Figure 6.3. While the number of female deaths has risen 
steadily since 1993, the number of male deaths has fluctuated to a greater degree over time. 
The peaks and troughs seen in the overall number of deaths appear to be as a result of these 
fluctuations.
Figure 6.3: Number of deaths in England and Wales registered under the drug misuse 
definition, by gender, 1993 to 2015
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The pattern seen in Scotland (see Figure 6.4) is similar to that seen in England and Wales, with 
the number of female deaths tending to rise more steadily than the number of male deaths, and 
the overall shape of the curve being more influenced by male than female death figures. It is 
worth noting that the number of female deaths in Scotland has increased by almost the same 
amount as the number of male deaths between 2013 and 2015 (females: 134 to 222; males: 
393 to 484), meaning that the number of female deaths has increased by 66% over the past 
two years, compared to an increase in male deaths of 23%.
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Figure 6.4: Number of drug-related deaths in Scotland, by gender, 1996 to 2015
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Toxicology
Data on the toxicology of deaths presented below are again presented by GMR. There are 
differences in the figures presented, in that the England and Wales data from the ONS is provided 
from all drug poisoning deaths, where a substance is mentioned on the death certificate, 
whereas the Scottish data from 2008 represents specifically where a drug was implicated in, or 
potentially contributed to, the cause of death.
Heroin is currently the most commonly mentioned drug at death in England & Wales and 
Scotland; however, in 1996, 1997, 2011 and 2012 methadone was more commonly mentioned 
than heroin in Scotland (see Figure 6.5).
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Figure 6.5: Number of deaths mentioning heroin/morphine and methadone  
in England & Wales and Scotland, 1996 to 2015
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Over the last 16 years the number of cases where benzodiazepines were mentioned on the 
death certificate has increased in England and Wales, but decreased from a peak in 2002 in 
Scotland. In 2002, benzodiazepines were mentioned in more deaths in Scotland than in England 
and Wales combined. Following a fall in the number of benzodiazepine-related deaths to a nadir 
in 2006, the number of cases has been increasing in recent years. Tramadol, pregabalin and 
gabapentin are also increasingly being mentioned on death certificates in the UK.
Ecstasy-type and MDMA deaths decreased in both registers to a low in 2010, and have since 
returned to a similar number (see Figures 6.6 and 6.7). Deaths involving NPS have increased 
greatly since 2010 in both England & Wales and Scotland. There were similar numbers of 
deaths in both registers in 2015; however, the nature of drugs involved differs, as mephedrone 
is responsible for the largest proportion of NPS deaths in England and Wales, whereas 
benzodiazepine-type substances are implicated in the majority of NPS deaths in Scotland. 
Deaths related to amphetamine have more than doubled in both registers since 2000.
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Figure 6.6: Number of deaths involving amphetamine, MDMA and ecstasy-type drugs, new 
psychoactive substances and mephedrone in England and Wales, 2000 to 2015
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Figure 6.7: Number of deaths involving amphetamine, ecstasy-type substances and NPS in 
Scotland, 2000 to 2015
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Age
England & Wales and Scotland have seen long-term increases in the proportions of drug deaths 
occurring in older age groups, and decreases in the proportions occurring in younger age 
groups (see Figures 6.8 and 6.9). 
Figure 6.8: Proportion of all drug-misuse deaths in England and Wales by age-group, 
1993 to 2015
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Figure 6.9: Proportion of all drug-related deaths in Scotland by age-group, 
1996 to 2015
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6.7 Complementary sources of data
6.7.1 National Drug-Related Deaths Database (Scotland)
The sixth report from the National Drug-Related Deaths Database (NDRDD) in Scotland was 
published in March 2016, examining the personal circumstances of those who died a DRD in 
Scotland in 2014 (Information Services Division, 2016c). The DRDs in the NDRDD report were a 
sub-set of the 613 DRDs published by NRS in August 2015 (National Records of Scotland, 2015).
In 2014, there were 575 cases identified as eligible for inclusion in the main NDRDD cohort (an 
increase of 28% from the 448 eligible cases in 2013). As with previous years, around three-
quarters (76%) were male. The proportion of deaths where the individual was aged 35 and over 
has increased over time, from half of deaths (50%) in 2009 to two-thirds (66%) of deaths in 2013; 
however, this proportion has remained at 66% in 2014. Similarly, while the mean age increased 
from 34.4 to 39.1 years in 2013, the mean age at death has remained at 39.1 years in 2014. 
Around the same proportion of individuals (85%) were known to be using drugs prior to death in 
2014 as in 2013, and two-thirds (66%) had a known history of intravenous drug use. Approximately 
three out of ten individuals (29%) were prescribed an opioid substitution treatment (OST) drug 
when they died (a decrease from 31% in 2013, but an increase from 21% in 2009). One-third 
of the cohort (34%) had been prescribed an OST drug at some point since 2009, a decrease 
since 2013 when over half (51%) had been prescribed an OST drug since 2009. However, the 
authors reported that the figure for 2014 may be an underestimate and did not publish inter-year 
comparisons for this figure. There had been a decrease in recent antidepressant prescribing 
in 2014, with 30% (n=172) of individuals prescribed an antidepressant in the 30 days before 
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death, compared to 37% in 2013. In three-quarters of these cases (n=136; 79%) this medication 
was present at post-mortem. Mirtazapine was the most commonly prescribed antidepressant, 
prescribed to 87 individuals (51% of those prescribed an antidepressant). There had also been 
a decrease in diazepam prescribing in 2014, falling to 13% of cases (n=75) from 21% in 2013. 
Three-fifths (60%) had experienced a psychiatric condition in the six months before death, a 
similar proportion to 2013.
Over half (53%) of those included in the cohort had been in contact with drug treatment services 
before they died, the same proportion as in 2013. Seventy per cent (n=404) had been in contact 
with at least one service (drug treatment, hospital, police or prison) which had the potential to 
address their problem drug use, or deliver harm reduction interventions, in the six months prior 
to death.
In 69% of cases, more than one drug was implicated in the death. Diazepam was the drug most 
frequently found to be present (70% of cases, a small increase since 2013, although down from 
77% in 2009), but implicated in less than one-third of these cases (20% of all cases). Opioids 
were the most commonly implicated class of drugs: together, heroin/morphine, methadone 
and buprenorphine were implicated in 76% of deaths. Heroin/morphine was present in 58% of 
cases and implicated in 52%; both of these proportions were the highest recorded since 2010. 
Methadone continued to be present and implicated in a decreasing number of cases; in 2014 it 
was present in 40% of deaths and implicated in 36% (compared to 47% and 42%, respectively, 
in 2013).
6.8 New developments in drug-related deaths
6.8.1 Public Health England reports
Public Health England analysis
In July 2015 PHE produced an analysis of trends in DRDs in England using the DMD, based on 
extracts of data received from ONS (Public Health England, 2015h). This followed the reported 
rise in deaths registered in England using the DMD by ONS for 2013 (Office for National Statistics, 
2014) and a national summit on DRDs in England held in January 2015. This report was updated 
in April 2016, using the ONS data released in September 2015, and covered deaths between 
1999 and 2013, with provisional data for 2014 (Public Health England, 2016g). 
For the 2015 analysis, PHE reported figures based on year of death, highlighting that registration 
delays meant that later years were incomplete. This analysis found that a large number of drug 
misuse deaths registered in 2013 had occurred in the same year (892 deaths), but that there 
had also been an increase in deaths registered after more than one year. In the 2016 analysis, 
the authors reported that there had been a large increase in the registrations of drug misuse 
deaths in 2014 (as there had been in 2013); however, the large majority of these deaths were 
classified as those that had been registered within six months. In total, there were 1,042 drug 
misuse deaths occurring in 2014 that were registered in that year, the largest number recorded 
to date.
In the latest report, PHE also showed that among deaths where heroin was mentioned on 
the death certificate, there was a clear long-term trend towards other substances (including 
alcohol) also being mentioned, and away from heroin being the only drug mentioned. A data 
linkage exercise between drug poisoning data and drug treatment data was included in the first 
report, and repeated in the 2016 update, which showed that around three-fifths (57%) of opioid 
misuse deaths in 2012 had received no treatment since at least 2006 (and possibly never). The 
proportion receiving treatment in the year prior to death had remained reasonably consistent, 
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at around one-third, over the full period studied (2008–2012). When considered in the context 
of prevalence estimates and treatment numbers, both analyses suggested that treatment had a 
significant protective effect for opioid users, corresponding to the findings of a previous report 
(White et al., 2015). However, they also suggested that there has been little change in the extent 
of the protective effect in recent years.
Public Health England inquiry into drug-related deaths
Following the two consecutive increases in the number of DRDs in England in 2014 and 2015, 
PHE and the Local Government Association convened a national inquiry to investigate the causes 
of these increases, and discuss how to prevent future premature deaths (Public Health England, 
2016i). The inquiry consisted of meetings of a national expert group to lead the investigation 
and review data; analysis of existing and commissioned data; and five local events held around 
England to direct the inquiry and gather intelligence on local practice to prevent DRDs. There 
were a number of recommendations for drug treatment service commissioners and providers, 
PHE, NHS England, Clinical Commissioning Groups and the Ministry of Justice, which included: 
ensuring treatment is easy and desirable to access, optimising interventions and retaining those 
in treatment for as long as they benefit; promoting risk management, adequate OST dosing and 
stop smoking services; intervening following non-fatal overdoses; supporting THN provision 
and naltrexone use; strengthening governance and competence in treatment services; sharing 
learning and improving shared information; and continue to research and investigate DRDs and 
their prevention. 
6.8.2 Office for National Statistics report on deaths involving ‘legal highs’
In April 2016 the ONS released an analysis of deaths caused by ‘legal highs’ in England and 
Wales that occurred between January 2004 and December 2013 (Office for National Statistics, 
2016b). ‘Legal highs’ were defined as psychoactive substances which were not controlled at 
the time of death, but which may have been subsequently controlled. Between 2004 and 2013 
there were 76 deaths in England and Wales where a ‘legal high’ was involved; by comparison, 
there were 7,748 deaths involving heroin and 1,752 deaths involving cocaine over the same time 
period. Between 2004 and 2013 around five in six (n=66; 87%) of all ‘legal high’ deaths were 
males, compared to 69% males for all drug misuse deaths over the same time period (Office for 
National Statistics, 2015). The median age at the time of death was 28 years for deaths involving 
‘legal highs’, ten years younger than all drug misuse deaths (38 years). ‘Legal high’ deaths 
were more likely than drug misuse deaths to have more than one substance (including alcohol) 
mentioned on the death certificate: 57% of deaths involved another substance, compared to 
35% of all drug misuse deaths. This may be due to the fact that NPS preparations often contain 
multiple chemicals in one package/tablet. The report also focused on mephedrone, analysing 
the number of deaths occurring before and after this substance was controlled in the UK. While 
use of mephedrone has decreased since the ban in April 2010, the number of deaths involving 
this substance rose from seven in 2010 to 22 in 2012, and has since risen to 44 deaths in 2015. 
However, the report argues that if mephedrone had not been banned, the number of deaths in 
2011 onwards may have been higher.
6.8.3 Role of benzodiazepines in drug-related deaths in Scotland
Benzodiazepines have now become one of the most common drugs found at the time of death 
in DRDs in Scotland (see section 6.4.2). In February 2016 NHS Scotland published a report 
looking into the role of these substances in DRDs and drug-associated mortality, the increasing 
availability of unregulated benzodiazepines, the use of large doses of benzodiazepine-type 
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drugs, and the risks of short- and long-term mental health and cognitive problems associated 
with routine and excessive benzodiazepine use (Johnson, Barnsdale, & McAuley, 2016). 
6.8.4 Cohort mortality study
Gao et al. (2016) conducted a cohort study looking at gender, age-group and quantity of 
methadone prescribed as risk factors for DRDs, and for methadone-specific DRDs, in Scotland’s 
methadone-prescription clients (Gao et al., 2016). The study found that between July 2009 and 
June 2013, methadone-specific DRDs were higher in those aged 35 and over (4.2 deaths 
per 1,000; 95% CI, 3.6 – 4.7) than for younger clients (1.9 deaths per 1,000; 95% CI, 1.5 – 
2.2). For methadone-specific DRDs, age related hazard ratios were steeper than for all DRDs; 
for example, those aged 45 and over experienced a hazard ratio of 2.9 (95% CI, 2.1 – 3.9) 
compared to 1.9 for all ages (95% CI, 1.5 – 2.4). The study also found that the highest quintile for 
quantity of prescribed methadone at cohort-entry (prescriptions of over 1960mg, representing 
for example 14 days at 140mg or 28 days at 70mg) was associated with an increased hazard 
ratio (1.8; 95% CI, 1.3 – 2.5).
6.8.5 Deaths in prison
In July 2015 the Prisons and Probation Ombudsman (PPO) reported on 19 deaths which 
occurred in prison between April 2012 and September 2014, where the prisoner was known, 
or strongly suspected to have been using NPS-type drugs before their death (Prisons and 
Probation Ombudsman, 2015). In November 2016 the PPO updated these figures, reporting 
that between June 2013 and April 2016 there had been 64 deaths in prisons associated with 
the use of NPS (Prisons and Probation Ombudsman, 2016) (see section 5.5.1).
6.8.6 Drug consumption rooms in Scotland
In April 2016 the Scottish Drugs Forum (SDF) published a report by Kirsten Horsburgh, Scotland’s 
National Naloxone Programme Co-ordinator, who is based at the SDF, on reducing DRDs. 
The report detailed survey results on stakeholders’ opinions on drug consumption rooms in 
Scotland, and a Winston Churchill Fellowship mission to Australia to assess Sydney’s medically 
supervised injection centre. The three recommendations of the report were: that there is a clear 
need for supervised injection facilities wherever there are large numbers of people injecting 
in public, therefore legislative changes should be made to allow the Scottish government to 
provide funding for a pilot site; that THN should be available free-of-charge, and promoted 
widely, to those most likely to witness an overdose; and that low threshold services should be 
widely available across the country.
In response to the increased number of HIV diagnoses among PWID in Glasgow in 2015 (see 
section 7.3.1), NHS Greater Glasgow and Clyde published a report in June 2016 which examined 
the health needs of people who inject in public places in the city, and also recommended the 
introduction of a safe injecting facility in Glasgow city centre (NHS Greater Glasgow and Clyde, 
2016). In October 2016, Glasgow City Joint Integration Board approved the development of a 
full business case for such a facility.
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7  Drug-related infectious diseases and 
other drug-related harms
7.1 Introduction
The UK government and devolved administrations have a number of policy and guidance 
documents outlining best practice for responses to the health correlates and consequences of 
drug use (often referred to as harm reduction). Principles of harm reduction aim to reduce the 
risky behaviour of those active drug users who are either unwilling or unable to abstain. Each of 
the UK and devolved administration drug strategies include harm reduction objectives. 
People who use drugs are at risk of both fatal and non-fatal overdose; experiencing periods 
of elevated overdose risk in the immediate period after leaving inpatient treatment and prison; 
and experiencing greater risk of contracting blood-borne viruses (BBVs) through injecting drug 
use. Reducing the harm associated from substance use has been a key priority of the 2010 
drug strategy, and harm reduction programmes aimed at injecting drug users have traditionally 
focused on reducing rates of infection and transmission, increasing the diagnosis of current 
infections, and improving the provision and treatment and support to infected individuals. This is 
often achieved through specialist programmes and initiatives, such as the take home naloxone 
programme, needle and syringe provision and vaccinations against some BBVs.
Injecting drug use is the most significant risk factor for hepatitis C, with about half of injecting 
drug users in England, Wales and Northern Ireland testing positive for this infection in 2015. 
Prevalence of hepatitis C among injecting drug users has been fairly stable over the last ten 
years. Hepatitis B prevalence among injectors dropped from 28% to 20% between the 2007 
and 2008 surveys and has dropped further since then to 13% in 2015. HIV prevalence in this 
cohort is one per cent, similar to that seen in recent years (Public Health England, 2016d).
HIV prevalence among ‘recent initiates’ to injecting substantially increased in 2015 to its highest 
level seen in the last ten years. However, this likely represents an increase in prevalence among 
men who have sex with men (MSM) rather than among the wider population who inject drugs.
7.2 National drug strategies on people who inject drugs
The UK Drug Strategy 2010, Reducing Demand, Restricting Supply, Building Recovery: 
Supporting people to live a drug free life (Her Majesty’s Government, 2010) includes a key best 
practice delivery outcome that all drug services are commissioned to prevent drug-related deaths 
and prevent the spread of BBVs. Public Health England (PHE) routinely publishes guidance on 
best practice and reports annual surveillance on a range of key indicators associated with BBVs 
in the UK. 
In Wales, Working Together to Reduce Harm: The Substance misuse strategy for Wales 2008-
2018 (Welsh Assembly Government, 2008a) sets out a national agenda for tackling and reducing 
the harms associated with substance misuse. Additional guidance is provided in Diagnostic 
Testing for hepatitis C, hepatitis B and HIV (Public Health Wales, 2014a); Blood Borne Viral 
Hepatitis Action Plan for Wales 2010–2015 (Welsh Assembly Government, 2010); and Together 
for Health – Liver Disease Delivery Plan (Welsh Government, 2015a). 
The Scottish government launched the HIV Action Plan in Scotland, December 2009 to March 
2014 (Scottish Government, 2009b) followed by the five year Sexual Health and Blood Borne 
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Virus Framework 2011–2015 (Scottish Government, 2011). Quality standards applicable to all 
HIV services (Healthcare Improvement Scotland, 2011) and quality indicators applicable to all 
hepatitis C services (Healthcare Improvement Scotland, 2012) have also been published. 
In Northern Ireland, responses to health correlates and consequences of drug misuse are broadly 
covered by the overarching strategy for alcohol and drugs misuse, the New Strategic Direction 
for Alcohol and Drugs Phase 2, 2011–2016 (Department of Health Northern Ireland, 2011). One 
of the overall aims of this strategy is to reduce drug-related harm and ensure continued support 
to further develop appropriate harm reduction approaches and strategies.
7.3  Blood borne viral infections amongst people who inject 
psychoactive drugs
7.3.1 HIV
Prevalence
The overall prevalence of HIV seen among people who inject drugs (PWID) in 2015 was similar 
to that seen in recent years. The prevalence of HIV among the current and former PWID taking 
part in the Unlinked Anonymous Monitoring (UAM) Survey across England, Wales and Northern 
Ireland in 2015 was 1.0% (95% CI, 0.6%-1.3%) (Public Health England, 2016c). Between 2005 
and 2014, prevalence varied between 1.1% and 1.6% (see Figure 7.1). In 2015 the HIV prevalence 
was 0.77% (95% CI, 0.01%-1.8%) in Wales, 0.65% (95% CI, 0.01%-1.9%) in Northern Ireland, 
and 1.0% (95% CI, 0.60%-1.4%) in England (see accompanying table DRID).
HIV prevalence among those who first injected during the preceding three years is an indicator 
of recent HIV transmission. The prevalence among these recent initiates participating in the UAM 
Survey of PWID was 2.6% (95% CI, 0.55%-4.7%) in 2015 (Public Health England, 2016c). This is 
a relatively large increase since 2014, when the prevalence among this population was 0.41%, 
and is the highest level seen in the past ten years (see Figure 7.1). In 2015, those with HIV in this 
group were men who reported having sex with men during the preceding year. The elevated 
prevalence of HIV in this group during 2015 therefore most probably reflects the increase in 
injecting drug use that has recently been seen among some groups of MSM, many of whom are 
HIV positive. This probably does not reflect an increase in the level of HIV transmission among 
PWID overall, where injecting drug use was the underlying route of transmission.
In Scotland, among those attending needle and syringe programmes (NSP) during 2015/16, 
1.9% were found to be HIV positive (Public Health England, Health Protection Scotland, Public 
Health Wales, & Public Health Agency Northern Ireland, 2016).
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Figure 7.1: The prevalence of antibodies to HIV among all participants and recent initiates* in 
the Unlinked Anonymous Monitoring Survey of people who inject drugs: England, Wales and 
Northern Ireland, 2005 to 2015
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*A recent initiate is someone who first injected during the preceding three years 
Source: (Public Health England, 2016c)
New cases
There were 182 new HIV diagnoses associated with injecting drug use reported in the UK 
during 2015, compared with 131 new diagnoses in 2014. Fifty of these diagnoses were reported 
from Scotland, compared with 17 in 2014. This increase is due to an outbreak of HIV in PWID 
in Glasgow (Public Health England et al., 2016). There were also 21 reported HIV diagnoses 
that were associated with MSM, for which injecting drug use was also reported as a risk (Public 
Health England et al., 2016). 
Glasgow typically records around 10 new diagnoses of HIV associated with injecting drug use 
each year; 42 new diagnoses with this risk were reported for 2015, the majority with subtype-C 
virus. Data indicate that this increase in diagnoses is related to transmission among a small 
but appreciable population of highly chaotic, vulnerable and often homeless people who 
inject psychoactive drugs, mainly heroin. This outbreak is being managed through increasing 
awareness of the risks of HIV, making HIV testing more accessible and proactively supporting 
the early treatment of those newly diagnosed to reduce the risk of onward transmission.
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7.3.2 Hepatitis C
PWID are the group with the highest prevalence of hepatitis C in the UK. Around 90% of the 
hepatitis C infections diagnosed in the UK will have been acquired through injecting drug use. 
During 2015, 14,134 hepatitis C infections were diagnosed in England, Scotland and Northern 
Ireland (Public Health England et al., 2016). There has been a marked increase in the annual 
number of new diagnoses throughout the UK over the last decade, reflecting the increased 
availability and easier access to voluntary confidential testing.
The overall prevalence of antibodies to hepatitis C (anti-HCV) among the current and former 
PWID participating in the UAM Survey of PWID was 50% (95% CI, 49%-52%) in 2015 (Public 
Health England, 2016c). This proportion has remained relatively stable over the last decade 
(see Figure 7.2). Anti-HCV prevalence in Northern Ireland was 27% (95% CI, 20%-35%), which 
is lower than in England (52%, 95% CI, 50%-54%) and Wales (53%, 95% CI, 47%-59%). While 
the hepatitis C prevalence among the participants in the UAM Survey in England and Northern 
Ireland has remained relatively stable over time, in Wales there has been an increase from 
19% recorded in the period 2003–05 (Public Health England, 2015c) (see accompanying table 
DRID). In England there were marked regional variations from 26% (95% CI, 19%-33%) in the 
West Midlands to 68% (95% CI, 63%-72%) in the North West (Public Health England, 2016c).
In Scotland, the estimated anti-HCV prevalence was 58% among current and former PWID 
surveyed at services providing injection equipment across mainland Scotland in 2015/16. This 
compares to 54%, 56%, 53% and 58% who tested positive in 2008/09, 2010, 2011/12, and 
2013/14 respectively (Public Health England et al., 2016).
The level of hepatitis C transmission among PWID in the UK appears to have changed little in 
recent years. Anti-HCV prevalence among recent initiates has also been fairly stable. Among 
those in this group participating in the UAM survey of PWID, prevalence was 24% (95% CI, 
18%-30%) in 2015 (Public Health England, 2016c). Over the last decade the prevalence in this 
group has ranged between 18% and 24% (see accompanying table DRID). In 2015, incidence 
of hepatitis C infection among PWID in the UK was estimated to be eight infections per 100 
person years of exposure (Public Health England, 2016e). In Scotland, the incidence of hepatitis 
C infections among PWID was estimated to be 11.5 infections per 100 person years of exposure 
during 2015/16 (Public Health England et al., 2016).
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Figure 7.2: The prevalence of anti-HCV among all participants and recent initiates* in the 
Unlinked Anonymous Monitoring Survey of people who inject drugs: England, Wales and 
Northern Ireland, 2005 to 2015
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Source: (Public Health England, 2016c)
7.3.3 Hepatitis B 
In 2015, 13% (95% CI, 12%-14%) of the current and former PWID who took part in the UAM 
Survey of PWID had antibodies to hepatitis B core antigen (anti-HBc, a marker of previous or 
current hepatitis B infection) (Public Health England, 2016c). This prevalence has remained 
relatively stable in recent years, but it is lower than the level seen ten years ago when prevalence 
was 26% (see Figure 7.3). The prevalence of anti-HBc varied by country: Northern Ireland, 6.5% 
(95% CI, 2.6%-11%; prevalence was 13% in 2005); Wales, 11% (95% CI, 7.0%-14%; prevalence 
was 9.3% in 2005); and England, 14% (95% CI, 12%-15%; down from 28% in 2005) (Public 
Health England, 2016c) (see accompanying table DRID).
The available data on reports of acute hepatitis B infections indicate that there are currently 
few of these among PWID, with most UK acquired cases associated with sexual activity. This 
is likely reflecting the impact of the marked increased in the uptake of the hepatitis B vaccine 
among PWID (Public Health England et al., 2016).
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Figure 7.3: The prevalence of anti-HBc among all participants and recent initiates* in the 
Unlinked Anonymous Monitoring Survey of people who inject drugs: England, Wales and 
Northern Ireland, 2005 to 2015
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7.4 Blood borne viral infections amongst people who inject image 
and performance enhancing drugs
During the 2014/15 sampling period 354 individuals took part in the UAM sub-survey of those 
who inject image and performance enhancing drugs (IPEDs) from across England and Wales, 
where participants provided a dried blood spot specimen that was tested anonymously for 
HIV, hepatitis C and hepatitis B. Of these participants, 0.56% (95% CI, 0.01%-1.3%) had HIV 
(compared with 1.0% in PWID using psychoactive drugs); 2.5% (95% CI, 0.9%-4.2%) anti-HBc 
(compared with 13% in those PWID using psychoactive drugs); and 5.1% (95% CI, 2.8%-7.4%) 
had anti-HCV (compared with 52% in those PWID using psychoactive drugs) (Public Health 
England, 2016c, 2016d).
In Scotland, among those surveyed attending NSP who had only injected IPEDs during the past 
six months, 11% had antibodies to hepatitis C in 2015/16 (Public Health England et al., 2016). 
The prevalence of BBV infections amongst IPED injectors in Northern Ireland is currently not 
known. A pilot survey of IPED injectors has recently been conducted in Northern Ireland; 
however, biological samples were not collected (UK Focal Point, 2016).
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7.5 Other drug-related infectious diseases
7.5.1 Tuberculosis
In total there were 5,758 cases of tuberculosis (TB) reported in England in 2015 (Public Health 
England, 2016h). Among the cases with known information on the four ‘social risk factors’ 
monitored among TB cases in England: 4.3% (221/5,189) had either a history of, or currently had, 
a problem with drug use; 3.9% (205/5,191) of alcohol misuse; 4.4% (229/5,171) of homelessness; 
and 3.9% (198/5,033) of imprisonment. Twelve per cent (579/4,910) of TB cases in 2015 had at 
least one of these social risk factors, compared with 9.8% (538/5,708) of cases in 2014. A higher 
proportion of the UK-born TB cases had at least one social risk factor when compared to non 
UK-born cases (22% versus eight per cent).
7.5.2 Other injection-related bacterial infections
Severe illnesses among people who inject drugs due to hygiene-related bacterial infections, 
including those caused by Staphylococcus aureus and Group A streptococci, continue to 
occur. Data from the mandatory enhanced surveillance of meticillin-sensitive S. aureus (MSSA) 
and meticillin-resistant S. aureus (MRSA) bacteraemias indicate that in 2015, of those with risk 
factor information, 11% of the MSSA bacteraemias were associated with injecting drug use, as 
were 9.6% of the MRSA bacteraemias. Severe Group A streptococcal (GAS) infections have 
also been reported among people who inject drugs. During 2014/15 there was a large outbreak 
of soft tissue infections among people who injected psychoactive drugs in the Lothian Health 
Board area of Scotland, with many of the cases requiring prolonged hospital admissions and 
extensive surgical interventions. Though a number of different organisms were detected, GAS 
infections, and in particular one less commonly seen type of S. pyogenes, were often detected 
in the cases. Many of the cases had used one of the recently emerged psychoactive drugs, 
ethylphenidate.57
In 2015, one-third (33%; 95% CI, 30%-35%) of individuals participating in the UAM Survey 
of PWID reported that they had experienced an abscess, sore or open wound, all indicating 
symptoms of injecting-site infection, during the preceding year (Public Health England, 2016c). 
This was similar to the level seen in recent years. There was an increase in symptoms of injection 
site infections among those aged under 25, from 24% in 2014 to 39% in 2015. However, the 
levels of injection site infections remained stable in those aged 25 and above. More women 
(38%) reported symptoms than men (31%). Among those attending NSP in Scotland during 
2015/16, 20% reported that they had experienced an abscess, sore or open wound, during the 
last year (Public Health England et al., 2016).
Among the participants in the 2014/15 UAM sub-survey of people who inject IPEDs, 14% (95% 
CI, 11%-18%) reported that they had ever experienced symptoms of injecting-site infection, 
with the proportion being highest among the 25-34 age group (17%) (Public Health England, 
2016d). This is a slight decrease from the 2012/13 report when 16% reported ever experiencing 
symptoms, and the proportion among the 25-34 age group was 22%.
57 See: http://www.hps.scot.nhs.uk/ewr/article.aspx?id=63352 
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7.6 Behavioural data: infection risks
The extent and patterns of infections over time reflect changing patterns of risk. Risk will be 
impacted by the extent of service provision, particularly the provision and uptake of harm 
reduction and health protection interventions such as NSP, opioid substitution treatment, 
vaccination and diagnostic testing services. The provision of these services is widespread in 
the UK, and provision and uptake have both improved over the last decade (see section 7.7).
7.6.1 Sharing of injecting equipment
People who inject psychoactive drugs
The level of direct sharing of needles and syringes reported by participants in the UAM Survey 
of PWID has declined from 28% (95% CI, 26%-30%) in 2005 to 16% (95% CI, 14%-18%) in 2015 
(Public Health England, 2016c) (Figure 7.4). Throughout the 2005 to 2015 period, direct sharing 
levels were higher among women than men: in 2015, 23% (95% CI, 18%-27%) of women reported 
direct sharing compared with 14% (95% CI, 12%-16%) of men. Direct sharing was found to vary 
across England (17%), Wales (13%) and Northern Ireland (17%). In England regional variations 
were reported, ranging from 4.0% (95% CI, 0.01%-8.4%) in the West Midlands to 22% in both 
the south of England (95% CI, 17%-26%) and in the south-west of England (95% CI, 15%-29%).
Sharing of any of the injecting equipment asked about in the UAM Survey of PWID (ie needles, 
syringes, mixing containers, or filters; direct and indirect sharing) was reported by 38% (95% CI, 
36%-41%) of those participating in the survey in 2015; this was the same as in the previous year 
(Public Health England, 2016c). Sharing of any of this equipment was reported by 38% of the 
participants in England (regional range: 25% to 51%), by 42% in Wales, and by 31% in Northern 
Ireland.
In Scotland, data from the Scottish Drug Misuse Database for 2014/15 indicates sharing of 
needles/syringes among those injecting drugs in the past month has decreased over time, 
with six per cent of this population reporting sharing of needles/syringes (Information Services 
Division, 2016f). This is the lowest percentage recorded since reporting began in 2006/07, when 
12% of the current injecting population reported currently sharing needles. There was little 
variation between NHS health boards, ranging from two per cent to nine per cent. However, 
the percentage of injectors reporting having shared needles/syringes in the past, but not in the 
previous month was higher at 33% across Scotland (ranging from 23% to 42% between NHS 
health boards). This percentage has remained stable since 2006/07. 
Among people reporting injecting in the past month, eight per cent reported sharing injecting 
paraphernalia in the past month, continuing the downward trend since 2006/07, and less 
than half the percentage seen in 2006/07 (20%). Again, there was similar variation between 
NHS health boards (ranging from five per cent to 12%). Forty-one per cent of current injectors 
reported sharing injecting paraphernalia in the past, ranging from 31% to 55% across the NHS 
health boards.
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Figure 7.4: The percentage of current injectors* in the Unlinked Anonymous Monitoring 
Survey of people who inject drugs reporting needle and syringe sharing: England, Wales and 
Northern Ireland, 2005 to 2015
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People who inject image and performance enhancing drugs
Among the participants in the 2014/15 UAM sub-survey of people who inject IPEDs, 13% (95% 
CI, 9.5%-17%) reported ever sharing any injecting equipment (Public Health England, 2016d).58 
This was the same level as that reported in 2012/13. 
People who inject new psychoactive substances
In England, Wales and Northern Ireland, 8.2% of those surveyed as part of the UAM Survey of 
PWID in 2015 reported that they had injected mephedrone during the preceding year. One-third 
(32%) of those currently injecting mephedrone reported sharing needles or syringes previously 
used by someone else. Only 18% of those who had not injected mephedrone reported sharing 
this equipment (Public Health England et al., 2016). 
7.6.2 Condom use and sexual behaviour in people who inject drugs
In 2015, two-thirds (66%, 95% CI, 65%-68%) of the PWID participating in the UAM Survey of 
PWID reported having anal or vaginal sex during the preceding year. This level has been steadily 
dropping since 2010, when 75% of respondents reported having anal or vaginal sex during 
the preceding year (Public Health England, 2016c). Of those who had sex in the last year, 40% 
(95% CI, 38%-43%) reported having had two or more sexual partners during that time. Of these 
individuals, only 22% (95% CI, 18%-25%) reported always using condoms for anal and vaginal 
sex. The proportion of women reporting always using a condom increased from 21% in 2014 
to 27% (95% CI, 20%-34%) in 2015. However, the proportion of males reporting always using a 
58 Needle, syringe or vial.
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condom has remained stable. This suggests increased efforts are required to improve the use 
of condoms in PWID.
Among the participants in the 2014/15 UAM sub-survey of people who inject IPEDs, 92% (95% 
CI, 89%-95%) reported having anal or vaginal sex during the preceding year, suggesting this 
cohort are more sexually active than participants in the main UAM Survey of PWID (Public 
Health England, 2016d). Within those who had sex in the previous year, 51% (95% CI, 46%-
57%) reported having had two or more sexual partners during that time, and of this 51%, 17% 
(95% CI, 11%-24%) reported always using a condom; a smaller proportion than in the main UAM 
Survey of PWID.
7.6.3 Men who have sex with men
There are on-going concerns about the injection of methamphetamine and mephedrone among 
some sub-groups of MSM, many of whom are HIV positive. These drugs are typically being used 
by these men during sex in a practice known as chemsex, where injecting equipment is often 
shared and condoms are not necessarily used. Although the scale of this behaviour remains 
unclear, specialist lesbian, gay, bisexual and transgender (LGBT) drug services are continuing 
to see an increase in the number of MSM who report injecting these drugs. The use and 
injection of these drugs has also been reported to be a factor in the increased transmission of a 
number sexually transmitted infections (Bourne, Reid, Hickson, Torres Rueda, & Weatherburn, 
2014; Kirby & Thornber-Dunwell, 2013).
Guidance documentation produced by Project NEPTUNE (Novel Psychoactive Treatment UK 
Network) has been developed for healthcare professionals who work alongside the LGBT 
population and MSM. It reports patterns of club drug use among LGBT populations, examines 
the factors that may impact on the use of substances, and discusses drug-related and other 
harms. It also looks at the use of drugs in a sexual context and at the risks associated with 
chemsex. The document addresses treatment responses to club drug use for MSM and is 
intended to guide improved service and treatment planning (Abdulrahim et al., 2016).
7.7  Prevention and control of drug-related infectious diseases: 
harm reduction services
7.7.1 Universal harm reduction
In the UK there are several government-funded websites that provide information on drug and 
alcohol use including harm reduction advice, such as FRANK, DAN 24/7 and Choices for Life 
(see section 3.4). Additionally, all treatment providers offer harm reduction advice as part of their 
range of interventions and some also make this available online (eg SMART).59 
Project NEPTUNE has been developed with the aim of improving clinical practice in the 
management of harms resulting from the use of NPS. One of the areas addressed by the 
project is harm reduction. The measures outlined comprise interventions aimed at preventing 
morbidity and mortality among individuals presenting to clinical settings, including measures to 
reduce the harms of new psychoactive substances for individuals and communities.
59 See: http://www.smartcjs.org.uk/
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7.7.2 Needle and syringe programmes
NSP are provided throughout the UK in a variety of settings, principally through pharmacies and 
specialist drug treatment services. There are also a small number of mobile syringe exchanges, 
usually attached to a local treatment provider, and in Wales there is a single vending machine 
which can be used to obtain syringes. NSP aim to reduce harm by offering advice on safer 
injecting practice, helping PWID to access treatment and signpost them to other relevant health 
services such as BBV testing, mental health services and welfare and advocacy services. 
They may additionally provide foil to drug users to encourage them to switch to non-injecting 
methods. NSP are commissioned locally and are monitored by local authorities to ensure they 
comply with clinical guidelines. Services are also available in environments to meet the needs 
of people who use IPEDs – for example outreach services in gyms.
Harm reduction initiatives providing NSP also exist in areas outside of specialist drug services; 
for example sexual health clinics may offer advice aimed at drug users. In addition, a number of 
specialist services exist for the needs of those who are engaging in chemsex. 
The vast majority (90%) of the participants in the UAM Survey of PWID from across England, 
Wales and Northern Ireland reported that they had used a NSP in 2015 (Public Health England, 
2016c).
Scotland
In Scotland, there were 288 injection equipment provider outlets reported to be operating in 
2014/15, of which 214 (74%) were pharmacy based (Information Services Division, 2016a). While 
this was an increase from 188 outlets in 2004/05, it represented a slight decrease from 2013/14 
(299 outlets) (see Figure 7.5). 
In 2014/15, 4.4 million needles/syringes were reported to have been distributed to PWID in 
Scotland, based on data collected from 95% (275/288) of the injection equipment provider 
outlets. This is similar to the number of needles/syringes (in the range 4.4 to 4.7 million per year) 
reported to have been distributed in recent years (2007/08 to 2012/13). The number of injecting 
paraphernalia items distributed to PWID has increased in recent years, with notable rises in the 
provision of filters and spoons/cookers between 2008/09 and 2009/10 and more recently in 
the provision of sterile water between 2012/13 and 2013/14. In 2014/15, the items distributed 
included: 3,211,000 filters; 3,176,000 spoons/cookers; 1,300,000 vials of sterile water; and 
4,200,000 wipes/swabs.
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Figure 7.5: Injection equipment provider outlets operating in Scotland between 2007/08 and 
2014/2015
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Source: (Information Services Division, 2016a)
Wales
The provision of NSP and other harm reduction services in Wales is monitored using the HRD. 
In 2015/16 the HRD was active in 46 statutory and voluntary sector NSP sites across Wales. 
In addition, the 215 community pharmacies providing NSP services were linked to the HRD 
in April 2014 (Public Health Wales, 2016a). Data from the HRD indicates that a total of 24,926 
unique individuals accessed NSP services (including community pharmacy) from April 2015 
to March 2016. Of these: 41% reported primary use of IPEDs; 40% opioids; 9.4% stimulants 
(including powder cocaine, crack cocaine, amphetamine, ecstasy); and 1.6% NPS. 
In 2015/16 a total of 3,398,314 syringes were distributed in Wales. Fifty-eight per cent 
(n=1,980,667) of syringes were distributed through pharmacy-based NSP, while specialist 
agencies distributed 42% (n=1,417,647) (see accompanying table NSP).
Northern Ireland
In Northern Ireland, NSP were available at 15 sites (14 pharmacies and one community 
action team service) in 11 areas in 2014/15, as well as from two needle exchange outreach 
services (Public Health Agency, 2016). The number of packs dispensed by pharmacies has 
increased year-on-year since 2007/08, reaching 34,258 in 2014/15, a 21% increase on 2013/14 
(n=28,284). In 2014/15 this totalled 288,615 needles distributed during 26,713 client contacts, 
predominantly (99%) through pharmacy-based NSP and the remainder via specialist agencies. 
Of the 20,939 contacts where the individual disclosed what they would use the needles for, 
50% were for opioids, 46% were for steroids, 3.4% were for tanning products and 0.2% were 
using amphetamines (values will not add up to 100% due to some clients using multiple drug 
types). 
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7.7.3 Hepatitis B vaccination
Hepatitis B is a vaccine-preventable infection that can cause long-term liver disease and liver 
cancer. The UK has a targeted vaccination programme focused on the population groups most 
at risk, including PWID.
The proportion of the PWID participating in the UAM Survey of PWID who reported having 
taken up an offer of the hepatitis B vaccination has increased markedly over time, rising from 
56% (95% CI, 54%-58%) in 2004 to 76% (95% CI, 75%-78%) in 2011. Uptake dropped slightly 
in the following years but had returned to 75% (95% CI 74%-77%) in 2015 (Figure 7.6) (Public 
Health England, 2016c). Uptake of hepatitis B vaccination was comparable in England (75%) 
and Wales (74%). Northern Ireland reported uptake of 84%.
Among the participants in the 2014/15 sub-survey of people who inject IPEDs, the level for 
uptake of the hepatitis B vaccination was lower, with 38% (95% CI 33%-43%) of those injecting 
IPEDs reporting this (Public Health England, 2016d).
In Scotland, among those attending NSP during 2014/15, 77% reported uptake of the hepatitis 
B vaccine (Public Health England et al., 2016).
Figure 7.6: Uptake of hepatitis B vaccination among participants in the Unlinked Anonymous 
Monitoring Survey of People Who Inject Drugs: England, Wales and Northern Ireland, 
2005–2015
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7.8 New developments
7.8.1 Drug testing at events
Welsh Emerging Drugs & Identification of Novel Substances Project
The Welsh Emerging Drugs & Identification of Novel Substances Project (WEDINOS)60 is a harm 
reduction service that collects and tests unknown/unidentified substances. Individuals can mail 
60 See: http://www.wedinos.org/
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samples for testing and the results are posted online. The website publishes information on the 
substance the individual intended to purchase as well as the actual contents of the sample. 
WEDINOS conducted an analysis of 56 ecstasy pills that were recovered from the site of a 
music festival in summer 2016, testing the samples for purity and strength. The average dose 
of MDMA in these tablets was 129mg, with a dose range of 8mg to 275mg. Of the 20 different 
‘brands’ recovered, 14 included tablets containing more than 140mg MDMA.
The Loop
The Loop61 is a not-for-profit Community Interest Company that provides harm reduction services, 
welfare and drug testing. In 2016, they offered a drug testing service at two English music 
festivals whereby attendees could take samples to be tested and find out what they contained. 
Approximately 200 people had substances tested at one of the events and received health 
and safety advice on drugs. They have previously tested drugs retrieved from amnesty bins in 
nightclubs and music festivals. The Loop has launched a social media campaign encouraging 
users to use less MDMA powder and wait for effects rather than re-dosing immediately – 
#CrushDabWait. 
7.8.2 Remove All Prescription and Illicit Drugs
An initiative know as RAPID (Remove All Prescription and Illicit Drugs) has been set up in Northern 
Ireland. Fourteen bins have been placed across Northern Ireland and offer individuals a safe 
way to dispose both prescription and illicit drugs. Over 65,000 tablets have been disposed of 
so far, over 90% of which were prescription drugs.62 
7.8.3 Foil legislation evaluation
Monitoring the legal provision of foil to heroin users (Home Office, 2016c) explored how the 
legislation to allow the lawful supply of foil to heroin users by drug treatment services has operated 
in practice. Findings indicated that the supply of foil increased following the commencement of 
the legislation, and that needle exchange professionals considered foil provision as beneficial to 
treatment and recovery outcomes. 
61 See: http://wearetheloop.co.uk/
62  See: http://www.publichealth.hscni.net/news/new-initiative-tackle-drugs-our-streets 
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8 Legal framework
8.1 Introduction
The Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971) controls the possession, 
supply and production of psychoactive substances that are considered dangerous or otherwise 
harmful when misused, and sets maximum criminal penalties for each offence. Drug use is not 
a crime in the UK, but possession, production, supply and trafficking (including importation and 
exportation) are. 
Penalties range from a warning, fine, or community sentence through to a custodial sentence, 
depending on the severity of the offence. Both recorded crime and arrests for overall drug law 
offences have been falling for several years.
The emergence of a large number of new psychoactive substances (NPS) has resulted in various 
different legislative approaches to tackle this issue. Initially, a small number of substances were 
classified under the Misuse of Drugs Act 1971. Temporary class drug orders (TCDOs) were 
then introduced through the Police Reform and Social Responsibility Act 2011 (Her Majesty’s 
Government, 2011b) to give a faster legislative response. The Psychoactive Substances Act 
2016 (Her Majesty’s Government, 2016f) was introduced with the intention of preventing the 
trade of these substances; unlike the two previous approaches, this is a blanket ban rather than 
being substance-specific.
With the recognition of drug use (particularly heroin and crack) as a major driver of acquisitive 
crime, initiatives have been introduced at all stages of the criminal justice system (CJS) aimed at 
engaging drug users in treatment. These include drug rehabilitation requirements (DRRs) as a 
sentencing option for offenders on probation, as well as the more recent Liaison and Diversion 
(L&D) scheme introduced in 2010.
8.2 Current legal framework
The Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971) is the principal legislation in 
the UK for the control and supply of psychoactive substances that are considered dangerous 
or otherwise harmful when misused.63 The act divides such substances into three classes (A, 
B and C) and sets maximum criminal penalties for illegal production, possession and supply in 
relation to each class (see section 8.4.1). 
Most drugs controlled under the act are also placed in one of the five schedules of the Misuse of 
Drugs Regulations 2001 (Her Majesty’s Government, 2001b), based on an assessment of their 
medicinal or therapeutic usefulness, the need for legitimate access and their potential harms 
when misused.64 The schedules determine the circumstances in which controlled substances 
63 Possession: In the UK it is unlawful to possess any quantity of a controlled drug, unless the individual is in 
possession of an authorisation in the form of a licence (for example a prescription), or the person can prove that they 
were unaware that the substance was a controlled drug. 
Supply and possession with the intent of supply: Supply defined as the simple act of passing a controlled drug 
from one person to another. According to the law, it is irrelevant if the act is done for profit or not. The financial gain 
has influences only on the sentence given. 
Production: In the UK it is illegal to produce any controlled drug, unless the individual is in possession of an 
authorisation in the form of a licence. Production is defined as ‘manufacturing, cultivating or production by any other 
method’.
64 See: https://www.gov.uk/government/policies/reducing-drugs-misuse-and-dependence/supporting-pages/
classifying-and-controlling-drugs 
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can be lawfully manufactured, possessed and distributed. Those drugs deemed to have no 
therapeutic value are placed on Schedule 1, meaning that they cannot be prescribed. Research 
can be conducted on these substances but this requires a licence to be obtained from the 
Home Office. Schedule 5 contains drugs that can be legally supplied and possessed without 
prescription.
Under the Misuse of Drugs Act 1971, police have special powers to stop, detain and search 
people on ‘reasonable suspicion’ that they are in possession of a controlled drug. Police may 
also enter and search premises with a warrant if there are reasonable grounds to suspect an 
offence against the act has been committed. A prison sentence is the most common outcome 
when found guilty at court of import/export and supply offences, but a fine, community sentence 
or conditional discharge are the most common disposals for possession offences (Ministry of 
Justice, 2016a). The range of possible penalties is covered in section 8.4.1.
The Psychoactive Substances Act 2016 (Her Majesty’s Government, 2016f) was introduced as 
a response to the increased use of NPS in the UK. This act is covered in greater detail in section 
8.3.1.
Prior to the implementation of the Psychoactive Substances Act 2016, the principle legislative 
response designed to tackle NPS was the creation of TCDOs, as part of the Police Reform and 
Social Responsibility Act 2011 (Her Majesty’s Government, 2011b). This act added provisions for 
12-month TCDOs to be made on specified compounds, putting these substances in a ‘temporary 
class’ under the Misuse of Drugs Act 1971. Therefore all the offences under the Misuse of Drugs 
Act 1971, with the exception of the possession offence, apply to these substances for the 
duration of the TCDO. This measure enables law enforcement activity against those trafficking 
or supplying temporary class drugs. Following the passing of the Psychoactive Substances Act 
2016, the option of using TCDOs still remains available to the government.
The Drugs Act 2005 amended the Police and Criminal Evidence Act 1984, introducing 
mandatory drug testing of detainees following arrest in certain circumstances (Her Majesty’s 
Government, 1984, 2005). The act also introduced a new offence of failing to attend a required 
assessment with a drug worker for those testing positive. These amendments provided a legally 
enforceable lever through which to identify drug using offenders on arrest and to engage them 
with treatment. 
8.3 Recent changes in legal framework
8.3.1 Recent changes to drug misuse legislation
Psychoactive Substances Act 2016
The Psychoactive Substances Act 2016, which came into force on 26 May 2016, prohibits the 
supply, production and trafficking of psychoactive substances within the UK (Her Majesty’s 
Government, 2016f). The act was brought in as a response to NPS and the speed at which 
new substances emerge, and covers all substances capable of producing a psychoactive effect 
with the following exemptions: drugs already controlled under the Misuse of Drugs Act 1971; 
medicinal products listed under the Human Medicines Regulations 2012; alcohol; nicotine and 
tobacco products; caffeine; and food and drink. The term ‘psychoactive substance’ refers to 
any substance which, by stimulating or depressing the central nervous system, affects the 
user’s mental functioning or emotional state upon consumption. In March 2016 the Advisory 
Council on the Misuse of Drugs (ACMD) provided advice, accepted by the government, which 
stated that alkyl nitrites (commonly referred to as ‘poppers’) did not fall within the scope of the 
act, as their specific mode of action was deemed to not have a direct psychoactive effect. 
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Unlike under the Misuse of Drugs Act 1971, the substances controlled by the Psychoactive 
Substances Act 2016 are not classified. The maximum penalties for each offence are the same 
for every substance covered by the legislation; penalties under the act are covered in section 
8.4.1. 
To provide proportionate disposal options for substances that have not had their harms 
assessed, individuals believed to be involved in the sale of psychoactive substances can be 
given a prohibition or premises notice by a senior police officer or local authority. These notices 
require individuals to cease their involvement in the specified prohibited activity. Failure to comply 
with these notices can result in prohibition or premises orders being placed on the individuals 
involved by the court; non-compliance with these orders can lead to a criminal prosecution. 
Importantly, prohibition and premises orders are made by the court based on the balance of 
probabilities, rather than beyond reasonable doubt, therefore requiring a lesser burden of proof 
to be able to close premises trading in psychoactive substances. This is not a linear process, 
and in cases where they deem it appropriate enforcement agencies are able to proceed straight 
to prosecution. In December 2016 the Home Office reported that since the Psychoactive 
Substances Act 2016 came into force in May, 31 headshops had closed down and 332 shops 
across the UK had stopped selling psychoactive substances covered by the act.65
While simple possession is not an offence under this legislation, possession of a psychoactive 
substance within a custodial institution is prohibited, and applies to prison staff and visitors 
as well as inmates. Police have special powers to stop, detain and search individuals on 
‘reasonable’ suspicion that they have committed, or are likely to commit, an offence under the 
Psychoactive Substances Act 2016. They also have powers to seize and detain psychoactive 
substances found in the course of the search. Furthermore, the act gives law enforcement 
agencies powers to close down UK-based websites trading in these substances. It is worth 
noting that an individual purchasing a psychoactive substance from a non-UK-based website 
may commit the offence of importation, and could be subject to the penalties discussed in 
section 8.4.1.
A change to the Misuse of Drugs Act 1971: control of ‘third generation’ synthetic 
cannabinoid receptor agonists
‘First’ and ‘second’ generation synthetic cannabinoid receptor agonists (SCRAs) were controlled 
as Class B substances under the Misuse of Drugs Act 1971 in the UK in 2009 and 2013, following 
reports to the government from the ACMD in 2009 and 2012 (Her Majesty’s Government, 2009a, 
2013a). In November 2014 the ACMD recommended a revised generic definition of SCRAs, to 
include the ‘third generation’ substances now available, which was revised over the course of 
2015 and 2016 to include newly emerged SCRAs and exclude prescription medications with 
similar structures. In December 2016 third generation SCRAs became controlled as Class B 
substances under the Misuse of Drugs Act 1971 (Her Majesty’s Government, 2016c). Therefore, 
while supply of these substances was already illegal under the Psychoactive Substances Act 
2016, this change in legislation made possession an offence too. 
A change to the Misuse of Drugs Act 1971: control of dienedione
In response to a request from UK Anti-Doping, the ACMD reviewed the physical and social 
harms of estra-4,9-diene-3,17-dione (dienedione), which was at the time included on the World 
Anti-Doping Agency’s prohibited list, but not controlled under the Misuse of Drugs Act 1971. 
In January 2016, the ACMD concluded that the harms associated with dienedione would 
be commensurate with those of other anabolic steroids. It was therefore recommended that 
65 See: https://www.gov.uk/government/news/psychoactive-substances-ban-6-months-on-almost-500-arrests-and-
first-convictions 
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dienedione be controlled as a Class C substance under the Misuse of Drugs Act 1971, and 
placed on Schedule 4 Part 2 of the Misuse of Drugs Regulations 2001 (Advisory Council on the 
Misuse of Drugs, 2016c). The government accepted this advice, and controlled dienedione as 
recommended in December 2016 (Her Majesty’s Government, 2016c).
Ketamine – rescheduling and patient group directions
In November 2015 ketamine was rescheduled from Part 1 of Schedule 4 to Schedule 2 of 
the Misuse of Drugs Regulations 2001 (Her Majesty’s Government, 2015a). This followed the 
ACMD’s recommendations and the results of a public consultation regarding possible effects 
of the changes to legislation which reclassified ketamine from Class C to Class B in 2014 (Her 
Majesty’s Government, 2014b). The amendments to the Misuse of Drugs Regulations 2001 
were made to ensure that ketamine could continue to be administered by nurses and other 
healthcare professionals under Patient Group Directions.
Temporary class drug orders on methiopropamine and ethylphenidate
Methiopropamine was controlled by the government under a TCDO in November 2015 (Her 
Majesty’s Government, 2015b). Methiopropamine had reportedly been used in place of 
ethylphenidate and other methylphenidate-related compounds following the introduction of a 
TCDO controlling these substances in April 2015. In November 2016 the government remade 
the TCDO on methiopropamine for a further 12 months, as the ACMD had reported that they 
were not able, at this stage, to recommend full control of this substance (Advisory Council on 
the Misuse of Drugs, 2016g; Her Majesty’s Government, 2016d). Similarly, in June 2016 the 
government remade the TCDO on methylphenidate-related substances for a further 12 months, 
as the ACMD were not able to provide full advice for control of these compounds before the 
TCDO expired (Advisory Council on the Misuse of Drugs, 2016b; Her Majesty’s Government, 
2016e).
8.3.2 Advisory Council on the Misuse of Drugs
Advice on the control of gabapentin and pregabalin
Recent concern over the misuse of the prescription medications gabapentin and pregabalin 
lead to the ACMD assessing the medical and social harms caused by these drugs. In January 
2016, the ACMD advised the government that due to their potential for misuse, and the fact 
that the harms associated with their misuse were commensurate with that of other controlled 
substances, gabapentin and pregabalin should be controlled under the Misuse of Drugs Act 
1971 as Class C substances, and placed on Schedule 3 of the Misuse of Drugs Regulations 2001 
(Advisory Council on the Misuse of Drugs, 2016e). While the Home Office accepted this advice 
in principle, they informed the ACMD that they will carry out a public consultation to assess the 
impact of these changes, in particular the changes to the Misuse of Drugs Regulations 2001 
(Home Office, 2016e).
Advice on the control of U-47,700 and ‘designer benzodiazepines’
As discussed in section 6.4, benzodiazepines have recently been associated with an increasing 
number of drug-related deaths, particularly in Scotland and Northern Ireland. While many 
misused benzodiazepines are listed in Class C of the Misuse of Drugs Act 1971, a number of 
substances that have been linked to these deaths, such as etizolam and diclazepam, are not. 
In December 2016, the ACMD reported to the government on the evidence of use and harm 
caused by these ‘designer benzodiazepines’, and advised that they should be controlled under 
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a TCDO (Advisory Council on the Misuse of Drugs, 2016a).66 At the same time, they reported 
on U-47,700, a synthetic opioid which has been associated with one death in the UK in 2016, 
and related to at least 46 confirmed deaths in the USA. Due to the risks posed by this opioid, 
the ACMD also recommended that it be controlled under a TCDO. The government, stating 
concerns about the well-established harms of these substances, requested further advice on 
the permanent control of U-47,700 and designer benzodiazepines under the Misuse of Drugs 
Act 1971 (Home Office, 2016f); therefore the ACMD responded by recommending placing 
U-47,700 under Class A, and the benzodiazepines under Class C, of the Misuse of Drugs Act 
1971 (Advisory Council on the Misuse of Drugs, 2016f). 
8.3.3 Recent debate surrounding drug legislation
Political discussion on changes to drug legislation
In September 2016 the All-Party Parliamentary Group for Drug Policy Reform published the 
report of an inquiry undertaken to investigate the use of medicinal cannabis in the UK (All-Party 
Parliamentary Group for Drug Policy Reform, 2016). The inquiry had included a review of the 
evidence of the effectiveness of medicinal cannabis, heard evidence from individuals about 
their use of medicinal cannabis, and set up online surveys of healthcare professionals and 
cannabis users about the role of cannabis-based medicines. The report recommended that the 
government accept that cannabis has a role as a medicinal product, and therefore be moved 
from Schedule 1 to Schedule 4 of the Misuse of Drugs Regulations 2001; that the government 
assesses the various models of allowing access to medicinal cannabis used worldwide; and 
that the government decriminalises home growing of small amounts of cannabis for medicinal 
use.
In July 2016, results of a poll of Members of Parliament indicated that the majority (58%) of those 
questioned supported the legalisation of cannabis for individuals using it for medical reasons.67
At their national conference in October 2016, members of the Scottish National Party voted in 
favour of a motion calling for the decriminalisation of cannabis for medical use. In their response, 
the Home Office stated that the UK government has no plans to legalise cannabis or devolve 
drug control. Additionally, in March 2016, the Liberal Democrat Party proposed a framework 
for how a fully regulated cannabis market could function in the UK (Liberal Democrats, 2016).
Royal Society for Public Health report into drug decriminalisation
In June 2016, the Royal Society for Public Health, supported by the Faculty of Public Health, 
published a report which suggested that approaches to reducing the harm linked to substance 
misuse could include the decriminalisation of all illegal drugs, and treating drug possession and 
use as a health issue rather than a crime (Royal Society for Public Health, 2016). An editorial in 
The Times newspaper supported this report, and suggested that decriminalisation should be 
seen as the first step to legalisation and regulation.68 
66 Benzodiazepines included by the ACMD in this report were: etizolam, diclazepam, flubromazepam, pyrazolam, 
deschloroetizolam, flubromazolam, nitrazolam, nifoxipam, clonazolam, 4’-chlorodiazepam, bromazolam, 
meclonazepam, adinazolam, metizolam, 3-hydroxyphenazepam and fonazepam.
67 See: http://www.telegraph.co.uk/news/2016/07/10/most-mps-back-legalisation-of-medical-marijuana-poll-finds/
68 See: http://www.thetimes.co.uk/edition/comment/breaking-good-svkvggj2k
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8.4 Drug law offences
8.4.1 Types of offences and range of penalties
Penalties under the Misuse of Drugs Act 1971
There are a number of activities related to controlled drugs that are considered offences under 
the Misuse of Drugs Act 1971 (Her Majesty’s Government, 1971). These are: possession; supply; 
possession with intent to supply; production; importation and exportation; and offences related 
to permitting the production, supply or use of a controlled drug on premises. The severity of the 
penalty applied is dependent on the class of the drug involved and the individual circumstances 
of the case. For each type of offence, the court considers the size of the operation/quantity 
of drugs involved, the individual’s role in the crime and any aggravating or mitigating factors in 
order to impose an appropriate penalty in accordance with the definitive guidelines (Sentencing 
Council, 2009, 2012).
Table 8.1 summarises the maximum penalties according to the offence, the classification of the 
drug involved, and the mode of prosecution (offences tried on indictment are those tried in a 
Crown Court; summary offences are those tried in a magistrates’ court).
First and second simple possession offences for cannabis and khat (for personal use) are 
dealt with using out-of-court disposals in England and Wales. In the case of first offences with 
no aggravating factors, this takes the form of a spoken ‘cannabis warning’ or ‘khat warning’. 
Second offences generally incur a penalty notice for disorder of £80 under the Criminal Justice 
and Police Act 2001 and the schedule to the Penalties for Disorderly Behaviour (Amount of 
Penalty) Order 2002 (Her Majesty’s Government, 2001a, 2009b).
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Table 8.1: Maximum penalties for drug possession, supply, intent to supply and production in 
the UK under the Misuse of Drugs Act 1971, by drug classification
Class Drugs included
Mode of 
prosecution Possession
Supply, intent 
to supply, and 
production
A
Crack cocaine, 
cocaine, heroin, LSD, 
MDMA, methadone, 
methamphetamine, 
psilocybin-containing 
mushrooms
Indictment
Up to seven years in 
prison, an unlimited 
fine, or both
Up to life in prison, an 
unlimited fine, or both
Summary
Up to six months 
in prison, a £5,000 
fine, or both
Up to six months in 
prison, a £5,000 fine, 
or both
B
Amphetamines, 
barbiturates, 
cannabis, 
codeine, ketamine, 
methylphenidate, 
synthetic 
cannabinoids, 
synthetic cathinones
Indictment
Up to five years in 
prison, an unlimited 
fine, or both
Up to 14 years in 
prison, an unlimited 
fine, or both
Summary
Up to three months 
in prison, a £2,500 
fine, or both
Up to six months in 
prison, a £5,000 fine, 
or both
C
Anabolic steroids, 
benzodiazepines (eg 
diazepam), gamma-
hydroxybutyrate 
(GHB), gamma-
butyrolactone (GBL), 
khat, piperazines (eg 
benzylpiperazine)
Indictment
Up to two years in 
prison, an unlimited 
fine, or both*
Up to 14 years in 
prison, an unlimited 
fine, or both
Summary
Up to three months 
in prison, a £1,000 
fine, or both*
Up to three months in 
prison, a £2,500 fine, 
or both
TCDO
Currently:
Methylphenidate-
based substances 
(including 
ethylphenidate) and 
methiopropamine, 
and their simple 
derivatives
Indictment
None, but police 
can take away 
a suspected 
temporary class 
drug
Up to 14 years in 
prison, an unlimited 
fine, or both
Summary
None, but police 
can take away 
a suspected 
temporary class 
drug
Up to six months in 
prison, a £5,000 fine, 
or both
*With the exception of anabolic steroids, where possession for personal use is not an offence 
Source: https://www.gov.uk/penalties-drug-possession-dealing
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Penalties under the Psychoactive Substances Act 2016
Possession within a custodial institution, supply, possession with intent to supply, production 
and import/export of a psychoactive substance are all prohibited under the Psychoactive 
Substances Act 2016; simple possession is not an offence (Her Majesty’s Government, 2016f). 
There is no classification of substances under the act; therefore penalties are the same for each 
substance. The penalties for each type of offence are shown in Table 8.2.
Table 8.2: Penalties under the Psychoactive Substances Act 2016
Offence Summary Conviction Conviction on Indictment
Possession in a custodial 
institution
Up to 12 months* 
imprisonment, a fine, or both
Up to two years 
imprisonment, a fine, or both
Possession with intent to 
supply
Up to 12 months* 
imprisonment, a fine, or both
Up to seven years 
imprisonment, a fine, or both
Supply/offer to supply Up to 12 months* 
imprisonment, a fine, or both
Up to seven years 
imprisonment, a fine, or both
Production Up to 12 months* 
imprisonment, a fine, or both
Up to seven years 
imprisonment, a fine, or both
Importation/exportation Up to 12 months* 
imprisonment, a fine, or both
Up to seven years 
imprisonment, a fine, or both
Failure to comply with a 
Prohibition or Premises order
Up to 12 months* 
imprisonment, a fine, or both
Up to two years 
imprisonment, a fine, or both
*In Northern Ireland, summary convictions can result in up to six months imprisonment rather than 12 months 
Source: (Her Majesty’s Government, 2016f)
8.4.2 Drug law offences
Data on drug law offences is available from various points in the CJS:
 • recorded crime data counts the number of drug offences brought to the attention 
of police and represents the widest measure of drug offences available in the UK. 
However, at present the individual drug involved is not recorded (except for cannabis 
possession offences in England and Wales)
 • arrests data records the number of persons who are arrested for a drug offence and 
represents a smaller proportion of drug offences, since some penalties such as formal 
warnings for cannabis do not constitute an arrest. This data is not available by drug or 
offence type
 • cautions and convictions data records the number of offences where an individual is 
found guilty at court or cautioned for a drug offence
Data from each level of the CJS cannot be compared for a number of reasons, including: 
time lag between offence and conviction; the basis on which the data is provided (offender or 
offence); counting rules; and year of data (calendar or financial year). It should be noted that 
changes in police activities and priorities will impact on the recording of drug offences and, as 
such, trends may not be entirely reflective of underlying levels of drug offending.
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Recorded crime: drug offences
There has been a downward trend in recorded drug offences in the UK in recent years; however, 
trends differ between the administrations (see Figure 8.1 and accompanying table DLO). Northern 
Ireland has seen a fairly steady increase in both supply/trafficking and possession offences 
recorded over the last decade, with around twice the number of each category reported 
in 2015/16 as were in 2006/07 (Police Service of Northern Ireland, 2016). Supply/trafficking 
offences in Scotland have fallen over the same time period, whereas possession offences have 
remained relatively stable (Scottish Government, 2016b). In England and Wales, the numbers of 
both offence types peaked between 2008 and 2010, and have since decreased. The number 
of possession offences in England and Wales in particular has seen a dramatic decrease, from 
213,651 in 2008/09 to 122,155 in 2015/16 (Office for National Statistics, 2016a).
Figure 8.1: Trends in recorded possession and supply/trafficking offences in the 
United Kingdom, 2006/07 to 2015/16
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Source: (Office for National Statistics, 2016a; Police Service of Northern Ireland, 2016; 
Scottish Government, 2016b)
Arrests for drug offences
Having risen between 2006/07 and 2010/11, arrests for drug offences in England and Wales 
have dropped in recent years, and as with recorded crime figures, are now below the level seen 
in 2006/07 (see Figure 8.2).
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Figure 8.2: Trends in arrests for drug offences in England and Wales,  
2006/07 to 2015/16
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Out of court disposals and sentencing of drug offenders
In 2015, there were 116,869 proven drug law offences69 in England and Wales, representing 
a 19% decrease from the previous year, which itself was a decrease of 17% from 2013. The 
majority of drug offences were dealt with outside of a court setting (60%). Of these, over half 
(55%) were in the form of a cannabis warning, one-third (33%) cautions, and 12% were penalty 
notices for disorder (Ministry of Justice, 2016a).
Of the 46,242 individuals sentenced at court for drug offences in England and Wales during 
2015, 19% were given immediate custody (Ministry of Justice, 2016a) (see Table 8.3). The most 
common sentence was a fine, meted out in 36% of cases. The vast majority (86%) of those 
convicted of import/export offences, and the greatest proportion of those convicted of trafficking 
offences (including supply offences), received immediate custody. Over half (53%) of individuals 
convicted of a possession offence were subjected to a fine as punishment.
Table 8.3: Number and percentage of offenders receiving each disposal at court for drug 
offence type in England and Wales, 2015
Immediate 
custody
Suspended 
sentence
Community 
sentence Fine Other
Total 
sentenced
n % n % n % n % n % n %
Import/export 421 86.4 45 9.2 9 1.8 9 1.8 3 0.6 487 100
Trafficking* 7,106 44.7 4,871 30.6 2,526 15.9 842 5.3 565 3.6 15,910 100
Possession 1,037 3.5 611 2.1 3,998 13.7 15,501 52.9 8,129 27.8 29,276 100
Other 54 9.5 152 26.7 186 32.7 93 16.3 84 14.8 569 100
Total 8,618 18.6 5,679 12.3 6,719 14.5 16,445 35.6 8,781 19.0 46,242 100
*Includes production, supply and possession with intent to supply 
Source: (Ministry of Justice, 2016a)
69 Defendants who have been proven to have committed an offence (includes convictions, cautions, cannabis warnings 
and penalty notices for disorder).
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8.4.3 Recent changes to drug law offences
Recorded police warnings in Scotland
In January 2016 Police Scotland, in conjunction with the Crown Office and Procurator Fiscal 
Service, implemented the new recorded police warning (RPW) scheme in Scotland. This scheme 
allows police officers dealing with low-level offenders aged over 16 (for example those caught in 
possession of a small amount of cannabis) to administer an RPW as an on-the-spot disposal at 
their discretion. An RPW can be used for offences which, if they were instead formally reported 
to the Procurator Fiscal, would most likely result in no action being taken due to the minor nature 
of the offence, or a non-court disposal being administered by the Procurator Fiscal. However, 
if the RPW is refused or appealed, a formal report may be sent to the Procurator Fiscal. RPWs 
are recorded on the Criminal History System for two years, but are not a finding of guilt.
Local policing priorities
Policing priorities for forces in England and Wales are set by locally elected Police and Crime 
Commissioners who have control over their policing budgets. Citing budgetary constraints and 
prioritisation of more serious offences, Durham, Derbyshire, Dorset and Surrey police forces 
announced in 2015 that they will no longer actively target people for possessing or growing 
cannabis for personal use.
More recently, it has been reported70 that Durham and Avon & Somerset police forces have 
been piloting schemes whereby individuals caught in possession of drugs are diverted into 
educational programmes. Individuals in Avon & Somerset can choose to attend a drugs 
education programme, while those in Durham sign a four-month contract stipulating the 
individual must not break the law, and must attend a series of drug awareness, restorative 
justice and community work programmes. If the programmes are completed successfully, 
the individual’s drug possession offence is dropped. 
8.5 Drug interventions in the criminal justice system
Rehabilitative and treatment opportunities are made available to those who need them at all 
stages of the CJS (police station, court, community sentence or custody) either on a voluntary 
basis or as part of a court-mandated sentence or post-release licence.
8.5.1 England and Wales
Drug rehabilitation requirement
A DRR is available to courts as a sentencing option, under Section 209 of the Criminal Justice 
Act 2003 (Her Majesty’s Government, 2003). DRRs can be made as part of a community order 
or a suspended sentence order, and the treatment element is provided from local drug services. 
These provisions present local providers with flexibility to tailor requirements to individual needs, 
changing patterns of substance misuse and moving towards a recovery-focused approach to 
treatment. 
The supervision on licence of low-to-medium risk offenders is now managed by community 
rehabilitation companies as part of the changes brought in by Transforming Rehabilitation 
(Ministry of Justice, 2013), with high risk offenders being supervised by the new the National 
Probation Service (see section 5.3.1). In Wales, the director of the National Offender Management 
70 See: http://www.vice.com/en_uk/read/drug-decriminalisation-in-uk-narcomania-heroin-crack 
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Service Wales is responsible for the planning and commissioning of drug treatment services for 
offenders on DRRs. 
Criminal Justice Integrated Teams and test on arrest 
The primary method of engaging drug misusing offenders with treatment services in England 
and Wales is through the interventions that formerly made up the Drug Interventions Programme 
(DIP). Criminal Justice Integrated Teams (CJITs) carry out drug assessments on arrestees and 
provide case management, low threshold interventions and referrals to structured treatment 
where appropriate. Mandatory test on arrest was implemented in 2006 for specified ‘trigger 
offences’ (ie those most associated with drug use: shoplifting, robbery, theft) in areas designated 
as being ‘DIP intensive’. Although DIP ceased to be a national programme from April 2013, 
the decision as to whether to continue funding such interventions is taken locally and these 
interventions are still widely in operation. The majority of local authorities continue to report 
CJIT activity to Public Health England, and around 28 police forces still run a drug intervention 
initiative based on drug testing on arrest. This suggests that the provision of such services has 
largely survived the transition to a locally led commissioning structure (personal communication 
– Home Office).
Liaison and Diversion
The L&D programme was created in 2010 in response to findings of the Bradley Report 
(Department of Health, 2009). L&D schemes are designed to identify, assess, screen and refer 
offenders who have mental health, learning disability, substance misuse or other vulnerabilities 
to an appropriate treatment or support service. Ten trial schemes were implemented from 
April 2014 with a further 15 schemes instigated from April 2015, taking coverage up to 50% of 
England. It is anticipated that full coverage will occur in 2020/21. 
8.5.2 Scotland
In Scotland, there are a number of interventions at different levels of the CJS, including diversion 
from prosecution to drug treatment/education, community payback orders with a drug treatment 
requirement, drug treatment and testing orders (DTTOs) for particularly high tariff offenders 
who are entrenched in their drug use, as well as services for prisoners post-release, including 
Throughcare Addiction Services (see section 5.6.2). DTTOs provide offenders with access to 
treatment services with which they are required to comply, combined with regular progress 
reviews from the court. A less intensive version (DTTO II) has been developed for lower tariff 
offenders, who are less entrenched in their drug use and offending. The scheme is operating in 
Edinburgh and the Lothians, and currently accounts for about a quarter of the DTTOs in these 
areas. The Scottish government will support wider availability of DTTO IIs across Scotland in 
2017 by working with the pilot site to produce guidance on how to develop and deliver a DTTO 
II service.
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9 Drug markets
9.1 Introduction
Most of the identified drug supply chains to the UK follow well-established trafficking routes. 
Heroin originates in Afghanistan and is transited through either Pakistan or Iran. Cocaine is 
produced in Colombia, Peru and Bolivia, with Spain and the Netherlands being the main transit 
hubs within Europe for cocaine en route to the UK. The Netherlands is the most significant 
source of traditional synthetic stimulant drugs such as ecstasy and amphetamine, while the 
majority of new psychoactive substances (NPS) bought online originate in China. There is 
domestic production of high potency cannabis within the UK; however, most cannabis comes 
from abroad. South and West Africa and the Caribbean are the main sources of herbal cannabis, 
while resin mainly comes from Morocco and Afghanistan. Branded ‘skunk’ is primarily imported 
from the Netherlands. 
The restricting supply strand of the UK Drug Strategy 2010, Reducing demand, restricting 
supply, building recovery: supporting people to live a drug free life (Her Majesty’s Government, 
2010) aims to make the UK an unattractive destination for drug traffickers. The Serious and 
Organised Crime Strategy (Her Majesty’s Government, 2013b) focuses, with regard to drugs, 
on: restricting the supply to the UK; engaging international partners to help disrupt Organised 
Crime Groups (OCGs) smuggling illicit drugs through the UK’s borders; and ensuring the 
retrieval of the proceeds and assets from the crimes these groups commit. The publication of 
the strategy coincided with the launch of the new National Crime Agency (NCA).
Drug seizure samples are tested for strength by the NCA. This analysis shows that the purity 
of small quantity heroin seizures (ie seizures primarily from users) fell from over 40% to below 
20% between 2009 and 2011; purity has risen since then and is now at the same level as it was 
before the drop (44%). Purity of small quantity cocaine seizures has also been rising since a low 
in 2009. The number of seizures of cannabis in England and Wales increased by more than a 
quarter between 2006/07 and 2011/12; however, this number has fallen over the past five years 
to a level below that seen in 2006/07. This trend is mostly due to the change in number of herbal 
cannabis seizures.
9.2 Supply to and within the country
The commentary provided below is based on correspondence with the NCA.
9.2.1 Domestic production
Cannabis
Cannabis cultivation within domestic and commercial premises is widespread across the UK, 
although most production sites are domestic dwellings. These dwellings are often converted 
with rooms fitted for different stages of production: seedling/cutting propagation; developing 
plants; those in final/harvest stages; and post-harvest drying. Equipment such as grow lights 
and systems to produce an environment where cannabis can be harvested in 10 to 12 week 
cycles are used. Initial start-up costs can run into thousands of Great British Pounds (GBP), 
but cyclical commercial scale production remains highly profitable. Production is predominantly 
controlled by British OCGs; involvement of Southeast Asian OCGs, utilising the labour of illegal 
immigrants and victims of modern day slavery, is significant but in decline. 
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Cultivation of the types of cannabis commonly referred to as ‘skunk’ continues to be widespread. 
While some of this is branded ‘skunk’ (types developed in the Netherlands, designed to give the 
user a range of experiences and tastes), the majority of that produced in the UK is non-branded. 
Branded varieties fetch a premium price and appeal to the connoisseur and experimental user. 
Amphetamine Sulphate
Production of amphetamine sulphate from precursors is rarely encountered in the UK; however, 
the conversion of amphetamine base to sulphate is becoming established. Liquid amphetamine 
oil and wet base for conversion are commonly imported from the Netherlands and Belgium. This 
process requires much less expertise, chemicals and equipment than is required for production 
from precursors, but offers control of quality. Production of amphetamine sulphate is most 
common in the north-east of England through direct links to supply sources in the Netherlands 
and Belgium.
9.2.2 Drug trafficking routes for imported drugs
Cocaine
Cocaine is almost exclusively produced in Colombia, Peru and Bolivia. Primary exit points in 
South America include Colombia, Venezuela, Ecuador, Peru, Brazil and Guyana. Drugs are 
commonly concealed within sea freight, air freight, yachts and air passengers. 
Cocaine transported to the UK in sea freight uses commercial freight shipping routes via major 
European ports in Spain, Belgium and the Netherlands, before onward transportation to the UK 
in smaller consignments. Primary entry into the UK is via commercial road transport, with the 
most common access points being ports on the north-east, east, south-east and south coasts 
of England. 
Yachts are commonly used to transport cocaine across the Atlantic, often sailing from a 
Caribbean island to the Iberian Peninsula. Cape Verde is an important trans-Atlantic staging 
post, as are other West African countries along the Atlantic coastline. From there, cocaine is 
distributed onwards to destinations across Europe, arriving in the UK by vehicle (most commonly 
commercial), but with general aviation (smaller aircraft/micro-craft) being increasingly used.
Air couriers commonly traffic cocaine direct from South America and the Caribbean in addition 
to transiting via West Africa, European hubs and (recently) the Middle East. South Africa is also 
a key transit location, with traffickers utilising the cover of air- and sea-facilitated trade routes 
and legitimate consignments.
Heroin
Heroin destined for the UK principally originates in Afghanistan, transiting through either Pakistan 
or Iran (depending upon the onward direction of travel). Some UK-bound heroin may also arrive 
into the EU via Ukraine, having travelled north from Afghanistan through central Asia. Heroin that 
comes to the UK via Pakistan is sent directly by air freight and air passengers as well as via eastern 
and southern Africa, having travelled south from the Makran coast through the Indian Ocean.
Heroin destined for the UK by land typically enters Turkey via Iran or Iraq, known as the ‘Balkan 
route’. Heroin is most commonly conveyed by land in goods vehicles along the Balkan route. 
The majority travel to Holland where the drugs are stored in warehouses before onward 
transportation to the UK in smaller quantities. The UK is most commonly accessed using ‘roll-
on/roll-off’ haulage, commercial and private vehicles via south-east and north-east coast ports, 
with heroin concealed within vehicle structures, cavities and consignment loads. 
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Amphetamine and MDMA/ecstasy
The Netherlands is the primary source for traditional synthetic stimulant drugs imported into 
the UK, with points of entry at ports in north-east, east and south-east England being most 
common, either direct from the Netherlands or via France. 
Cannabis 
The Netherlands is the primary source for skunk cannabis imported to the UK. The main 
points of entry are the north-east, east and south-east ports of England, either direct from the 
Netherlands or via France. 
The most common sources of herbal cannabis are South Africa, West Africa and the Caribbean. 
Importation to the UK is frequently direct via air couriers, maritime freight vessels and containers. 
Morocco and Afghanistan are the major sources for UK-bound cannabis resin. Moroccan 
resin generally routes overland via Spain and France, although much enters the UK directly in 
maritime freight. The Netherlands is a hub for cannabis resin destined for the UK, with south-
east ports being the primary UK access points. Afghan resin tends to follow traditional heroin 
routes into the UK. 
New psychoactive substances 
NPS are commonly ordered via the internet and then shipped to the UK from sources in China 
and India. Prior to the introduction of the Psychoactive Substances Act 2016 (Her Majesty’s 
Government, 2016) much of this trade was conducted on the ‘clearnet’. Transit points such as 
Spain are believed to hold larger consignments which are broken down to supply individual 
online orders, which are most commonly despatched via the fast parcel system to the UK. 
9.2.3 Drug trafficking within the country
The UK drug market is exploited by a very diverse demographic of drug dealers/distributors of a 
wide range of nationalities. Nationals from more than 30 countries are believed to influence the 
drugs threat at organised crime level within the UK. British OCGs exert the largest influence by 
nationality in each of the main drug markets with Albanian, Turkish, Pakistani, Jamaican, Somali, 
Lithuanian, Irish (Rep), Nigerian and Vietnamese gangs also involved. It is also recognised 
that foreign nationals play a significant role in the provision of transport and logistics for drug 
trafficking towards and into the UK.
Drugs are concealed in many ways during domestic distribution. Vehicle concealments (as those 
encountered at ports) are increasingly prevalent. An established supply trend has developed 
involving urban gangs distributing user quantities of heroin and crack cocaine into country and 
coastal towns and cities from central hubs. Gangs acquire drugs from OCGs, send ‘runners’ 
out to establish markets in wider locations and then exploit young and vulnerable people to 
facilitate onward supply and safe houses. This activity is facilitated via a ‘line’ – a trusted mobile 
phone number which is accessed by customers having been introduced by a runner. The 
line facilitates a 24-hour demand and supply market, with the mobile phone commonly being 
isolated in an urban location, with runners able to respond to requests upon demand. London 
is the most prolific (but by no means the only) urban hub.
NPS are often ordered over the internet by the end user in quantities of less than one kilogram 
(kg). Transportation is via traditional postal and parcel delivery services.
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9.2.4 Diversion of controlled medicines
There has been increasing concern about the diversion and illicit supply of medications in recent 
years. In 2016, the Advisory Council on the Misuse of Drugs (ACMD) reported on the extent of 
this in the UK. The investigation found that the most common diverted medicines were opioids 
and benzodiazepines, and the amount of diverted pregabalin and gabapentin is increasing. It is 
likely that the rising number of online pharmacies with unethical prescribing practices may be 
behind this increase, as well as diversion of wholesale supplies (Advisory Council on the Misuse 
of Drugs, 2016d). 
As part of the ACMD’s investigation, it was reported that the UK Medicines and Healthcare 
products Regulatory Agency (MHRA) and the Irish Health Products Regulatory Authority had 
uncovered illegal diversion of prescription-only medicines from the regulated supply chain to the 
criminal market, including significant diversion from one UK wholesaler. As part of the MHRA’s 
ongoing investigation, two pharmacists have been arrested following the purchase of at least 
200,000 packets of benzodiazepines and other medications, of which only a small proportion 
had been dispensed.71 A number of other arrests and seizures have been made. 
9.3 Prices and purity
9.3.1 Market influences
The value of the GBP against the US Dollar and Euro remains an important factor in drug market 
trends, as cocaine and heroin are traded in these currencies en route to the UK and within 
distribution hubs accessed by OCGs supplying the UK. When the value of the GBP drops, no 
market adjustment is made by suppliers to UK-based customers, hence less spending potential 
following exchange and greater wholesale outlay leads to reduced profit margins. This has 
previously generated UK domestic wholesale price increases.
Despite significant cocaine seizures bound for the UK between 2014 and 2016, the wholesale 
(kg) price has declined by about 15% during the same period. Part of the decline can be 
explained as a recovery from some unnecessary high prices that had to settle down as they 
were generating adulteration down to unacceptable purity levels towards the retail market. It is 
also accepted, however, that the high volumes of cocaine being smuggled towards and into 
the UK are compensating for the losses and allowing a competitive market to prevail. This is 
reflected in lower wholesale prices, less need to bulk and higher purity user deals at the same 
retail prices as before this period. 
9.3.2 Street-level price data from law enforcement sources
Street/retail deals tend to be in one gram units for cocaine, amphetamine, MDMA, NPS, 
ketamine and high quality skunk cannabis, with other cannabis types typically being sold for 
1/8th ounce (3.5 grams). Heroin and crack cocaine are commonly sold as ‘bags’ and ‘rocks’ 
respectively, in 0.1 gram and 0.2 gram deals. 
Street-level price data from law enforcement sources suggest that the price of most drugs 
remained stable in 2015 (see Table 9.2). After rising in 2014, the prices of cannabis resin and 
sinsemilla fell back to around the levels seen in 2013. The price per tablet of ecstasy/MDMA 
remained at £5 in 2015.
71 See: https://www.gov.uk/government/news/regulator-investigating-the-diversion-of-prescription-only-medicines 
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Table 9.1: Common street-level prices of certain illicit drugs in the United Kingdom, 2007–2015
Price per gram except where otherwise stated
2007 2008 2009 2010 2011 2012 2013 2014 2015
Amphetamine £9.00 £10.00 £10.00 £10.00 £10.00 £10.00 £10.00 £10.00 £10.00
Cannabis herb* £3.95 £2.85 £2.85 £2.82 £5.00 £5.00 £3.00 £2.86 £2.86
Cannabis resin* £2.82 £2.85 £2.85 £2.82 £5.00 £5.00 £3.00 £5.20 £2.86
Cannabis 
(sinsemilla)†
£6.21 £5.63 £7.15 £7.15 £10.00 £10.00 £8.50 £15.20 £10.00
Cocaine powder £46.00 £40.00 £40.00 £40.00 £40.00 £40.00 £40.00 £40.00 £40.00
Crack cocaine £65.00 £65.00 £60.00 £50.00 £50.00 £60.00 £60.00 £60.00 £60.00
Ecstasy/MDMA (per 
tablet)
£3.00 £3.00 £2.50 £2.50 £5.00 £3.00 £3.00 £5.00 £5.00
Heroin £48.00 £45.00 £45.00 £45.00 £40.00 £40.00 £50.00 £50.00 £50.00
LSD (per dose) £3.50 £3.00 £3.00 £3.00 – – £3.00 £3.00 £3.00
Mephedrone – – – £10.00 £20.00 £20.00 £15.00 – –
Ketamine – – – £25.00 £25.00 £20.00 £20.00 £20.00 £20.00
*Price per gram converted from the 1/8oz street deal equivalent, except for in 2011 – 2013, where prices were 
reported on a gram basis 
†Price per gram converted from the 1/8oz street deal equivalent between 2007 and 2010; from 2011 prices are 
reported on a gram basis 
Source: National Crime Agency
9.3.3  Purity of drugs and composition of drugs/tablets in the domestic 
market
From forensic insight, the majority of adulteration tends to take place before the drug reaches 
the ‘street dealer’. Their means of profit making will more often be division and reduction in 
deal size for the very small amounts. For example, if a street dealer buys quarter of an ounce of 
heroin (3.5 grams) and sells in 0.08 gram, rather than 0.1 gram deals, this will provide 44 deals 
at £10, instead of 35 deals; an additional return of £90 in return for a small outlay. 
Purity of powdered drugs may be affected by the size and nature of the supply chain, of which 
many forms are present in the UK. Short supply chains, consisting, for example, of importer to 
retail supplier to user, facilitate the sale of high and bulked quality products, as control remains 
entirely with those importing and dealing. An example of a longer supply chain might include an 
importer, national distributor, regional distributor, local supplier and street dealer before reaching 
the consumer. In this scenario there is likely to be bulking with cutting agents at each stage to 
maximise profits. This can result in a lack of insight of purity, as each onward transaction adds 
distance from the importation. In such a scenario, purity can very often only be guessed or 
generally assessed by use. 
Data on the purity of drugs/tablets is provided by the NCA using samples from a number of 
forensic agencies. The data is collected from tests conducted on police seizures within the 
domestic market including seizures of packages weighing up to 25 grams from users and 
from one or two stages above street level. As such, the mean purities reported for substances 
may be higher than if data were based on street-level seizures alone. Purity data is shown in 
Table 9.2.
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Table 9.2: Mean percentage purity/potency of small quantity drug seizures in England and 
Wales, 2007 to 2015
2007 2008 2009 2010 2011 2012 2013 2014 2015
Amphetamine (%) 11 8 8 8 10 5 7 12 10
Cocaine powder (%) 33 29 20 24 26 37 38 36 44
Crack cocaine (%) 52 43 27 31 26 30 36 37 48
Ecstasy (mg/tablet) 52 33 44 49 71 102 † 90 †
Heroin (%) 40 43 44 35 18 20 29 36 44
†No data available 
Source: National Crime Agency
Amphetamine
Amphetamine purity has appeared to stabilise following a decrease in purity seen in 2012 
and 2013. Almost all amphetamines seized are cut with caffeine, while other common diluting 
agents include lactose and glucose.
Cocaine
Cocaine entering the UK tends to be sold at premium prices as a high quality commodity, or is 
adulterated. The average purity of powder cocaine has now more than doubled since a nadir 
of 20% in 2009, and was 44% in 2015. Levamisole is commonly detected in wholesale cocaine 
seizures (added at the point of production) while benzocaine is used to bulk out the product 
within the UK and remains the most significant adulterant used for cocaine. Other adulterants 
detected by forensic agencies include caffeine and phenacetin. Current indications within the 
UK marketplace demonstrate common approximate adulteration rates for cocaine between 
importation and street level distribution of one / two parts adulterant to one part commodity (1:1 
or 2:1). Purity of crack cocaine has followed a similar patter to that of cocaine in powder form 
over the past ten years.
Heroin
Currently, heroin being imported into the UK is at a consistently high purity. Less adulteration 
is being seen, resulting in higher purity heroin available at street-level which may, however, vary 
unpredictably between batches. While the price of user deals remains stable, the purity of a £10 
bag (0.1 gram) can range from five to fifty per cent.
After a large decrease in the purity of street-level heroin in 2010 and 2011, which was largely 
sustained in 2012, the purity of this drug has risen back to levels seen in the late 2000s, and in 
2015 was 44%. 
9.3.4 Wholesale drug market prices
The kg remains the most common wholesale trading weight for all solid and powder drugs, with 
the exception of crack cocaine which is packaged following domestic conversion. As such, an 
ounce (28 grams) has become the most frequently encountered trading unit, with each ounce 
capable of making 280 x 0.1 gram ‘rocks’.
Tablet and paper tab drugs, such as ecstasy and LSD, are most commonly traded in 1,000, 
5,000 and 10,000 unit batches at wholesale. 
Common wholesale prices include for certain illicit drugs in the UK are shown in Table 9.3. 
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Table 9.3: Common wholesale prices of certain illicit drugs in the United Kingdom, 2015
 
Lower price 
(GBP)
Upper price 
(GBP)
Cocaine (kg) 28,000 38,000
Heroin (kg) 19,000 25,000
MDMA crystal (kg) 4,000 6,000
Amphetamine (kg) 1,000 4,000
Cannabis resin (kg) 800 1,000
Cannabis herb (kg) 900 1,800
Cannabis skunk (kg) 4,000 8,000
Ecstasy tablets (1,000 tablets) 1,500 5,000
Source: Personal communication – National Crime Agency
9.4 Drug supply reduction activities
9.4.1 Areas of activity of supply reduction
In the last year, progress towards restricting supply has included several pieces of new 
legislation: the Serious Crime Act 2015 (Her Majesty’s Government, 2015c) was introduced for 
counter-terrorist work and has four components: prosecuting and disrupting people engaged in 
serious and organised crime (Pursue); preventing people from engaging in this activity (Prevent); 
increasing protection against serious and organised crime (Protect); and reducing the impact of 
this criminality where it takes place (Prepare). On illicit drugs, the strategy particularly focuses on 
restricting the supply to the UK, engaging international partners to help disrupt OCGs smuggling 
illicit drugs through UK borders and ensuring the retrieval of the proceeds and assets from the 
crimes these groups commit. 
There has been widespread national activity to support the implementation of the Psychoactive 
Substances Act 2016 (see section 8.3.1). Following awareness raising campaigns by local police 
forces, hundreds of retailers across the United Kingdom have either closed down or are no 
longer selling psychoactive substances. As of August 2016, police forces had made nearly 200 
arrests. Action by the NCA has resulted in the removal of psychoactive substances being sold 
by UK-based websites.
9.5 Drug seizures 
9.5.1 Trends in drug seizures in England and Wales
As UK drug seizure data has not been available on a consistent basis in the past six years, data 
from England and Wales have been used to comment on trends. Cannabis has remained the 
most commonly seized drug throughout the period, and therefore is the main influence on the 
trend in total number of drug seizures (Home Office, 2016g). The number of seizures of herbal 
cannabis increased between 2006/07 and 2008/09, and remained stable for three years, but 
has decreased since then (see Figure 9.1). The quantity of herbal cannabis seized does not 
reflect this trend, as the vast majority of seizures are carried out by police forces, but Border 
Force are responsible for seizing the greatest quantity of herbal cannabis, which may include 
single high quantity seizures (see Figures 9.2, 9.3) (Home Office, 2016g). Over the past ten years 
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there has been a substantial decrease in the number and quantity of cannabis resin seizures, 
most likely reflecting a decreased use of this type of cannabis in England and Wales.
Figure 9.1: Number of cannabis seizures made by police forces and Border Force in England 
and Wales, 2006/07 to 2015/16
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While accounting for a much smaller proportion of the total, the number of cannabis plant 
seizures trend shows a similar pattern to that of herbal cannabis (see Figure 9.1). There was 
a large increase in the number of seizures between 2006/07 and 2011/12, which has been 
followed by a downwards trend for four years. The quantity of cannabis plants seized steadily 
rose more than eightfold from 2004 (data not shown) to 2009/10. However, since then fewer 
plants have been seized each year, and the total quantity seized has fallen by 48% from the 
peak of 758,943 in 2009/10 to 393,702 in 2015/16 (see Figure 9.2). 
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Figure 9.2: Quantity of seizures, in kilograms, of selected drugs by police forces and Border 
Force in England and Wales, 2006/07 to 2015/16
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Figure 9.3: Proportion of the number and quantity of seizures made by police forces* and 
Border Force in England and Wales, 2015/16
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The number of seizures of heroin decreased between 2008/09 and 2012/13 (see Figure 9.4). 
The number of seizures has since stabilised, and in 2015/16 was 8,050 (down from a peak 
of 13,463 in 2007/08). Similar to the cannabis data, the quantity of heroin seized over the last 
decade has varied greatly, again primarily influenced by the quantity of seizures made by Border 
Force (see Figures 9.3 and 9.5).
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Figure 9.4: Number of seizures of selected drugs by police forces and Border Force in 
England and Wales, 2006/07 to 2015/16
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The number of cocaine powder seizures decreased from a peak of 24,659 in 2008/09 to 15,815 
in 2014/15; this number decreased slightly again in 2015/16, to 15,588 (see Figure 9.4). The 
quantity of cocaine powder seized this year was 4,228kg, the highest amount seen in the past 
ten years (see Figure 9.5). Crack seizure numbers have remained stable for the past five years, 
and this figure was 4,718 in 2015/16 (see Figure 9.4). While the greatest quantity of cocaine 
powder is seized by Border Force, virtually all crack cocaine seizures (number and quantity) are 
made by the police force, reflecting the importation of cocaine powder from abroad, and the 
domestic production of crack cocaine within the UK (see Figure 9.3). 
Seizures of ecstasy tablets (both number and quantity) declined between 2006/07 and 
2010/11. The number of seizures has remained stable since this time (n=2,906 in 2015/16); 
the quantity seized has increased since 2010/11, although not to the level seen in 2006/07 (see 
Figures 9.4 and 9.5).
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Figure 9.5: Quantity of selected drugs seized by police forces and Border Force in England 
and Wales, 2006/07 to 2015/16
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